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HCMV  is  a  near-ubiquitous  (3-herpesvirus  that  asymptomatically  infects  the 
majority of  immunocompetent adults.  However,  in the immunodeficient or the 
immunosuppressed,  HCMV  becomes  a  major  cause  of  morbidity.  Solid 
organ  transplant  recipients  require  immunosuppressive  regimens  prior  to 
organ  transplantation;  the  resultant  reduction  in  their T-cell  responses  leads 
to  an  increased  risk of uncontrolled  HCMV  replication,  which  left  unchecked 
is associated with HCMV disease.
In this thesis we observed fluctuations of HCMV-specific CD4 and CD8 T-cell 
populations  in  20  renal  transplant  patients  during  the  six  months  following 
transplant  using  flow  cytometry.  The  frequencies  of  these  populations  were 
related  to  incidences  of viraemia.  Patients  suffering  viraemic  episodes  post­
transplant  had  significantly  decreased  HCMV-specific  CD8+  cell  responses 
when compared to individuals who remained HCMV PCR  negative and a link 
was established  between  the  absolute  numbers of  HCMV-specific CD4 cells 
and the size of the HCMV-specific CD8 response.
Temporal  increases  in  virus-specific  CD8  responses  were  also  observed, 
which  corresponded  with  decreases  in  the  incidences  of  HCMV  viraemia
2after  immunosuppressive  regimens  were  reduced.  Further work focused  on 
the  emergence  of  CTL-escape  mutants  in  individuals  who,  despite  having 
detectable  HCMV  epitope-specific CD8  responses failed to  prevent viraemic 
episodes.  Although  no  mutations  were  detected  in  the  patients  analysed,  a 
substitution  analysis  was  performed  on  a  defined  epitope  to  determine  the 
possible  effects  of  any  substitutions  on  MHC  I  molecules  binding  and 
recognition  by  CTLs.  Results  showed  a  variety  of  substitutions  could 
abrogate  IFNy  production  by  CTLs  whilst  binding  and  stabilising  MHC  I 
complexes.
I  also demonstrated for the first time that  individuals  suffering from  common 
variable  immunodeficiency  (CVID)  -  who  lack  the  capacity  to  mount  their 
own  B-cell  responses,  had  detectable  HCMV-specific  T-cell  responses  and 
did  not  suffer symptomatic  HCMV  infection,  indicating  that  control  of  HCMV 
replication  could  be  mediated  by  the  T-cell  arm  of  the  adaptive  immune 
response.
3Acknowledgements
I  would  like  to  thank  Professors  Vincent  Emery  and  Paul  Griffiths  and  Dr 
Duncan  Clarke  for their supervision,  encouragement  and  input  over the  last 
three  years.  I  would  also  like to  thank  Dr  Paul  Sweeney  and  the  nurses  on 
the  renal ward,  who  I  have continually pestered over a period of at least two 
of  those  years  for  samples.  Thanks  also  to  Professor  David  Webster  for 
giving  me  access to the CVID group who  have greatly increased the data in 
my work and  Professor George Janossy who  has  given  invaluable  help  into 
both the writing and the structure of the thesis.
Mrs  Emma  Hainsworth  has  been  tireless  in  the  pursuit  and  recruitment  of 
patients  suitable  for  this  study  and  has  consequently  made  my  life  a  lot 
easier.  Also  Dr  Raza  Muhammed  and  Dr  Anu  have  been  instrumental  in 
aiding my collection of patient data.
In  Virology,  Keirissa  Lawson  has  given  me the  most guidance  in  all  aspects 
of  immunology  -   both  practical  and  theoretical,  without  her  I  would  still  be 
sitting  bewildered  in  front  of  the  FACs  machine.  Great  thanks  to  all  of  the 
other people in research past and present: Sapna, Gaia,  Hoe Nam,  Ed, Ting, 
Jacqueline,  Esteban,  Shalene,  Frank  and  Huib.  Also  many  thanks  to  the 
diagnostic staff in virology especially Chris, Claire,  Kali and Gill.
Dr  Angelina  Moseley  has  been  a  great  help  in  showing  me  how  to 
communicate the writing of this work and Collette Smith in  PCPS has given a 
great deal of statistical guidance.
4Table of ContentsTable of contents
Title Page  1
Abstract  2
Acknowledgements  4
Table of contents  6
Figures  11
Tables  17
Glossary  18
Amino acid list  22
Chapter 1  23
Introduction  23
1.  1   Classification  24
1.  2 Structure and Morphology  24
1.  3 HCMV life cycle  25
1.3.  1 HCMV genome  26
1.3. 2 DNA Replication  27
1.3.3  DNA packaging and virus assembly  33
1.  4 Epidemiology and Transmisison  35
1.  5 Latency  37
1.  6 Infection of Solid Organ Transplant Patients  39
1.  7 HCMV Pathology  42
1.  8 Drugs  45
1.8.  1 1mmunosuppressive Drugs for Solid Organ Transplants  45
61.8. 2 Antiviral Therapy  49
1.  9 Immune Responses to HCMV  56
1.9.  1 1nnate immune responses to HCMV  56
1.9.2  Adaptive immune responses  59
1.9.2.  1 Humoral immune response  59
1.9.2. 2 CDS' cell response  60
1.10 Evasion of cellular immune responses  83
1.  11  CVID patients  84
1.12 Aims of project  86
Chapter 2  90
Materials and Methods  90
2.  1   Cell Culture  91
2.1.  1   Growth and Maintenance of T-2 Cell Lines  91
2.1. 2 Isolation of PBMCs from Whole Blood  91
2.1. 3 Freezing PBMCs for ex vivo tetramer staining  93
2.1. 4 Thawing PBMCs  93
2. 2 PCR  94
2.2.  1  Primers for amplification of sequences encoding CD8 epitopes  94
2.2. 2 Nested polymerase chain reaction (PCR)  96
2.2. 3 Agarose Gel Electrophoresis  98
2.2. 5 Transformations using the ligation reactions  101
2. 3 Peptides  103
2. 4 Enzyme-Linked Immuno Spot (ELISpot) using modified peptides  104
2.  5 Peptide Stabilization Assay  105
72.  6 Ethical approval  107
2.  7 Serology  107
2.  8  HLA Typing  107
2.  9  Patient study population and design  107
2.  10 Immunosuppression  109
2.  11  Routine HCMV  109
2.  12 Intracellular Cytokine Staining of Stimulated CD4+  and CD8+  cells  109
2.  13 Tetramer staining  112
2.  14 Statistical analysis  114
Chapter 3  115
CD4* Responses to HCMV in Renal Transplant Patients  115
3.1  Introduction  116
3.2 Kinetics of HCMV-specific CD4+  T-cell re-emergence in Renal Tx Patients 118
3.3 CD4 responses to the tegument protein pp65  125
3.4 Comparing HCMV CD4 responses in renal transplant patients  129
3.5 Comparison of CD4 Responses in Months 1   to 3 and 4 to 6  133
3.6 The relationship between HCMV-specific CD4+  and CD8+  responses  135
3.7 Discussion  138
8Chapter 4:  144
HCMV-specific CD8* Responses in Renal Transplant Recipients  144
4.  1   Introduction  145
4. 2 CD8+  responses to pp65 in renal transplant patients  148
4.2. 2 Frequency of IE1-specific CD& populations post-transplant  153
4.2. 3 Responses of combined  pp65/IE1-specific CDS' populations post­
transplant  154
4. 3 Percentages CD8 Responses in Months 1-3 and 4-6 post-transplant.  158
4. 4 Measuring the Absolute Numbers of HCMV-specific CD8+  T-cells  163
4. 5 Absolute CD8 Responses in Months 1-3 and 4-6 Post-Transplant.  168
4. 6 pp65-specific CD8+  responses in viraemic and non-viraemic patients  173
4.  7 Are responses towards IE1  protective at different thresholds?  183
4. 8 Discussion  187
Chapter 5  192
Do HCMV CTL-Escape Mutants Occur in Viraemic Renal Transplant Patients? 
192
5.  1   Introduction  193
5.2 Do Mutations occur within CTL epitopes in renal transplant patients?  196
5.3 Effect of amino acid substitutions in tNLVPMVATV on recognition by CTLs.
200
5.4 HLA-stabilisation assay  205
5.5 Peptide competition assay using  IFNy ELISPOT  209
95.6 Peptide competition assay using T2 cell HLA stabilisation assay
5.7 Discussion
212
214
Chapter 6  220
T~cell Responses to HCMV in Patients with Common Variable 
Immunodeficiency (CVID)  220
6.  1   Introduction  221
6. 2 CVID responses to HCMV antigens  223
6. 3 Comparison of T-cell responses  225
6. 4 Analysis and comparison of HCMV-specific Tetramer populations  231
6.  5 Discussion  241
Chapter 7  246
Discussion  246
References  257
Appendix  308
List of Companies and Reagents Used  308
pGemT-easy vector map and LB plate recipe  312
Viral loads and Lymphocyte counts of viraemic transplantees  313
10Figures
Chapter 1
Figure 1.  1   HCMV genome structure.................................................................................27
Figure 1.  2 Temporal Hierarchy of HCMV-expressed genes.......................................29
Figure 1.  3 The structure of the Major Immediate Early Promoter  (MIEP).................30
Figure 1.  4 Cyclosporin........................................................................................................45
Figure 1.  5 Tacrolimus..........................................................................................................46
Figure 1.  6 Mycophenolate mofetil.................................................................................... 47
Figure 1.  7 Ganciclovir..........................................................................................................52
Figure 1.  8 Foscarnet............................................................................................................54
Figure 1.  9 Cidofovir............................................................................................................. 55
Figure 1.  10 Activation of Naive T-cells by antigen presenting cells(APCs)............64
Chapter 2
Figure 2.  1   Sedimented layers formed after centrifugation of whole  blood...............92
Figure 2.  2 1.5% agarose gel showing nested PCR products....................................100
Figure 2.  3 Histogram showing HLA-A*0201  expression on T2  cells........................106
Figure  2.  4  FACS  density  plots  and  histograms  showing  staining  on  stimulated
PBMCs............................................................................................................................111
Figure 2. 5 Staining  to determine Perforin and CD57 phenotypes...........................113
11Chapter 3
Figure 3.  1   FACS analysis plots of IFNy production in response to HCMV lysate. 121 
Figure  3.  2  Relative  contributions  of  antigens  to  the  HCMV-specific  CD4+   T-cell
response........................................................................................................................122
Figure 3.  3 Fluctuations in HCMV-specific CD4+  populations over a six month period
post-transplant..............................................................................................................123
Figure  3.  4  Longitudinal  analysis  of  the  absolute  number  of  circulating  HCMV-
specific CD4+  cells, which were able to express CD69 and IFNy......................124
Figure  3.  5  Fluctuations  in  pp65-specific  CD4+   populations  as  quantified  by  the 
percentage  of cells  expressing  IFNy and  CD69  over a  six  month  period  post­
transplant........................................................................................................................127
Figure 3.  6  Longitudinal  analysis of the absolute  number of circulating  IE1-specific
CD8+  cells that were able to express CD69 and IFNy on stimulation  128
Figure 3.  7 Comparison of global CD4+   responses  to  HCMV  between  viraemic and
non-viraemic renal transplant patients.....................................................................131
Figure 3.  8 Comparison of global  CD4+  responses  to  HCMV  between  viraemic and
non-viraemic  renal  transplant  patients  over the.entire  six  month..period  post­
transplant  132
Figure 3.  9 Comparison of the absolute  number of  HCMV-specific CD4+   responses 
of  20  renal  transplant  patients  in  months  1-3  and  months  4-6  post-transplant.
.........................................................................................................................................134
Figure  3.  10  Relationship  between  the  percentages  of  HCMV-specific  CD4+   and 
CD8+   T-cell  populations  taken  from  patients  at  one  month  intervals  for  six
months post-transplant................................................................................................136
Figure 3.  11  Relationship between the absolute number of HCMV-specific CD4+  and 
CD8+   T-cell  populations  taken  from  patients  at  one  month  intervals  for  six 
months post transplant................................................................................................137
12Chapter 4
Figure 4.  1   FACS analysis plots of  IFNy production  by CD8+ T-cells  in  response to
IE1  and pp65 antigens............................................................................................149
Figure 4.  2  Numbers  of seropositive  individuals with  consistent detectable  (>0.1%)
CD8+  T-cell responses against IE1  and/or pp65...................................................151
Figure 4.  3  Fluctuations  in pp65-specific CD8+  populations over a six month period
post-transplant.............................................................................................................. 152
Figure  4.  4  Fluctuations  in  IE1-specific  CD8+   populations  over  a six  month  period
post-transplant.............................................................................................................. 155
Figure  4.  5 The  relative contributions of  CD8+   responses  to pp65  and  IE1  in  renal
transplant patients during the six months post-transplant.................................. 156
Figure 4. 6 Fluctuations in IE1  and pp65-specific CD8+  populations over a six month
period post-transplant................................................................................................ 157
Figure 4.  7 Comparison of pp65-specific CD8+  responses in twenty renal transplant
patients in months 1   to 3 and months 4 to 6 post-transplant.............................160
Figure  4.  8  Comparison  of  IE1-specific  CD8+   responses  in  twenty  renal  transplant
patients in the first three and second three months post-transplant................161
Figure  4.  9  Comparison  of  IE1  and  pp65-specific  CD8+   responses  in  twenty  renal 
transplant  patients  in the first three  and  second three  months  post-transplant.
  162
Figure  4.  10  Longitudinal  analysis  of  the  absolute  number  of  circulating  pp65- 
specific CD8+  cells that are able to express CD69 and IFNy on stimulation.. 165 
Figure 4.  11  Longitudinal analysis of the absolute number of circulating  IE1-specific
CD8+  cells that are able to express CD69 and  IFNy on stimulation................. 166
Figure 4.  12 Absolute number of circulating HCMV-specific CD8+  cells that are able 
to  express  CD69  and  IFNy on  stimulation  in  renal  transplant  patients  over six 
months............................................................................................................................167
13Figure 4.  13  Comparison  of the absolute  number of pp65-specific CD8+   responses
in months  1-3 and 4-6 post-transplant.....................................................................170
Figure 4.  14 Comparison of the absolute number of  IE1-specific CD8+  responses in
months 1-3 and 4-6 post-transplant.........................................................................171
Figure 4.  15 Comparison of the absolute number of combined pp65 and IE1 -specific
CD8+  responses in the months 1-3 and 4-6 post-transplant.............................. 172
Figure  4.  16  Comparison  of  the  percentages  of  pp65-specific  CD8+   T-cells  in
patients suffering viraemic episodes and those that do not...............................177
Figure 4.  17 Comparison of the absolute  numbers of pp65-specific CD8+  T-cells  in 
patients  suffering  viraemic  episodes  and  those  that  do  not  during  the  first 
month  (upper panel)  and  total  six  month  period  post-transplant  (lower panel).
.........................................................................................................................................178
Figure 4.  18 Comparison of the percentages of IE1-specific CD8+  T-cells in patients 
suffering viraemic episodes and those that do not during the first month (upper
panel) and total six month period post-transplant (lower panel)........................179
Figure  4.  19  Comparison  of  the  absolute  numbers  of  IE1-specific  CD8+   T-cells  in 
patients  suffering  viraemic  episodes  and  those  that  do  not  during  the  first 
month  (upper panel)  and  total  six  month  period  post-transplant  (lower panel).
  180
Figure 4.  20 Comparison of the percentages of pp65 and  IE1-specific CD8+  T-cells 
in  patients  suffering  viraemic  episodes  and  those  that  do  not  during  the  first 
month  (upper panel)  and  total  six  month  period  post-transplant  (lower panel).
  181
Figure  4.  21  Graph  to  compare  the  absolute  numbers  of  HCMV-specific  CD8+   T- 
cells  in  patients  suffering  viraemic  episodes  and those that  do  not during  the 
first  month  (top  panel)  and  total  six  month  period  post-transplant  (bottom 
panel)..............................................................................................................................182
14Figure 4.  22 Proportion of patients with CD8+  T-cell responses to IE1  and/or pp65 in
viraemic (left panel) and non-viraemic (right panel) patients............................. 184
Figure  4.  23  A  comparison  of  the  percentages  of  stratified  IE1-specific  CD8
responses in viraemic and non-viraemic patients.................................................185
Figure  4.  24  A  comparison  of the  absolute  numbers  of  stratified  IE1-specific  CD8 
responses in viraemic and non-viraemic patients.................................................186
Chapter 5
Figure  5.  1   Chromatogram  showing  the  sequence  of  amplified  DNA  encoding
HCMV CTL epitopes...................................................................................................198
Figure 5. 2 Peptide variants  made............................................................................202
Figure  5.  3  FACS  plot  of  healthy  HCMV  seropositive  HLA-A*0201-restricted
individual with  responses to  NLVPMVATV.  Blot used gates of lymphocyte and
CD3+  populations.........................................................................................................203
Figure  5.  4  IFNy ELISPOT  showing  responses  of four  individuals  to  NLVPMVATV
peptide variants............................................................................................................204
Figure  5.  5  Increase  in  HLA-A*0201  expression  in  T2  cells  pulsed  with
NLVPMVATV variants.................................................................................................207
Figure  5.  6  Increase  in  HLA-A*0201  expression  in  T2  cells  pulsed  with
NLVPMVATV variants................................................................................................ 208
Figure  5.  7  ELISPOT to  determine  concentration  of  NLVPMVATV that  elicits  50% 
IFNy production,  a  peptide  concentration  of  ~0.75|aM  was  found  to  stimulate
50% of the maximum production of IFNy...............................................................210
Figure  5.  8  Results  of  IFNy  ELISPOT  titrating  in  the  C5  variant  against  75|iM  of 
wildtype peptide...........................................................................................................211
15Figure  5.  9  FACS  analysis  showing  mean  fluorescence  intensity  (MFI)  created  by 
stabilisation of HLA class I complexes by co-incubation of T2 cells with wildtype
peptide and titrated concentrations of the C5M variant.......................................213
Chapter 6
Figure 6.  1   Analysis of CD4+  and CD8+  T-cell responses to HCMV antigens in CVID 
patients...........................................................................................................................224
Figure  6.  2  Comparison  of  pp65-specific  CD8+   T-cell  responses  between  CVID 
patients,  healthy age-matched controls  and viraemic  renal transplant patients.
........................................................................................................................................ 227
Figure  6.  3  Comparison  of  IE1 -specific  CD8+   T-cell  responses  between  CVID 
patients,  healthy age-matched  controls  and viraemic  renal transplant patients.
  228
Figure 6.  4 Comparison of combined  IE1  and pp65-specific CD8+  T-cell  responses 
between  CVID  patients,  healthy  age-matched  controls  and  viraemic  renal
transplant patients........................................................................................................ 229
Figure  6.  5  Comparison  of  global  CD4+   T-cell  responses  to  whole  virus  lysate 
between  CVID  patients,  healthy  age-matched  controls  and  viraemic  renal
transplant patients........................................................................................................ 230
Figure  6.  6  FACs  analysis  of  CD57  staining  in  CD8+   CD3+   Tetramer populations..
..........................................................................................................................................233
Figure 6.  7  FACs analysis of perforin  staining  in CD8+  CD3+  Tetramer populations..
..........................................................................................................................................234
Figure 6. 8 CD8+  Phenotypes  of four CVID patients....................................................235
Figure 6. 9 CD8+  Phenotypes  of four age-matched healthy controls......................236
Figure 6.  10 Examples CD8+   Phenotypes renal transplant patients......................237
16Figure  6.  11  Comparison  of  the  percentages  of  HCMV  epitope-specific  tetramer 
stained  CD8+  cells  between  CVID patients,  age-matched  healthy controls and
viraemic renal transplant patients........................................................................... 238
Figure  6.  12  Comparison  of  the  percentages  of  HCMV  epitope-specific  tetramer
stained CD8+ cells......................................................................................................239
Figure  6.  13  A comparison  of the  percentages  of  HCMV  epitope-specific tetramer 
stained  CD8+   cells  (upper  panel)  and  CD8+   cells  (lower  panel)  that  express 
intracellular perforin................................................................................................... 240
Tables 
Chapter 1
Table  1.  1   List of known CD4 and CD8 epitopes identified in pp65 and  IE1  proteins
......................................................................................................................................... 69
Chapter 2
Table  2.  1   List  of  NLVPMVATV  variants  with  conservative  and  non-conservative
substitutions.................................................................................................................103
Table 2. 2  Table detailing renal transplant patient informations............................... 108
Chapter 5
Table  5.  1   Table  showing  information  on  patient  samples  and  the  sequence  data 
obtained from clones of the amplified sequences encoding designated epitopes 
....................................................................................................................................... 199
17Glossary
Adenosine Triphosphate  ATP
Allophycocyanin  APC
Antibody-dependent cytotoxicity  ADCC
Antigen determining region  AD
Antigen Presenting Cell  APC
Base pair  bp
Bone Marrow Transplant  BMT
2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole  BDCRB
5-bromo-4-chloro-3-indolyl-a-D-galactopyranoside  X-gal
Broncho-alveolar lavage  BAL
Cluster of Differentiation  CD
Common variable immunodeficiency  CVID
Complement control protein  CCPs
Cytopathic effect  CPE
Cytosine Triphosphate  CTP
Cytotoxic T-Lymphocyte  CTL
Dendritic Cells  DC
Deoxyribonucleic Acid  DNA
Dideoxy-nucleotide-triphosphates  ddNTPs
Endoplasmic reticulum  ER
Enzyme Linked Immuno Spot  ELISPOT
Epidermal growth factor  EGF
Epidermal growth factor receptor  EGFR
Fluorescein isothiocyanate  FITC
18Fluorescence Intensity  FI
Fluorescence Activated Cell Sorter  FACS
Foetal calf serum  FCS
Ganciclovir  GCV
Glucocorticoid receptors  GR
Glycoprotein B  gB
Granzyme A  GrA
Granzyme B  GrB
Guanosine monophosphate  GMP
Guanosine Triphosphate  GTP
Gut-associated lymphoid tissues  GALT
Granulocyte monocyte colony stimulating factor  GM-CSF
Heparin Sulphate Proteoglycan  HSPG
Human Cytomegalovirus  HCMV
Human Herpes Virus 5  HHV5
Human Herpes Virus 6  HHV6
Human Herpes Virus 7  HHV7
Human Immunodeficiency Virus  HIV
Human Leucocyte Antigen  HLA
Immediate Early  IE
Immunoglobulin  Ig
Inosine monophosphate dehydrogenase  IMPDH
Interferon gamma  IFNy
Interleukin  IL
Intravenous  iv
19Inverted Repeats IR
Isopropyl a-D-thiogalactopyranoside IPTG
Killer inhibitor receptors KIRs
Kilo Dalton kDa
Lysosome associated membrane protein lamp
Major Capsid Protein MCP
Minor Capsid protein mCP
Major Histocompatibility complex MHC
Major Immediate Early MIE
Major Immediate Early Promoter MIEP
Monocyte derived macrophage MDM
Microtubule organizing centre MTOC
Murine cytomegalovirus MCMV
Mycophenolate mofetil MMF
Mycophenolic acid MPA
Natural Killer cell NK cell
Nuclear factor for activated T-cells NFAT
Nuclear factor kappa B NF-kB
Nucleotide triphosphates NTPs
Open  Reading  Frame ORF
Peridinin chlorophyll protein PerCP
Peripheral Blood Mononuclear Cell PBMC
Precursor assembly protein protease pAP
Phosphate Buffered Saline PBS
Phycoerythrin PEPolymerase Chain Reaction PCR
Protein Kinase C PKC
Pre-emptive therapy PET
Retinal pigment epithelium RPE
Reverse transcriptase RT
Ribonucleic acid RNA
Small capsid protein SCP
Thermus Aquaticus Taq
T-Cell  Receptor TCR
Toll-like receptor TLR
Transporter associated with antigen processing TAP
Tumour necrosis factor alpha TNFcc
UL16-binding protein ULBP
Unique Long Region UL
Unique Short Region Us
21Amino acids
Alanine Ala A
Arginine Arg R
Asparagine Asn N
Aspartic acid Asp D
Cysteine Cys C
Glutamine Gin Q
Glutamic acid Glu E
Glycine Gly G
Histidine His H
Isoleucine He 1
Leucine Leu L
Lysine Lys K
Methionine Met M
Phenylalanine Phe F
Proline Pro P
Serine Ser S
Threonine Thr T
Tryptophan Trp W
Tyrosine Tyr Y
Valine Val V
22Chapter 1  
Introduction
23Chapter 1: Introduction
1.1 Classification
Human  cytomegalovirus  (HCMV),  or  human  herpes  virus  5  (HHV5),  is  the 
prototype  member  of  the  Betaherpesvirinae  subgroup  of  the  family 
herpesviridae,  which  includes  two  other  human  viruses:  human  herpes 
viruses  6  and  7  (HHV6  and  HHV7).  Cytomegaloviruses  were  so-named 
because  of  their  distinctive  cytopathic  effect  (CPE);  causing  “Owl’s-eye” 
intranuclear occlusions  in  infected cells  [1,  2].  HCMV  is a complex virus that 
contains  a  large  double  stranded  (ds)  DNA  genome,  which  encodes  more 
than  200  open  reading  frames  (ORFS).  Similar to  other  cytomegaloviruses, 
HCMV  infection  is  highly  species-specific  -  being  confined  either  to  the 
human  population  or  to  human-derived  cells  in  culture,  indicative  of  a  long 
period of co-evolution with the host [3].
1. 2 Structure and Morphology
HCMV  possess  the  morphology  of  a typical  herpesvirus  in  that  it  is  a  large 
enveloped  virus,  of  150-200nm  diameter,  with  an  amorphous  tegument that 
surrounds  an  icosahedral  capsid  [4].  The  capsid  enclosing  the  HCMV 
genome  is composed of  162  hexagonal  capsomeres  [5,  6].  The  surrounding 
tegument is closely associated with  a lipid bilayer,  which  is thought to derive 
from the host’s nuclear membrane [4]. Through this lipid bilayer protrude viral 
glycoprotein  spikes,  these  are  incorporated during the  budding  process from 
both  the  nuclear  and  cytoplasmic  membranes  [4,  7].  Two  further  virus-like 
particles  can  be  detected  following  in  vitro  virus  culture;  dense  bodies, 
lacking  nucleocapsids are composed solely of viral tegument proteins and an
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envelope,  and  non-infectious  enveloped  particles,  which  consist  of 
enveloped capsids lacking the electron-dense genome core [8].
1.3  HCMV lifecycle
HCMV  is  able  to  infect  a  wide  variety  of  tissues  and  cell  types,  although 
attachment  and  penetration  of  the  virus  can  occur  in  permissive  and  non- 
permissive  cells  alike.  Initial  attachment  is  thought  to  be  mediated  through 
glycoprotein  B  (gB)  binding  to  poly-anionic  heparin  sulphate  proteoglycan 
(HSPG)  moieties  that  are  found  distal  to  the  cell  surface  [9],  although  the 
heterodimic  complex  of  glycoproteins  M  and  N  (gM  and  gN)  also  both 
contains  heparin  binding  sites  [9].  Further  interactions  subsequently  occur 
with other cellular receptors of between 30 and 36kd in size, which are found 
at  closer  proximity  to  the  cell  surface  [10],  together  these  interactions  are 
believed to result in virus penetration.
Because  HCMV  infection  stimulates  the  activation  of  similar  signalling 
pathways to those induced by ligation of epidermal growth factor (EGF) to its 
receptor  (EGFR),  Wang  et  at.  chose  to  investigate  EGFR  as  a  possible 
receptor for  HCMV,  and gB was  indeed discovered to be the  ligand [11,  12]. 
However,  other  cells  permissive  for  HCMV  infection,  such  as  monocytes, 
macrophages  and  dendritic  cells,  lack  EGFR  expression,  from  which  it  can 
be surmised that presence of EGFR  is dispensable for HCMV entry [13].  Yet 
the  gB/EGFR  interaction  may  induce  a  signalling  cascade  in  target  cells 
priming them  for  HCMV  replication  [12].  Glycoprotein  B’s  ability to  bind toll­
like  receptor  2  (TLR2)  is  also thought to  initiate  another  signalling  cascade,
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which  leads  to  the  activation  of  innate  immune  responses  such  as  the 
induction  of  type  I  interferons  [14].  The  binding  of the  heterotrimeric  HCMV 
glycoprotein  complex  gCIII,  consisting  of  gH/gL,  gO  and  gB  to  integrins  is 
believed  to  be  necessary  for  membrane  fusion  and  subsequent 
internalisation  of  HCMV  [12].  Other  receptors  have  also  been  implicated  in 
this  process,  although  the  principal  one  required  for  entry  has  not  yet  been 
elucidated.  Penetration  occurs  through  a  pH-independent  fusion  event 
between  the  virus  envelope  and  the  cell  membrane  [15].  Once  inside  the 
cytoplasm the nucleocapsids make their way towards the nucleus; on arrival, 
approximately  20-30  minutes  post-infection  [16],  expression  of  immediate 
early genes can  be detected.
1.3.  1  HCM V genome
At 235kb, the  HCMV genome is the largest of any virus known to infect man. 
Similar to other human  betaherpesviruses,  HCMV contains a G/C-rich,  linear 
bi-partite,  E-class  genome;  this  means  that  HCMV  has  two  constituent 
genome parts,  the  unique short (Us)  and  unique long  (Ul)  regions, which  are 
themselves both flanked by direct and inverted repeat (IR) sequences. These 
are  in  turn  capable  of  isomerization  producing  four  different  linear  genome 
arrangements  [17-19].  The  direct  repeat sequences  are found  at the termini 
of  both  segments,  within  these  regions  are  contained  cleavage  and 
packaging cis-acting sequences pac-1 and pac-2 [20].
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1.3.  2 DNA Replication
HCMV replication was initially thought to be relatively slow, with production of 
progeny  virus  requiring  between  48  and  72  hours  in  vivo.  However,  more 
recently the  in vivo doubling time has been predicted to be  nearer 24 hours 
[21].
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Figure  1.  1  HCMV  genome  structure  kindly  donated  by  Professors  Griffiths  and 
Emery (2001).
Similar to other herpes viruses,  HCMV genes are expressed  in  a temporal, 
hierarchical  manner.  These  are  stratified  according  to  the  appearance  of 
virus  transcripts  and  consequently  proteins  in  infected  cells,  namely: 
immediate-early (IE), early (E) and late (L) genes (Fig.  1.2) [22-24]. The first
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group of genes to  be expressed are known  as the  immediate early  (alpha or 
IE)  genes.  Their  expression  occurs  in  the  absence  of  de  novo  protein 
synthesis,  as  expression  is  unaffected  by  the  presence  of  cyclohexamide 
and anisomycin  [25]  and  is  believed to be initiated  by the tegument proteins 
ppUL82  and  ppUL69  [26].  The  most  important of these  genes  are  encoded 
by  the  major  IE  (MIE)  locus  of  the  HCMV  genome,  and  their  expression  is 
regulated by the  MIE  promoter (MIEP -  see  Fig.  1.3).  Transcripts expressed 
from  open  reading  frames  (ORFS)  within  this  region  undergo  differential 
splicing giving rise to multiple mRNA species [27]. One of the most abundant 
transcripts,  composed  of  exons  1-4,  encodes  the  nuclear  phosphoprotein, 
IE1  [27].  This gene product has been demonstrated to be critical for efficient 
replication of HCMV in vitro [28] as  IE1 -deficient mutants were found to have 
a  severely  impaired  capacity  for  replication  in  vitro.  Although  IE1 -deficient 
mutants could still replicate, albeit at a reduced level, other IE genes were, to 
a degree, able to compensate for its loss [28, 29].
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Figure  1.  2  Temporal  Hierarchy  of  HCMV-expressed  genes,  picture  provided  by 
Professor Vincent Emery
IE  gene  products  are  required  for  the  transactivation  of  the  Early-phase 
HCMV  genes  (Beta  or  E  genes)  [30-32]  and  certain  other  host  genes. 
Furthermore,  they  are  also  able  regulate  their  own  expression  through 
binding  MIEP  [33].  The  loci  encoding  IE  regulatory  proteins  are  UL36-38, 
UL122/123 (IE2 and  IE1  respectively, both are encoded by the MIE region), 
UL84,  UL112/113  and  IRS1/TRS.  UL112/113  gene  products  are 
transactivator  proteins,  which  bind  to  and  activate  the  UL54  promoter  in 
association  with  other  MIE  proteins  [34,  35].  Early-phase  genes  (E-genes) 
encode  proteins  necessary for viral  DNA  replication.  Late  phase  (L genes) 
genes  are  only  expressed  following  the  onset  of viral  DNA  replication  and 
include genes encoding the structural components of the virion.
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Figure 1. 3 The structure of the Major Immediate Early Promoter (MIEP), image 
provided by Professor Vincent Emery.
HCMV  DNA  replication  occurs  through  both  theta  and  rolling  circle 
mechanisms,  depending  on  such  circumstances  as  the  cell  type  and  its 
differentiation  state  [36].  Theta  replication  would  result  in the  production  of 
closed-circular  episomes,  whereas  rolling  circle  replication  results  in  the 
formation  of  linear,  unit-length,  concatameric  genomes,  which  can 
subsequently be packaged, cleaved and incorporated into virions [37]. These 
systems are analogous to those employed by certain bacteriophages, which
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also  have  both  lytic  and  lysogenic  lifecycles;  it  is  conceivable  that  one  of 
these  strategies  may  be  used  for  latent  infection  to  achieve  genome 
persistence,  whilst the other  may be  used during  productive  lytic replication. 
Whether  these  two  strategies  occur  separately  or  whether  a  switch  exists 
that  regulates  either  or  both  is  unknown  [38].  However,  HCMV  genome 
arrangement  is  believed  to  be  related  to  the  virus’s  replication  strategy. 
Bolovan-Fritts  et  al.  [39]  described  episomal  forms  of  the  HCMV  genome 
present  in  latently  infected  cells,  indicating  that  theta  replication  occurs 
during  latency  (where  viral  genomes  can  persist  in  infected  cells  without 
active  replication).  During  active  replication,  linear  concatamers  of  HCMV 
genomes  were  produced,  potentially  allowing  the  gene  expression  from 
certain promoters required for full DNA replication [39].
Viral  DNA  replication  requires  proteins  working  in  trans through  a  c/s-acting 
replicator  sequence  (or/-Lyt)  that  is  found  within  the  UL  region  [40].  The 
expression  of  eleven  genes  is  required  for  or/-Lyt-mediated  replication. 
These include an origin-binding protein,  pUL84,  which  associates with  IE2579
[41],  a single stranded  DNA-binding protein  (pUL57)  [42],  a helicase-primase 
complex  encoded  by  the  genes  UL70,  UL102,  UL105  [42]  and  the  DNA 
polymerase  itself  UL54  with  its  accessory  factor,  a  double  stranded  DNA- 
binding  protein  pUL44,  which  also  co-precipitates  with  the  uracil-DNA 
glycosylase homolog ppUL144 [43].
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The  replication  mechanism  used  by  HCMV  is  believed  be  analogous to that 
of  other  herpes  viruses.  Initial  binding  of  pUL84  to  the  origin  of  replication 
initiates  the  cycle  [44],  where  it  is  subsequently  joined  by  the  helicase- 
primase complex  and  pUL57 [45],  which  respectively  unwind  helical  DNA at 
the replication fork, whilst priming for synthesis of the lagging strand and also 
preventing  the  re-annealing  of  unwound  single-stranded  DNA  sequences
[42].  These  complexes  create  a  bubble  in  the  episome that,  when joined  at 
either  end  by  the  polymerase  complex,  proceeds  to  unwind  the  double 
stranded  DNA  and  replicate  the  single  strands  in  both  directions;  once  this 
cycle is complete one strand is displaced and replication continues using the 
remaining strand [42].
Rolling  circle  replication  occurs  when  the  circularised  genome  is  cut 
producing  a  3’  hydroxyl  group  and  a  5’  phosphate  group  [46].  Nucleotides 
are added to the 3’ end synthesizing a new DNA strand using the inner circle 
of  DNA  as  a  template;  this  displaces  the  5’  end  causing  it  to  form  linear 
double-stranded  DNA  through  lagging-strand  DNA  synthesis,  which  is  then 
cleaved forming  genome-length concatamers  [46].  Cleavage  occurs through 
a terminase  complex  that  is  composed  of  pUL56  [47]  and  pUL89  cutting  at 
the  p a d   site  [48].  The  pUL89  gene  product was  shown  to  be  a  part  of this 
complex  as  BDCRB  (2-bromo-5,6-dichloro-1-beta-D-ribofuranosyl 
benzimidazole  -   a  potent  inhibitor  of  HCMV  DNA  processing  and  packing) 
resistance  maps  to  it  [49,  50].  pUL56  also  associates  with  linear  DNA  and 
viral  nucleocapsids  in  vivo,  and  it  has  been  suggested  that  pUL56  first 
associates  with  concatameric  DNA  through  recognition  of  splice  motifs
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known  as  pac sequences  [51].  Binding  at these  sites  recruits  pUL89,  which 
cleaves the  linear DNA into genome  length copies;  pUL56 is then thought to 
drive  the  translocation  of  the  concatamer-terminase  complexes  in  to 
procapsids  using  an  ATP-dependent  process  [52,  53].  Because  pUL56  is 
known  to  interact  with  procapsids  this  may  be  an  early  phase  of  DNA 
processing  and  packing for the assembly of  mature virions  by a  mechanism 
analogous to that found in bacteriophages [49].
1.3.  3 DNA packaging and virus assembly
Upon  cleavage  at the  pac sites,  unit-length  HCMV  DNA,  in  a  complex  with 
pUL56,  pUL89  and  UL104,  then  associates  with  the  preformed  HCMV 
capsids.  UL104 is believed to act as a portal protein that allows the viral  DNA 
into  the  capsid  [54].  Pac-2-directed  cleavage  causes  the  end  of  the 
sequence,  denoted the S-terminal fragment, to be preferentially inserted  into 
the  maturing  capsid  rather  than  the  L-terminal  fragment  near  the  pac-1 
element [55, 56].
The  assembly of  procapsids  is  controlled  by the  major capsid  protein  (MCP 
or  UL86  [57])  and  the  precursor  assembly  protein  protease  (pAP  or  UL80), 
which  is auto- cleaved to yield AP complexes  [58].  These  proteins  associate 
in the cytoplasm  and their interaction allows the translocation of the resultant 
complex into the  nucleus [58,  59]. Once there, AP precursors form a scaffold 
around  which  minor  capsid  protein  (mCP),  along  with  me  and  bp,  form 
trimeric  complexes,  which  in  turn  produce  hexons  and  pentons.  Together 
these  form  the  dense  core  ring  inside  the  pro-capsids.  The  small  capsid
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protein  (SCP,  UL48/49 [60]) then binds to the surfaces of procapsids and the 
MCP-AP  complex  dissociates  through  proteolytic  cleavage  mediated  by 
UL80  [61].  Following  this,  viral  DNA  is  packaged  into  the  pro-capsids, 
displacing AP, this process  is  mediated by the UL97-encoded protein  kinase 
[62,  63].  The  virus  particle  then  buds  from  the  nuclear  membrane, 
incorporating  several  virus  glycoproteins  during  the  process  [4].  However, 
although  some  of  the  mature  virions  incorporate  glycoproteins  and  lipid 
envelopes that are initially derived from the nuclear membrane, the tegument 
proteins are incorporated while this virus in the cytoplasm. This indicates that 
there  is  a  process  of  re-envelopment  occurs  that  allows  incorporation  of 
tegument  proteins  [64,  65].  Transport of the virus  particle to the  cell  surface 
is  inhibited  by the Golgi-disrupting agent brefeldin  A,  indicating that it occurs 
via the  Golgi  [66,  67],  which  would  consequently  allow the  N-  and  O-linked 
glycosylation of the virion constituents. The accumulation of virus  particles in 
the  golgi  causes  the  formation  large  inclusion  bodies  causes  a  distortion  in 
the  shape  of  the  nucleus  giving  it  a  kidney  bean-like  appearance  [4]. 
Together these  phenomena  can  be  observed  under  a  light  microscope  and 
give  the  characteristic  Owls  eye  cytopathology  associated  with 
cytomegalovirus infection [68].
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1. 4 Epidemiology and Transmission
HCMV  infection,  which  is  usually  assessed through  the  presence  of  HCMV- 
specific  IgG  antibodies,  is  almost  ubiquitous  with  seroprevalence  ranging 
between  70-100%  [69].  Seropositive  individuals  shed  HCMV  in  most  bodily 
fluids  including  blood,  saliva,  tears,  breast  milk,  cervico-vaginal  secretions 
and urine [4].  Numerous factors also influence the prevalence of HCMV such 
as:  socio-economic conditions,  hygiene  and  proximity of  contact with  others 
[70].  Prevalence  generally  increases  with  age  and  transmission  can  occur 
both  horizontally  and  vertically  [4].  Vertical  transmission  arises  as  a 
consequence  of  either  intrauterine  infection,  perinatal  infection  [71]  or 
through  ingestion of breast milk [72,  73],  which  itself accounts for the bulk of 
vertical infections [74]. Transplacental  HCMV transmission is most frequently 
associated with  neonatal  morbidity although only 5% of congenitally infected 
babies display symptoms [75].
Horizontal  transmissions  occur  throughout  life  but  are  most  commonly 
acquired  during  childhood  [76].  Child-to-child  transmission  in  day  care 
centres  is  responsible  for  many  early  infections  [76],  possibly  through 
‘mouthing’  of  hands  and  toys  by  infants  [77-79]  .  Sexual  contact  is  an 
important  means  of virus spread  in  later life,  where  an  individual  is  exposed 
to bodily fluids from an infected partner [80].
The  majority  primary  infections  following  horizontal  transmission  are 
asymptomatic  in  the  immunocompetent,  although  a  minority  of  cases  are 
associated  with  an  infectious  mononucleosis-like  syndrome  often  mistaken
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for  EBV  mononucleosis  [81].  The  incubation  period  of  HCMV,  which  takes 
into  account  the  date  of  primary  infection  and  the  onset  of  virus  shedding, 
has been predicted to be anywhere between four and eight weeks [82].
Following  primary  infection,  HCMV  achieves  life-long  latency  in  the 
immunocompetent.  Latency  can  be  defined  as  the  persistence  of  the  viral 
genome  that  cannot  be  detected  in  leucocytes  or  secretions  taken  from 
patients  by  conventional  laboratory  techniques  [83].  Latency  is  punctuated 
throughout  life  by  asymptomatic  sporadic  shedding  normally  controlled  by 
immune  responses  [83],  this  can  be  shown  through  detection  of  infectious 
virus particles in both urine and saliva [82].  Consequently,  HCMV-associated 
diseases  usually  occur  in  the  immunocompromised,  where  the  immune 
response  is  either  insufficient  or  inappropriate.  Examples  of  patient  groups 
most  likely  to  be  affected  by  HCMV-associated  diseases  are  -  neonates, 
HIV-infected  individuals  or  transplant  patients  who  require 
immunosuppression to prevent rejection of transplanted organs.
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1.5 Latency
Following  the  resolution  of  primary  infection,  HCMV  is  able  to  establish 
lifelong  latency.  One site of latency is the bone  marrow [84] where  HCMV  is 
thought  to  reside  in  CD34+  haematopoietic  progenitor  cell  populations  [84- 
86].  These  cells  differentiate  into  CD33+  CD10+,  CD1a+  and  CD14+  or 
CD15+  myeloid-committed  dendritic  cell  populations  on  infection,  this 
population supports HCMV latency while allowing the restricted expression of 
several latency-associated transcripts [86].
Full  reactivation  of  HCMV  from  latency  can  be  observed  when  latently- 
infected  monocyte-derived  DC  progenitor  cells  are  stimulated  either  with 
fibroblast-conditioned  medium  or  with  IFNy,  TNFa,  IL-4  or  GM-CSF;  this 
process leads to further differentiation  and/or activation  events in these cells 
[87-90].  Reactivation  of  murine  cytomegalovirus  (MCMV)  has  also  been 
shown  in  monocyte  that  were  induced  to  differentiate  into  mature 
macrophages [91-94].
Such  events  induce  the  MIEP  to  express  IE  genes  through  activation  of 
protein  kinase  C  (PKC)  and  nuclear factor kappa  B  (NF-kB)  [95].  These  are 
involved  in  the  remodelling  of  the  differentiation-dependent  chromatin 
structures  associated  with  the  promoter  [96,  97],  as  histone  acetylation  has 
been  shown  to  control  lytic  gene  expression,  thus  resulting  in  HCMV  lytic 
gene  expression  [32].  In  fully  permissive  cells  the  MIEP  associates  with 
acetylated histones, while in  non-permissive cells,  such as monocyte derived 
macrophages  (MDMs),  the  MIEP  associates  with  heterochromatin  protein  1,
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which  has  been  associated  with  a  gene  silencing  activity.  Differentiation- 
dependent  expression  patterns  of  HCMV  has  also  been  shown  in  other cell 
types that may similarly act as latency reservoirs [98].
These  issues  suggest  that  an  environment  where  the  latency  reservoir  is 
exposed  to  inflammatory  cytokines,  which  frequently  occurs  as  a  result  of 
physiological  stress to the  host,  induces the differentiation  and consequently 
activation of latently infected cells that in turn reactivates of HCMV [87].
Other  findings  suggest  that  whole  virus  particles  can  accumulate,  and 
therefore achieve latency,  in the vacuoles of monocyte-derived macrophages 
(MDMs)  [68].  These vacuoles  are  believed to derive from  the  golgi  complex 
but do not form  part of either the early or the  late endosomal  compartments, 
as  they  lack  endosome-associated  markers  such  as  rab5  and  transferring 
receptor  and  lamp  1   (CD107a)  and  Iamp2  (CD107b)  respectively  [68].  The 
kinetics  of  HCMV  replication  have  been  shown  to  be  slower  in  HCMV- 
infected  MDMs;  with  the  appearance  of  early  and  late  gene  transcripts 
peaking  at  5-7 days  post-infection compared with  infection  of fibroblast  lines 
which peaks at 5-48 hours [92].
Perturbations  in  the  microtubule  transport  networks  have  been  shown  to 
occur  in  MDMs  13-15  days  post-infection  [99].  This  would  have  several 
consequences:  vacuoles  would  be  prevented  from  fusing  normally  with 
lysosomes, thus enabling virus particles to avoid the immune response while 
preventing  virus  egress  [99]  and  the  fusion  of  vacuoles  with  the  plasma
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membrane  may also  result  in  cytopathic  effect  [68].  HCMV  is  also  known to 
infect  “immune  privileged  sites”  [97,  100]  such  as  the  retinal  pigment 
epithelium  (RPE),  infection  of  such  sites  would  render  the  virus  protected 
from  immune  responses  [97].  Furthermore,  HCMV  has  developed  multiple 
immune-evasion  strategies  that  would  render  many  infected  cells 
undetectable by immune surveillance (see below).
1. 6 Infection of Solid Organ Transplant Patients
Immunosuppressive  therapies  are  necessary  to  prevent  the  rejection  of 
donated  organs  in  patients  requiring  solid  organ  transplants.  Without  such 
regimens  the  cellular  immune  responses  of  the  recipient  would  reject  the 
donor  organ  on  the  basis  of  it  being  “non-self”.  However,  the  resultant 
decrease  in  T-cell  populations  would  predispose  patients  to  certain 
previously-controlled  infections,  such  as  CMV  -  these  in  turn  can  cause 
disease,  and  in  the  context  of  solid  organ  transplants  the  major  cause  of 
morbidity is HCMV.
Several  factors  affect  the  risk  and  severity  of  HCMV-associated  disease, 
such as the level and duration of immunosuppressive treatments, the organ’s 
source  (i.e.  live  or cadaveric  donor),  poor  HLA-matching  of the  organ  to the 
recipient, the type of organ transplant and,  most crucially, the donor/recipient 
HCMV serostatus [101,  102]. As mentioned previously,  HCMV remains latent 
in  the  majority  of  individuals  but  can  be  reactivated  by  immunosuppressive 
therapies, cytotoxic drugs and  inflammation.  Inflammation would  result in the 
release  of  inflammatory  cytokines  such  as  tumour  necrosis  factor-alpha
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(TNFa);  these,  in  turn,  activate  nuclear transcription  factors  such  as  NF-kB 
and PKC, which stimulate the HCMV major immediate early promoter (MIEP) 
and  allow  HCMV  to  reactivate  from  latency  [103-105].  It  has  been 
demonstrated  in  numerous  patient groups that the  extent to which  the virus 
replicates,  as determine by the viral  load, can also be a determining factor of 
determining the risk of disease  [106-108].
In  transplant  patients  HCMV  replication  may  result  either  from  the  primary 
infection  of  a  seronegative  recipient  by the  organ  from  a seropositive  donor 
(D7R'),  a  reinfection  from  the  seropositive  donor  organ  in  a  seropositive 
recipient  (D7R+)  [109]  or  through  reactivation  of  virus  in  the  seropositive 
recipient  (D7R+ or  D*/R+)  [110].  Because  60-80%  of  adults  are  seropositive 
for  HCMV  the  likelihood  that  either  the  donor  or  the  recipient  harbours  the 
virus is high.  In the context of renal transplant patients,  15-50% excrete virus 
post-transplant  and  of  these  30-40%  develop  HCMV-associated  disease 
[106,  111].  Patients  can  be  divided  into  high  and  low-risk  categories  based 
on their susceptibility to developing  HCMV-associated disease.  Individuals at 
highest  risk of developing  HCMV-associated  disease  are  patients who were 
seronegative  (D R )prior to transplant and  receiving organs from seropositive 
donors (D+R ) [70].
Low-risk  patients,  such  as  those  who  are  either  HCMV-seropositive  prior to 
transplant or those that receive an organ from a seronegative donor,  can still 
experience  febrile  illness  and  end-organ  disease  through  virus  reactivation, 
although this  is  less  likely to cause serious illness [109].  HCMV-seropostivity
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consequently  affords  a  level  of  protection  against  HCMV-disease;  this  may 
be  due  to  pre-existing  humoral  or  virus-specific  cellular  component  of  the 
immune  responses,  which  may  be  retained  to  some  degree  despite 
immunosuppression.  Seropositive  patients  can  still  suffer  from  HCMV 
disease  should  they  receive  an  organ  from  a  seropositive  donor,  these 
incidences  of  disease  probably  occur  as  a  result  of  reinfection  from  the 
seropositive  organ  rather  than  through  reactivation  of  the  virus  by  the 
recipient [109].
Determination  of  HCMV  serostatus  prior  to  transplant  therefore  gives 
valuable  prognostic  information  on  the  potential  risk  of  HCMV-associated 
disease.  It also  allows the  incidence  of  disease to  be drastically  reduced  by 
avoiding  the  transplantation  of  organs  from  seropositive  donors  to 
seronegative  individuals;  although this  is  not  always  possible  due to the  low 
number  of  donors,  consequently  high  risk  individuals  need  to  be  identified 
and  may be placed on  antiviral  regimens to  reduce the potential  for infection 
and possible subsequent disease.
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1. 7 HCMV Pathology
Without  treatment  up to  60%  of  high-risk  D+R'  renal  transplant  patients  will 
develop  HCMV  disease from  the  resultant  primary  infection  [105,  112].  This 
can  either  be  a  self-limiting  syndrome,  which  includes  symptoms  such  as 
leukocytopenia,  fever,  malaise  and  febrile  illness  manifested  during  virus 
excretion - both are resolved in the majority of patients [4]. Yet some of these 
patients  progress to  develop  more  severe  HCMV-associated  diseases  such 
as  pneumonitis,  retinitis,  nephritis,  gastrointestinal  ulceration,  severe  hepatic 
dysfunction  and  impaired graft function  [4].  Individuals in this  high-risk group 
have  no  pre-existing  virus-specific  immunity;  their  requirement  for 
immunosuppression also  limits the number of T-cells available to establish  a 
subsequent  HCMV-specific  adaptive  response.  Immunosuppression  also 
predisposes  individuals  to  secondary  infection  by  pathogens  such  as 
Pneumocystis  jiroveci  and  carinii,  Candida,  Nocardia  asteroids, 
Cryptococcus  neoformans  and  Aspergillus  along  with  other  bacterial 
pathogens  [113,  114].  In  fact  >90%  of  solid  organ  transplant  patients  have 
been  reported  to  have  developed  these  infections  while  they  were  infected 
with either HCMV of other immuno-modulating viruses,  indicating that HCMV 
could result in further immune-suppression [115].
Primary  HCMV  infection  has  also  been  linked  with  allograft  injury  (through 
fibrosis),  dysfunction  and  rejection,  although  the  exact  mechanisms 
mediating  rejection  are  unclear.  It  is  possible  that  HCMV  can  do  this  either 
directly through  expression  of  MHC-I  homologues  on  infected donor cells  or 
indirectly  through  the  altered  expression  patterns  of  MHC  molecules  that
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occurs  as  a direct  result of infection,  these would  render infected cells  more 
vunerable  to  recognition  and  subsequent  rejection  as  “non-self”  [116,  117]. 
Other indirect effects of  HCMV that  may  mediate  rejection  could  include the 
virus’  ability to  upregulate  the  expression  of  proinflammatory  cytokines  and 
adhesion  molecules.  Indeed,  HCMV infection  has  been shown to  upregulate 
expression of adhesion molecules  ICAM-1  (CD54) and LFA-3 (CD58)  in vitro 
despite the presence of ganciclovir and foscarnet, indicating that this process 
is  mediated  by  early  virus  transcripts  and  may  also  exacerbate  organ 
rejection  [118].  HCMV  infection  of  fibroblasts  has  been  shown  to  directly 
upregulate  secretion  of  the  proinflammatory  cytokines  IL-6  and  fractalkine 
[119],  both of which have antiviral activities in addition to being able to cause 
vascular inflammation and may also result in rejection [120].
Although  it  occurs  infrequently  in  solid  organ  transplants,  HCMV  retinitis  is 
common  in  other  immunocompromised  groups.  HCMV-infected  retinal 
pigment epithelial  (RPE)  cells  are  exposed to  higher levels  of both  IFNyand 
TNFa.  These  cause  HCMV  reactivation,  via  a  NF-KB-independent 
mechanism  [121]  and  immunopathology  ensues  through  upregulation  of 
FasL  by  immediate  early/early  viral  transcripts  on  infected  cells  [122,  123]. 
Ligation  of  Fas  expressed on  activated  leucocytes  by  FasL on  infected cells 
results  in their apoptosis,  an  acute  infection  can  normally be  resolved  in this 
way  but  chronic  virus  replication  may  result  in  the  prolonged  destruction  of 
the RPE and hence retinitis.
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Some pathologies that occur as a result of  HCMV infection  may be  immune- 
driven  where  virus  specific  immune  responses  result  in  the  destruction  of 
HCMV-infected  tissues.  Pneumonitis  is  one  such  example;  detection  of  NK 
cells  and  CD4+  and  CD8+  T-cells  has  been  shown  in  the  bronchoalveolar 
lavage  (BAL)  of bone  marrow transplant patients and  proposed to  contribute 
to  inflammation through  destruction  of  HCMV-infected  lung  tissue  [124].  Yet 
increased  frequencies  of  infiltrating  CD4+  and  CD8+  T-cell  have  previously 
been shown to be protective against pneumonitis,  and frequencies of both of 
these T-cell  populations  are  much  decreased  in these  individuals  compared 
to  normal  healthy  controls  [125].  It was therefore  suggested  that  a  possible 
cause  of  this  inflammation  was  the  secretion  of  high  levels  of  TNFa  by 
alveolar  macrophages  stimulated  by  NK  cells  through  IFNy  [125].  HCMV- 
driven  immunopathology  through  virus-specific  CD8+  T-cell  has  also  been 
suggested  as  a  cause  of  gastrointestinal  disease  in  HIV-1  co-infected 
individuals.  Here  gut-associated  lymphoid  tissues  (GALT)  from  two  HIV-1- 
infected  individuals  with  chronic  diarrhoea  were  shown  to  contain  high 
frequencies of HCMV-specific CD8+ T-cells [126].
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1.8 Drugs
1.8.1  Immunosuppressive Drugs for Solid Organ Transplants 
Cyclosporin
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Figure 1. 4 Cyclosporin
Cyclosporin is cyclic peptide of  11  amino acids that was isolated in Norway in 
1970  from  two species  of fungus  [127,  128].  It functions  by  associating  with 
cyclophilin and this heterodimeric complex then inhibits the dephosphorylase 
activity  of  calcineurin,  which  prevents  the  translocation  of  the  nuclear factor 
for  activated  T-cells  (NFAT)  into  the  nucleus  [129,  130],  where  it  would 
otherwise  activate  the  transcription  of  IL-2  and  other  cytokines  [131-134]. 
Since  IL-2  major  growth  factor  for  T-cells  a  lack  of  IL-2  results  in  the 
inhibition of T-cell proliferation.
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Tacrolimus
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Figure 1. 5 Tacrolimus
Similar  to  cyclosporine,  Tacrolimus  (FK506)  is  a  fungal  metabolite;  in  this 
case it was isolated from Actinomyces spp38 [130,135]. Together with FKBP 
(FK506-binding  protein)  it  forms  a  complex  that  inhibits  the 
dephosphorylation  activity  of  calcineurin  [128],  thereby  preventing  the 
transcription of IL-2 and thus prevents lymphoproliferation [128,  136].
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Mycophenolate mofetil
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Figure 1. 6 Mycophenolate mofetil
Mycophenolate  mofetil  (MMF  or  RS-61443),  is  the  ester  derivative  of 
mycophenolic acid (MPA). Once ingested,  MMF is hydrolyzed in the intestine 
and blood by esterases to become  MPA,  which  reversibly inhibits eukaryotic 
inosine  monophosphate  dehydrogenases  (IMPDH)  [137].  This  prevents  the 
de  novo  synthesis  of  guanosine  monophosphate  (GMP)  [138-140],  which 
consequently  leads  to  decreased  levels  of  guanosine  triphosphate  (GTP) 
and  hence  reduces  deoxyguanosine  triphosphate  (dGTP)  [141].  This  has  a 
cytostatic  effect  on  cells,  which  is  more  pronounced  in  lymphocytes  than  in 
other  cell  types  as  they  require  de  novo  synthesis  of  purine  nucleotides 
whereas other cells do not [142].
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Corticosteroids
Prednisolone is one of a family of immunosuppressive corticosteroids used in 
the transplantation  milieu.  These  are  believed  to  associate  with  intracellular 
glucocorticoid  receptors  (GRs).  Together  these  complexes  move  into  the 
nucleus where they dimerize and then bind GR-binding  motifs at target gene 
promoters  and  block  expression  of  various  genes  encoding  cytokines  and 
enzymes  [130,  143,  144].  There  is  also  evidence  that  corticosteroids  can 
suppress  transcription  factors  such  as the  Jun/Fos  complex  (AP1)  and  NF- 
kB,  thereby  preventing  the  transcription  of  genes  such  as  IL-2  and  other 
cytokines [130,  145,  146].
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1.8.  2 Antiviral Therapy
There  are  two  main  strategies  for  preventing  HCMV  disease  in  transplant 
patients:  prophylactic  and  pre-emptive therapy.  Prophylactic therapy can  be 
further  subdivided  into  universal  prophylaxis  -  where  antivirals  are 
administered  universally  to  all  patients  post-transplant,  and  targeted 
prophylaxis - where antiviral drugs are administered to all individuals deemed 
to  be  at  high  risk  of  developing  HCMV-associated  disease,  such  as  those 
that  are  D7FT,  commencing  immediately  after transplantation.  Incidences  of 
HCMV replication in liver transplant patients undergoing prophylaxis with oral 
ganciclovir  has  been  shown  to  be  significantly  reduced  [147].  Prophylactic 
administration of three daily doses of oral ganciclovir or a once-daily dose of 
valganciclovir for 100 days post-transplant were compared in >350 D+R' solid 
organ  transplant.  Results  demonstrated  valganciclovir  to  be  better  at 
preventing  HCMV  disease  during  the  period  of  prophylaxis  than  patients 
treated  pre-emptively  [148,  149].  Prophylaxis  is  also  preferable  for  the 
treatment  of  other  herpes  virus  infections  and  in  reducing  the  risk  of  HCMV 
mediated graft rejection in transplant patients [150].
However,  several  studies  have  established  that  a  large  proportion  of  D+R' 
individuals  on  prophylaxis  display  HCMV  disease  in  the  proceeding  months 
following  cessation  of treatment,  therefore  prophylaxis  could  be  argued  only 
to  delay  the  onset  of  HCMV  disease  and  not  prevent  it  [114,  147,  148]. 
Other  potential  problems  include  the  unnecessary  treatment  of  individuals 
who  would  not  develop  HCMV  with  antiviral  drugs;  not  only  would  this  be 
expensive,  but  it would  result in the patients being  exposed to the potentially
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toxic  side-effects  of  the  antiviral  drugs.  Indeed,  prolonged  prophylaxis  with 
ganciclovir  and  foscarnet  is  myelosuppressive  and  may  result  in  mortality 
due  to  fungal  infection  and  HCMV  disease  [151,  152].  There  is  also  an 
increased  risk  of  the  emergence  of  ganciclovir  resistant  mutants,  with 
mutations  predominantly occurring  in  UL97 and  UL54 genes,  in patients that 
are  subjected  to  prolonged  treatment  with  suboptimal  levels  of  ganciclovir 
[153].
Pre-emptive therapy  (PET)  is  in  many ways a preferable strategy as  it  relies 
on  frequent  monitoring  of transplant  patients  for  HCMV  replication  by  either 
antigenemia  or  frequent  measurements  of  viral  load  [154].  Treatment  is 
initiated  only when  virus  replication  is detected,  thus  preventing  exposure of 
non-viraemic  patients  to  the  toxic  side-effects  of  the  drugs,  whilst  also 
minimizing  the  costs  [155]  .  However,  this  method  relies  on  the  ability  to 
rapidly  and  reliably  detect  systemic  virus  replication  and  frequent  and 
prolonged monitoring of individuals at high risk of developing disease.
Studies  have  shown  pre-emptive  therapy  with  ganciclovir  to  be  more 
effective  in  preventing  HCMV  disease  in  liver  transplant  patients  than 
prophylaxis with  aciclovir,  with  4%  patients on  pre-emptive therapy suffering 
HCMV  disease  compared  to  29%  on  aciclovir  prophylaxis  [156].  Another 
comparison between  prophylactic and pre-emptive therapy,  using ganciclovir 
on  lung  transplant  patients,  showed  pre-emptive  therapy  to  be  as  safe  but 
also  more cost-effective  [155].  One important advantage of  PET is that  high- 
risk  D+R  patients  are  exposed  to  small  amounts  of  virus  antigen  prior  to
50Chapter 1: Introduction
initiation  of  therapy,  these  would  be  available to  the  immune  system  during 
the  initial  replicative  burst  [151,  154].  Such  antigen  exposure  should  be 
sufficient  to  prime  adaptive  HCMV-specific  humoral  and  cell-mediated 
responses  that  would  be  useful  for  controlling  future  episodes  of  HCMV 
replication  [157].  This  might  explain  why  a  large  proportion  of  individuals 
subjected  to  prophylactic  treatment  suffer  HCMV  viraemia  in  the  6  months 
after  cessation  of  prophylaxis  [157].  Studies  in  bone  marrow  transplant 
patients  comparing  the  use  of  pre-emptive  ganciclovir  to  prophylactic 
ganciclovir  showed  an  increase  in  both  the  incidence  of  invasive  fungal 
infections  and  the  incidence  of  other virus  infections  in  individuals  receiving 
ganciclovir  prophylaxis  [158],  although  this  is  probably  due  to  the 
neutropenia associated with prolonged use [158].
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Ganciclovir (and Valganciclovir)
Ganciclovir
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Figure 1. 7 Ganciclovir
Ganciclovir  (9-(1,3-Dihydroxy-2-propxy)-methylguanine,  GCV)  is  a 
deoxyguanosine  analogue.  It  has  a  much  improved  (one  hundred-fold) 
efficacy  against  HCMV  infection  compared  to  HSV  infection  [159].  Although 
HCMV  lacks  a thymidine  kinase,  mono-phosphorylation  of  GCV  is  achieved 
by the  HCMV-encoded  protein  kinase,  UL97  [160,  161].  GCV  is  successive 
di-  and  tri-phosphorylated  by  cellular  kinases  [161].  The  tri-phosphorylated 
form  of  ganciclovir  selectively  inhibits  the  viral  DNA  polymerase  by 
competing  with  dGTP  for  incorporation  into  the  elongating  viral  DNA. 
However,  unlike  acyclovir  it  is  not  an  obligate  chain  terminator  because  of 
the  presence  of  a  3’  hydroxyl  group,  this  also  results  in  some  cell  toxicity 
[162].  GCV  resistance  maps  to  at  least  one  mutation  at codons  460,  520  or 
591-607 [163-165] within the UL97 locus,  as this gene product alone controls 
phosphorylation  of  GCV  in  HCMV-infected  cells  [166-168].  Other,  rarer, 
resistance mutants also map to the viral  DNA polymerase  UL54 [163]. These
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may  occur  as  a  result  of  the  prolonged,  sub-optimal  use  of  GCV  during 
maintenance therapies or possible as a result of prophylaxis.
In  infected  cells  GCV  triphosphate  accumulates  to  levels  that  are  one 
hundred-fold  higher  than  in  uninfected  cells  [169].  Ganciclovir  has  proven 
useful  in the treatment of  HCMV retinitis in  HIV patients [170],  although side- 
effects  such  as  granulocytopenia  and  thrombocytopenia  can  occur  as  a 
result  of  its  use  [171].  Furthermore  oral  administration  of  GCV  has  the 
increased  benefit  in  retinitis  treatment  of  having  fewer  side-effects,  such  as 
sepsis  and  neutropenia,  which  are  associated  with  intravenous 
administration  [172].  Treatment  of  pneumonitis  with  ganciclovir  has  been 
shown to be a success in renal transplant patients [173], although not in BMT 
patients [174].
Valganciclovir  is  a  valine  ester  prodrug  of  ganciclovir,  which  increases  the 
oral  bioavailability  of  ganciclovir  [175].  Activation  of  valganciclovir  into 
ganciclovir  occurs  on  its  hydrolysis  by  intestinal  and  hepatic  esterases;  its 
subsequent  mode  of  action  is  therefore  the  same  as  ganciclovir.  Plasma 
drug  levels  achieved  with  oral  900mg  valganciclovir  once-daily  are  1.7-fold 
greater than to  10OOmg of ganciclovir taken thrice-daily and is as effective as 
three daily does of 5mg/kg ganciclovir taken intravenously (i.v.) [175,  176].
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Foscarnet
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Figure 1. 8 Foscarnet
Foscarnet  (Trisodium  phosphoformate)  is  a  organic  analogue  of  inorganic 
pyrophosphate  [177,  178].  Foscarnet  functions  by  non-competitively 
inhibiting  the  virus  DNA  polymerase  by  blocking  the  pyrophosphate-binding 
site  [179].  Foscarnet  is  able to the  inhibit replication of all  herpes  virus  DNA 
in  vitro and also  has  been shown to  have antiretroviral  activity.  Furthermore, 
at  treatment  concentrations  foscarnet  does  not  bind  to  eukaryotic  DNA 
polymerases.  It  is  used  as  an  alternative  treatment  in  individuals  with 
ganciclovir resistance,  and  is particularly effective  in the treatment  of  HCMV 
and  HIV  retinitis  in  AIDS  patients,  where  it  benefits  from  its  antiretroviral 
activity [180,  181].  The  main draw-backs of its  use are its  high  nephrotoxicity 
and  its  poor  oral  bioavailability,  which  requires  it  to  be  administered 
intravenously three times daily [182].
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Cidofovir
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Figure 1. 9 Cidofovir
Unlike  other  nucleoside  analogues  Cidofovir  does  not  require 
phosphorylation  by  viral  thymidine  kinases  or  HCMV  UL97  to  achieve  its 
antiviral  effect.  It  is  instead  phosporylated  to  its  active  form  (Cidofovir- 
diphosphate)  by  cellular  enzymes,  which  are  present  in  both  infected  and 
non-infected  cells  [183].  Cidofovir-diphosphate  competitively  inhibits  dCTP 
incorporation  into  the  elongating  DNA  by  DNA  polymerase  [183,  184]. 
Cidofovir  also  has  a  prolonged  half-life  when  compared  to  ganciclovir  and 
foscarnet;  this  enables  less  frequent  administration  of  treatment  which  is 
required to be administered  intravenously (either once weekly or every other 
week)  [171].  Like foscarnet cidofovir is highly nephrotoxic and must therefore 
be administered with probenecid to prevent irreversible kidney damage [185]. 
It  has  been  used  successfully  in  the  treatment  of  HCMV-retinitis  in  AIDS 
patients [186].
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1. 9 Immune Responses to HCMV
As  mentioned  before,  HCMV  establishes  a  life-long  latent  infection  in 
myeloid-lineage  cells  in  immunocompetent  individuals  [87],  with  sporadic 
virus  shedding  occurring  at  mucosal  surfaces.  Innate  immune  responses 
(such as those provided by natural  killer cells and complement)  and  humoral 
immune  responses  both  play  important  roles  in  controlling  HCMV  infection. 
Adaptive  cellular  immune  responses  are  crucial  in  controlling  HCMV 
replication  and  any  disruption  in  T-cell  responses;  either  through 
immunosuppressive  treatments  required  by  transplant  recipients  or 
becoming  immunocompromised  following  infection  with  HIV  leads  to 
uncontrolled virus replication and HCMV-associated disease.
1.9.  11nnate immune responses to HCMV
1.9.1.  1   NK cells
Natural  killer  (NK)  cells  provide  protection  against  primary  HCMV  infection, 
clinical  evidence  supporting  this  comes  from  reports  of  a  NK  cell-deficient 
patient  who  succumbed  to  severe  HCMV  infection  [187].  NK  cells  are 
recruited to infected tissues and activated by  macrophage-derived cytokines, 
such as  IL-12,  TNFa,  IFNa and  IFNp,  induced by HCMV infection between  2 
to  4  days  post-infection  [188].  Synergistic  stimulation  of  NK  cells  by  IL-12 
and  TNFa  also  increases  the  ability  of  NK  cells  to  produce  IFNy [189].  NK 
cells  are  able  to  recognise  virus-infected  cells  through  alterations  in  MHC 
class  I  expression  or  glycosylation  of  other  cell-surface  glycoproteins  that 
occur  as  a  result  of  viral  infection,  leading  to  the  “missing-self”  hypothesis 
[190].  On  ligation  with  a  further  ‘activation  signal’,  provided  by  ligation  of
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molecules  such  as  NKG2D,  NK cells  are  able  to  lyse  infected  cells  through 
release  of  cytotoxic  granules  [191].  Following  stimulation  with  IL-12  (in 
synergy with TNFa) NK cells are also able to secrete large quantities of IFNy, 
which  attract  and  activate  components  of  both  innate  and  naive  adaptive 
immune responses [188].
Avoidance of NK responses by HCMV
HCMV-mediated  down-regulation  of  MHC  I  molecules  on  infected  cells 
serves  as  a  mechanism  for  avoidance  of  the  CD8  T-cell  response  (see 
below).  However,  it  renders  infected  cells  more  susceptible  to  NK  cell 
recognition.  HCMV  has  therefore  developed  multiple  strategies  for  NK  cell- 
avoidance;  these  include  encoding  decoy  inhibitory  molecules  on  infected 
cells,  which  are  able to  ligate  inhibitory  receptors  on  NK cell  surfaces  [192]. 
One  HCMV  decoy  molecule  is  the  MHC  I  homologue  -  UL18,  which 
associates  with  p-microglobulin  [193].  This  complex  migrates  to  the  cell 
surface where it prevents  NK cell-mediated  lysis by associating with the  NK- 
inhibitory  receptor  CD94  [194,  195].  Expression  of  UL18  has  been  shown 
previously  in  PBMCs  isolated  from  immunocompromised  organ  transplant 
patients  suffering  active  HCMV  replication,  this  suggests  that  UL18 
expression  occurs  coincidently  at  a  time  of  potential  NK-mediated  lysis, 
possibly preventing recognition of  infected cells [196].  The cellular receptors 
for  UL18  have  since  been  found  to  be  related  to  killer  inhibitor  receptors 
(KIRs) found on the NK cells [197,  198].
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HCMV  infection  also  upregulates  the  expression  of  a  non-classical  MHC  I 
molecule  -  HLA-E,  on  the  surface  of  infected  cells  [199,  200]  through  the 
expression  of  the  leader peptide  of  gpUL40.  The  product  of the  UL16  gene 
has  been  found  to  bind  UL16-binding  proteins  (ULBPs)  [201];  these  are  a 
family  of  MHC  class  l-like  molecules  that  bind  NK  cells  by  interacting  with 
NKG2D  molecules  on  their  surfaces.  Through  intracellular  sequestration  of 
NKG2D-binding  proteins [202],  UL16  prevents them overriding the inhibitory 
signals  provided  by NK cell  recognition of MHC  I  molecules thereby allowing 
NK-mediated  cytolysis  [203].  More  recently  UL141  and  UL142  have  been 
shown to block  NK cell  activity.  UL141  is thought to achieve this  by blocking 
the surface expression of CD155 on infected cells; this prevents it ligating NK 
receptors  CD96  and  CD226  and thus  blocks  NK  cell  activation  [204].  While 
expression of the  MHC  l-related  HCMV-encoded  UL142 gene  has also been 
shown to selectively inhibit lysis by certain NK cell clones in vitro [205].
1.9.1.  2 Complement-mediated immune responses
Complement  proteins  are  another facet of the  innate  immune  response  and 
can  function  in  a  variety  of  ways.  The  ‘alternative’  complement  pathway 
results  in  deposition  of complement complexes on  surfaces of virus-infected 
cells  causing  cell  lysis;  although  HCMV  can  circumvent  this  through 
upregulation  of  complement  control  proteins  (CCPs)  on  the  surfaces  of 
infected  cells  [206].  Complement  also  interacts  with  the  humoral  response, 
mediating  antibody-dependent  cytotoxicity  (ADCC)  via  the  Fc  portions  of 
virus-associated antibodies.  HCMV  is able to avoid this through  encoding  its 
own  Fc  receptor  homologues,  which  are  capable  of  binding  and  “mopping
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up”  opsonizing  antibodies  [207].  Furthermore,  virus  particles  have  been 
shown  to  incorporate  complement control  proteins,  CD46,  CD55  and  CD59, 
into  their  envelopes,  thus  reducing  complement-mediated  lysis  of  virus 
particles [206, 208, 209].
1.9.2 Adaptive immune responses
1.9.2.  1  Humoral immune response
Individuals known to be seronegative prior to solid organ transplant are more 
susceptible  to  HCMV-associated  disease  than  those  who  are  seropositive; 
Indicating  that  circulating  HCMV-specific  antibodies,  along  with  other 
adaptive  immune  responses  confer  some  degree  of  protection  against 
HCMV  disease  [4].  Moreover,  infusion  of  high-titre  HCMV-specific  sera  into 
pre-transplant  patients  reduces  the  incidence  of  disease  associated  with 
primary  infection  [210].  Antibody  responses  are  normally  directed  against 
viral  glycoproteins  B  (gB),  gN,  gM,  and  gH  [211],  the  tegument 
phosphoprotein  pp150  and  the  phosphoprotein  pp52  [212].  Predictably,  the 
majority  of  neutralising  responses  are  focused  towards  viral  envelope 
glycoproteins,  specifically  gB,  gH  [211]  and  the  heterodimeric  gN/gM 
complex  to  which  62%  of  seropositive  donors  mount  a  humoral  response 
[213,  214]  .  Within  gB  there  is  linear  antigen  determining  region  (AD-1) 
against which the  majority of seropositive  individuals  mount their gB-specific 
humoral  responses towards.  This  region  lies  between  codons  552-635  [215] 
and  is  highly  conserved  possibly  because  it  has  a  functional  role  as  an 
oligomerisation  site  required  for  the  formation  of  gB  multimers  essential  for 
the  production of infectious viruses [216].  In  addition to  being  able to directly
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neutralise  HCMV,  humoral  responses  can  also  work  in  tandem  with 
complement, as mentioned above.
1.9.2.  2 CD8+ cell response
Virus-specific  CD8+  cells  recognise  short  peptide  stretches  of  8-10  amino 
acid residues in length,  presented to them on the surfaces of infected cells in 
the context of  MHC  class  I  molecules,  which  are expressed on all  nucleated 
cells  [217].  The  peptides  are  normally  derived  from  endogenously 
synthesised  proteins,  such  as  those  produced  by  intracellular  parasites  like 
viruses  [218].  Proteins  are  cleaved  by  the  20S/26S  proteasome  [219,  220] 
and  transported  into  the  lumen  of  the  endoplasmic  reticulum  (ER)  by  the 
heterodimeric transporter associated with  antigen  processing  (TAP)  proteins 
[221].  Here the peptides are further trimmed to between 8-10 amino acids  in 
length  by  an  ER  aminopeptidase  [222-224].  The  newly-formed  MHC  class  I 
molecules  are  partially  folded  and  transported  to  the  lumen  of  the 
endoplasmic  reticulum  where  they  associate  with  the  chaperone  protein 
calnexin  [189].  When  the  Beta2-microglobulin  associates  with  the  MHC  I 
molecule calnexin  is displaced by a complex of different chaperone proteins, 
calreticulin  and  Erp57  [189].  The  unloaded  MHC  I  molecules then  associate 
with  TAP  proteins  through  the  adaptor  protein  tapasin  [217].  Peptide 
fragments  synthesised  in  the  cytosol  are then  transported  into  the  lumen  of 
the  ER  through  the  TAP  proteins  and  loaded  into  the  MHC  class  I  complex 
and complete the folding  process at which point the stabilised  MHC  l/peptide 
complex  is transported to the surface of infected cell via the golgi  apparatus. 
At the surfaces they can be recognised by the TCR of CD8+ T-cells [189].
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However,  the  interaction  between  the  peptide/MHC  I  complex  and  the  TCR 
alone is insufficient for the activation of naive T-cells,  and would  result in the 
formation  of  anergic cell  populations.  Subsequent co-stimulatory signals  are 
required  in  order  for  their  full  activation  [225]  (Fig.  1.10).  These  co­
stimulatory molecules are present only on the surfaces of antigen  presenting 
cells  (APCs),  such  as  dendritic cells  (DCs).  Following  antigen  uptake,  APCs 
home  to  secondary  lymphoid  organs  where  they  encounter  naive  CD8  and 
CD4 T-cell populations [189].
Co-stimulatory  molecules  include  CD40L,  which  interacts  with  CD40  on  the 
surface of the  naive T-cells [226],  and  members of the B7 family, which  bind 
CD28  or  CTLA-4  [227,  228].  Following  these  ligations,  T-cells  become 
activated  and  undergo  clonal  expansion;  giving  rise  to  a  population  specific 
for  the  presented  antigen.  In  the  case  of  CD8+  cells,  activation  allows 
recognition  of  specific  epitopes  on  the  surfaces  of  infected  cells  and  results 
in their subsequent lysis. This results either through  release of perforin  [229- 
231] and other lytic granules or through  ligation of the  Fas  Ligand [232-235]. 
Ligation  of  the  TCR  with  a  cognate  antigen  in  the  context  of  MHC  class  I 
results  in  the  mobilisation  of  intracellular  Ca2+  ions,  this  in  turn  signals  the 
mobilisation  of  secretory  granules  [236-238].  Pre-formed  granules  are  then 
transported,  in  a polarised  manner to the site of  stimulation via microtubules 
using  a  kinesin  family  motor  towards  the  microtubule  organizing  centre 
(MTOC).  The  MTOC  is  polarised  towards  the  point  of  contact  at  the 
immunological synapse and therefore  re-orientates the cytoskeleton towards 
the target cell  [238-241].  The  lysosome then  uses  actin-based  movement to
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travel  the  short  distance  from  the  periphery  of  the  cell  surface  to  the  cell 
surface  itself,  whereupon the  endosome and  cellular  membranes fuse  using 
SNARE and  Rab proteins and the contents of the lysosome are released into 
the  periplasmic  space  adjacent  to  the  target  cell  [189].  Both  the  release  of 
cytolytic  granules  and  the  ligation  of  Fas  receptors  on  target  cell  surfaces 
induces  an  apoptotic  response  and  thus  destruction  of  the  target  cell  [231, 
242, 243].
CTLs  are  also  effective  at  controlling  virus  replication  in  parts  of  the  body 
which would either be at risk of damage from a large cytolytic response, such 
as  the  brain  or  where  infected  cells  would  outnumber the  CTLs  by  several 
orders  of  magnitude,  such  as  in  the  liver.  Here  CTLs  can  control  virus 
infection  through  the  secretion  of  IFNy  and  TNFa  cytokines,  as  shown 
through  adoptive  CTL  transfer  experiments  in  HBV  transgenic  mice,  where 
virus clearance is not just mediated by lysis of infected cells on recognition of 
cognate peptide [244-247].  These cytokines are  not  released in the stringent 
polarised  manner that would be focused on an individual target cell; they are 
released  into the general  environment where they can  affect a  much greater 
number of infected cells without needing to destroy them directly [248].  IFNy 
also  functions  by  activating  macrophages  and  DCs;  enabling  them  to  better 
phagocytose  debris  from  virus  infected  cells  and  present  them  more 
efficiently  by  upregulating  presentation  by  of  MHC  class  I  and  II  molecules, 
which  would  in  turn  permit  better  recognition  by  other  CD8  and  CD4  T-cell 
populations.  Both  IFNy and TNFa can  also  activate  NK cells,  enabling  them
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to  better  recognise  infected  cells  and  produce  cytokines  such  as  IFNy 
themselves [189].
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Figure  1.  10 Activation of  Naive T-cells by antigen  presenting  cells  (APCs),  these 
take up the virus or viral proteins and present them either in the context of MHC I or 
II, to  CD8+  or CD4+   cells  respectively.  However, this  is  insufficient for activation  of 
the  T-cells  and  causes  anergy.  Co-stimulatory  signals  provided  by  B7/CD28 
interactions  provide  signals  for full  activation  and  expansion  of  antigen-specific  T- 
cell populations.
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CD8+  cells in HCMV infection
HCMV-specific  CD8+  cytotoxic  T-lymphocytes  (CTLs)  remain  the  adaptive 
immune  responses’  most  potent  method  of  controlling  HCMV  infection  and 
there  are  several  lines  of  evidence  to  support  this  statement.  First  an 
increase  in the CD8+ population  during  acute  HCMV  infection  coincides with 
recovery  in  immunocompetent  individuals  [249,  250].  Secondly,  adoptive 
transfer  of  HCMV-specific  CD8+  populations  into  immunosuppressed 
allogeneic  bone  marrow transplant  (BMT)  recipients  has  been  shown  to  be 
effective  in  preventing  HCMV  disease  and  controlling  virus  replication  [251, 
252]  .  It  has  also  been  demonstrated  that  HCMV-specific  CD8+  cells  are 
capable  of  killing  infected target cells  in  vitro [250],  and  can  afford  a certain 
degree  of  protection  from  HCMV  infection  in  stem-cell  and  renal  transplant 
patients  [253-256].  Immunodeficiency  that  results  either  from  HIV  infection 
or  through  immunosuppression  decreases  the  absolute  number  of  CD8+  T- 
cells,  these  in  turn  lead to  a  reduction  in the  ability of the  patients to control 
HCMV replication thereby predisposing them to associated diseases.
Targets of the HCMV-specific CD8+  response
The  majority  (70-90%)  of  HCMV-specific  CD8+  T-cells  responses  were 
initially  believed  to  be  targeted  against  several  epitopes  in  the  major  late 
lower matrix phosphoprotein,  pp65  (UL83)  [257],  with frequencies commonly 
reaching  10%  of  the  total  CD8+  populations  in  certain  healthy 
immunocompetent  and  immunocompromised  individuals  [258].  Indeed  Lang 
et  al.  [259]  described  one  healthy  seropositive  individual  with  50%  of  their 
total  CD8+  response  directed  against the  NLVPMVATV  epitope within  pp65.
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These CD8+ populations were found to be functionally more heterogenous in 
healthy  than  in  immunocompromised  individuals,  with  only  small 
subpopulations having any functional HCMV-specific cytolytic activity [260].
Being  a structural  component of the virus,  pp65  is processed  and  presented 
to the  alternative  MHC-I  pathway after virus  penetration  and  in  the  absence 
of  virus  gene  expression  [261].  Because  pp65  is  present  prior  to  the 
expression of immediate early genes it is also  able to phosphorylate another 
potent  CTL  target,  IE1,  thereby  preventing  its  proteosomal  processing  and 
subsequent association with  MHC  I  molecules [262]. This might enable pp65 
to remain the immunodominant protein  in the  majority of infected  individuals. 
However,  in  certain  immunocompromised  patient  groups  IE-1  has  been 
found  to  be  immunodominant  [263].  Reddehasse  [261]  suggested two  main 
reasons  for this  observation,  first,  mutations  occurring  in  the  kinase  domain 
of  pp65  prevents  it  from  being  able  to  phosphorylate  IE1,  and  thus 
abrogating  its  processing.  Second,  several  clinical  isolates  of  HCMV  have 
been  found  to  express  lower  levels  of  pp65;  which  could  render  them  less 
able to phosphorylate  IE1.  It is also conceivable that pp65-specific CD8+ cell 
populations  become  exhausted  due  to  the  strong  immunogenicity  of  the 
antigen,  leading to  increases in  populations specific for other targets  (see fig 
2  for  a  list  of  known  CD8  and  CD4  epitopes).  The  presence  of  pp65  in 
infected cells prior to viral gene expression  may also indicate that MHC  I and 
II  down-regulation  by  US2-11  gene  products  (see  below)  would  not  affect 
pp65 recognition and processing.
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Recent work  has  demonstrated that the  CD8+ T-cell  response  is  far broader 
than  previously thought  [264,  265].  Using overlapping  peptide sets  spanning 
the  entire  HCMV  proteome  other  targets  elucidated  in  this  study  included 
UL48  and  UL122  (IE2),  which,  along  with  IE1  and  pp65,  form  the targets to 
which the majority of individuals mount detectable HCMV-specific responses. 
Although  the  largest  responses  were  directed  against  IE1,  pp65,  UL82 
(pp71),  UL36  and  UL32,  which together appeared to form  the  bulk of  global 
HCMV-specific CD8+ responses a range of other proteins were also targeted, 
although  the  role of that the other  responses  play  in the  control  of  HCMV  is 
not yet fully understood.
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CD8+ epitopes
PP65 Start Length HLA Type Reference
NLVPMVATV 495 9 A2 [266]
VLGPISGHV 14 9 A2 [267]
MLNIPSINV 120 9 A2 [267]
QYDPVAALF 328 9 A24 [268]
VYALPLKML 113 9 A24 [269]
RPHERNGFTV 265 10 B7 [266]
TPRVTGGGAM 417 10 B7 [266]
EFFWDANDIY 511 10 B12 [262]
IPSINVHHY 123 9 B35 [270]
YYTSAFVFPTKDVAL 181 15 B35 [266]
VFPTKDVAL 187 9 B35 [266]
DDVWTSGSDSDEELV 397 15 B35 [266]
IHASGKQMWQARLTV 148 15 B52 [271]
GKQMWQARLTVSGLA 152 15 B52 [271]
TRQQNQWKEPDVYYT 169 15 ? [271]
NQWKEPDVYYTSAFV 173 15 ? [271]
IE1
YILEETSVM 315 9 A2 [272]
ELKRKMIYM 199 9 B18 [273]
CVETMCNEY 279 9 B18 [273]
DEEDAIAAY 379 9 B18 [273]
EEEEGAQEER 354 10 A2 [274]
VLEETSVML 316 9 A2 [275]
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CD4 epitopes
PP65 Start Length HLA Type Reference
LLQTGIHVRVSQPSL 41 15 DR15 (DQ6) [271]
IIKPGKISHIMLDV 281 14 DR53 (DQ3) [271]
GKISHIMLDVAFTSH 285 15 DR53 (DQ3) [271]
PQYSEHPTFTSQYRI 361 15 DR11 [276]
EHPTFTSQYRIQGKL 365 15 DR11 [276]
FTSQYRIQGKLEYRH 369 15 DR11 [276]
KYQEFFWDANDIYRI 508 15 DR52 [276]
FFWDANDIYRIFAEL 513 15 DR52 [276]
PPWQAGILARNLVPMV 485 16 ? [276]
AGILARNLVPMVATV 489 15 ? [276]
ARNLVPMVATVQGQN 493 15 ? [276]
IE 1
DKREMWMACIKELH 162 14 DR8 [277]
Table 1.1  List of known CD4 and CD8 epitopes identified in pp65 and IE1 
proteins
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CD8* responses during primary infection
Shortly  after  primary  infection  (~1  month),  a  powerful,  focused  HCMV- 
specific  CD8+  response  arises.  The  bulk  of  this  CD8+  population  has  a 
lymphocyte-homing  CD62L+  phenotype  and  expresses  high  levels  of 
granzyme  (GrA),  which  is  needed for induction  of apoptosis  in  infected cells 
[278]. The increase of this population corresponds with a decrease in HCMV- 
DNAemia  [279].  These  populations  control  the  initially  infection  and  then 
differentiate into different memory subpopulations that are maintained at high 
levels throughout life.
Memory CD8+  cells
In  normal  healthy  individuals  HCMV-specific  CD8+  T-lymphocyte  responses 
are  capable  of  controlling  virus  replication  [265].  Several  studies  have 
demonstrated that large,  heterogenous  HCMV-specific CD8+  populations are 
maintained throughout life, yet questions remain as to how these populations 
arise,  how  they  differ  functionally  to  populations  focused  against  other 
viruses and how they are retained [260, 280, 281].
Because  such  populations  are  virus-specific  and  remain  able  to  react  to 
sporadic virus reactivation indefinitely, they are often referred to as “memory” 
T-cells.  The  initial  paradigm  for T-cell  memory proposed that  naive cells and 
memory cells could  be differentiated through their phenotypes.  Naive T-cells 
expressed  the  RA  isoform  of  the  molecule  CD45,  while  memory  T-cells 
displayed  the  RO  isoform.  These  isoforms  arise  from  differential  splicing  of 
the  CD45  transcript  [282,  283].  However,  it  is  now  clear  that  CD45ROH lQ h
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populations  can  revert  back  into  a  CD45RAH igh  phenotype.  Furthermore,  it 
was initially believed that revertant cells, which were also CD28' and CCR7', 
were terminally  differentiated  and  would  thus  die  off.  CCR7  is  a  chemokine 
receptor  required  for  homing  to  secondary  lymphoid  tissues  [284]  therefore 
CCR7‘  T-cell  subsets  are  been  termed  “effector-memory”  populations 
because they  are found  in  peripheral  tissues  and  at sites  of viral  replication 
[284].  Similarly,  CCR7+  memory T-cells  are termed  “central  memory”  due to 
their  presence  in  secondary  lymphoid  organs.  During  persistent  HCMV 
infection  the  proportion  of  CD8+  cells  expressing the  co-stimulatory  receptor 
CD28+  diminishes  [285]  and  the  proportion  of  these  cells  that  become 
CD577CD85j+  increase  [286,  287].  This  phenotype  also  increases  with  age 
[288],  from this one can surmise that the older the individual, the less  naive, 
or  more  antigen-experienced,  the  T-cell  population  and  that  this  can  be 
driven by HCMV infection [289].
Wills  et  al.  reported  that  different  CD8+  sub-populations  arise  as  a 
consequence  of  HCMV  infection  [290].  Naive T-lymphocytes tend to  display 
a  CD45RAHi9h/CD287CD277CCR7+  phenotype,  while  during  acute  primary 
HCMV  infection  pp65-specific  CD8+  populations  display  a 
CD45ROHigh/CD287CD277CCR7' phenotype,  and  after recovery  most of this 
population  switches  to  a  CD45RAH,gh/CD28/C D 27/C C R 7'  phenotype;  this 
was  previously  thought  to  be  the  phenotype  for  terminally  differentiated  T- 
cells  [292]  .  Appay  et  al.  [291]  described  a  similar  HCMV-specific  CD8+  
population  in  healthy  seropositive  individuals;  demonstrating  that  the  same 
populations  to  exhibit  shortened  telomere  length  and  contain  high  levels  of
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GMP,  granzyme  A  (GrA)  and  perforin.  Following  in  vitro  stimulation  with 
HCMV peptides this  “terminally differentiated” population  regained the  ability 
to  undergo clonal  expansion,  reverted  back to the  RO  isoform,  up-regulated 
CCR5  (expression  of  which  is  associated  with  homing  to  inflamed  tissues, 
and retained strong cytolytic activity [290].
T-cell Memory in the Immunocompromised Host
Increases  in  the  proportion  of  HCMV-specific  CD8+  cells  in  HCMV- 
seropositive  liver  transplant  patients  were  noted  6  to  33  months  post­
transplantation  when  compared  with  healthy  seropositive  individuals  [293]  . 
These  cells,  which  were  predominantly  of  a  CD28 CD27'  phenotype,  also 
expressed  high  levels  of  granzyme  B,  perforin,  and  CD95  ligand  and  were 
thus classified as being “effector cells”. These populations are likely to be the 
same  as  described  in  healthy  individuals  [291].  However,  such  populations 
would  increase  in  magnitude  with  each  corresponding  bout  of  virus 
replication,  this  would  be  likely  to  result  in  increased  frequencies  of  these 
populations  in  the  immunocompromised  host.  Such  antigen-experienced 
“effector-memory”  populations with  increased cytolytic  potential  were termed 
“late-memory”  and  contrast  with  the  phenotypes  of  CD8+  memory  cell 
populations  that  become  enriched  following  chronic  infection  with  other 
viruses such as EBV,  HCV and HIV [291].
Gamadia  et al.  [294]  demonstrated that the  majority of  HCMV-specific CD8+  
cells  found  within  renal  transplant  patient  groups  on  immunosuppressive 
therapies  were  also  of  a  CD45RA/RO/CD277CCR77perforin7granzyme  B+
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late-stage  phenotype.  The  suggestion  being  that  the  proportion  of  these 
HCMV-specific  “effector-memory”  cells  rises  with  time  in 
immunocompromised  patients  whilst  the  remainder  of  the  CD8+  population 
remains  phenotypically  stable.  The  same  paper  [294]  reported  that  healthy 
seropositive  patients  and  donors  had  a  lower  proportion  of  HCMV-specific 
CD8+ cells to renal-transplantation recipients and that these were mostly of a 
“central”  memory  phenotype  that  resided  within  secondary  lymphoid  organs 
(i.e. CCR77CD27+/CD28 ).
In  HCMV  seropositive,  immunocompromised  HIV1-infected  patients,  both 
HIV-1-specific  CD4+  and  CD8+  populations  steadily  decrease  while  HCMV- 
specific CD4+ and  CD8+ populations continue to expand  [295].  One possible 
explanation  is  that  virus-specific  “effector-memory”  T-cell  populations  are 
found  at the  site  of viral  replication.  Since  HIV-1  predominantly  replicates  in 
the  lymphoid  tissues,  targeting  CD4+  cells  that  are  CCR7+,  whilst  also 
expressing CCR5,  a co-receptor for HIV-1,  CD4+ cells  become depleted  and 
consequently  HIV-specific  CD8+  populations  cannot  be  maintained  [296, 
297].  HCMV-specific  “effector-memory”  CD4+  and  CD8+  populations,  which 
are  CCR7',  home  to  HCMV  target  areas  such  as  the  salivary  glands,  the 
retina  and  the  lungs,  thereby  avoiding  depletion  in  the  lymphoid  tissues 
through HIV1  replication [295].
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Clonality of HCMV-specific CD8 populations
Within  both  immunosuppressed  and  immunocompetent  seropositive 
populations,  HCMV-specific CD8+  populations tend to become  oligoclonal,  a 
phenomenon  common  to  infection  with  other  persistent viral  infections  such 
as  Epstein  Barr virus  (EBV)  and  HIV-1  [298,  299].  These CD8+  populations, 
which  also tend  to  express  the  senescence  marker CD57  [300]  while  being 
CD28‘,  are  believed  to  undergo  massive  expansion  with  each  viral 
reactivation  [301].  High  viral  loads  frequently  occur  during 
immunosuppression  and  would  therefore  account  for  the  large  numbers  of 
HCMV-specific  cells  in  those  individuals.  The  proportion  of  these  cells  also 
increases  throughout  life,  albeit  probably  at  a  slower  rate,  with  the  average 
healthy  adults  having  5-20%  CD57+  CD28-  T-cells  [299,  302-304].  These 
cells  are  usually  perforin+  and  yet show a decreased  ability to  proliferate  on 
stimulation with cognate antigens [305].
Peggs  and  colleagues  [306],  confirmed  work  by  Gillespie  et  al.  [260],  by 
demonstrating that HCMV-specific CD8+ populations remain relatively high in 
immunocompetent  patients  following  resolution  of  primary  infection,  this  is 
consistent  with  the  theory  that  there  is  a  constant  restimulation  of  the 
immune  response  throughout  life  by  the  virus.  Paradoxically,  viral  loads,  at 
least in the whole blood and plasma of immunocompetent individuals remain 
very  low  [307].  Such  a  phenomenon  could  be  explained  by  the  partial 
expression of early-phase  HCMV proteins on the surfaces of monocytic cells 
which  may continually stimulate CTL populations  [298,  306]  instead of active 
viral  replication  where  all  proteins  would  be  expressed  widening  the  targets
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for the CTL response.  In this scenario one would expect a large proportion of 
these CD8+ T-cells to be IE1-specific yet this are not always the case.
Efficacy of the HCMV-specific CD8 response
One  major  consideration  must  be  made  of  the  HCMV-specific  CD8+ 
response,  this  is:  are  such  large  CD8+  populations  functionally  active? 
Hassan-Walker  et  a\.  [308]  reported  that  non-viraemic  liver  transplant 
patients  undergoing  tacrolimus  regimens  displayed  70%  activation  in  their 
pp65-specific  CTL  population,  this  contrasted  to  5%  activation  in  healthy 
patients.  In  this  study  median  expression  levels  of  the  activation  marker 
CD38  were  used  to  quantify  the  activation  status  of  the  CD8  population. 
Although  tacrolimus  regimens  have  previously  been  shown  to  reduce  levels 
of  both  CD4+  and  CD8+  T-cell  activation,  HCMV  replication  was  still 
controlled  [308].  The  concept  of  a  protective  threshold  level  of  HCMV- 
specific  CD8+  populations  being  required  in  order  for  control  of  HCMV 
infection  was  hence  proposed.  When  CD8+  population  levels  fall  below  this 
threshold the balance would tip in the favour of virus replication, which would 
consequently  become  uncontrolled.  This  balance  is  also  influenced  by  viral 
load  thresholds;  in  hepatic  [108],  renal  [106]  and  bone-marrow  [309] 
transplants,  where viral  loads  may  supersede this  critical  point  possibly due 
of the  lack of  an  effective T-cell  response;  this would  potentially  result  in  an 
increased risk of disease development.
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As  mentioned  previously,  high  frequencies  of  HCMV-specific  CD8+  T-cells 
accumulate  over time  in  healthy  individuals.  The  highest  frequencies  would 
therefore  be  expected  to  occur  in  the  elderly,  where  reactivations  have 
occurred  most  frequently  [310-312].  Studies  investigating  epitope-specific 
responses,  using  MHC  class  I  tetramers,  in  the  elderly  show  that  although 
the percentages of CD8 cells able to recognise specific epitopes was highest 
in  elderly populations  [313],  the  proportions of this population that were able 
to  secrete  IFNy  in  response  to  stimulation  with  the  cognate  peptide  was 
much  reduced  when  compared  with  younger  individuals,  rendering  them 
dysfunctional  [314].  Indeed,  the  sheer  numbers  of  virus-specific  cells  that 
accumulate  during the  course  of  life  might well  result in  a lack of  circulating 
naive CD8+ T-cells in later years,  potentially predisposing the elderly to other 
lethal  infections  [315-317];  diseases  would  therefore  not  occur  as  a  direct 
consequence  of  the  lower  proportion  of  functional  cells,  but  rather  the 
decreased  numbers  of  remaining  naive  cells  would  be  unable  to  cope  with 
new pathogens [317, 318].
Some  immunosuppressed  individuals  also  still  suffer  episodes  of  HCMV 
replication,  and therefore  might  be  prone  to  associated  diseases,  in  spite  of 
large  virus-specific  CD8+  populations.  This  suggests  that  the  size  of  the 
HCMV-specific  response  might  not  be  as  critical  as  its  antiviral  quality. 
Studies  have  demonstrated  that  CTLs  specific  for  HCMV  contained  perforin 
and  could  therefore  be  classed  as  being  potentially  cytolytic  and  yet  these 
same populations are less able to produce  IFNyon stimulations [319]. These 
cells  may  correspond  to  senescent  CD57+  populations  that  are  potentially
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cytolytic  although they  have  a decreased  capacity to  proliferate  [305].  While 
cytotoxicity  is  important  in  the  control  of  most  virus  infections,  it  can 
sometimes  result  in  an  inappropriate  response  that  causes 
immunopathology, especially when the magnitude of antigen-specific CTLs is 
so large. This suggests that a heterogenous CD8+ T-cell population would be 
the best way of controlling HCMV infection.
1.9.2.  3 CD4+ cell function
CD4+  cells  recognise  peptides  of  between  13  and  18  residues  in  length 
presented  in the context of  MHC  II  molecules found solely on the surface of 
antigen-presenting  cells  (APCs).  Once  fully  activated,  a  process  also 
requiring  co-stimulation,  CD4+  cells  differentiate  further  into  either  of  two 
distinct populations, these can  be defined  by their cytokine profiles,  Th1  and 
Th2.  The  basis  for this  polarisation  is  influenced  by  several  factors  such  as 
the  cytokine  milieu  in  which  activation  occurs,  antigen  dose,  the  ratio  of 
dendritic  cells  (DCs)  to  T-cells  and  the  polarity of  DC  response  (either  DC1 
or  DC2).  During  primary  infections  a  rise  in  the  Th2-polarised  CD4+  T-cell 
population,  which  secretes  cytokines  such  as  IL-4,  IL-5  and  IL-13,  drives 
antibody production.  During the peak of acute infections Th1  responses tend 
to  predominate,  these  can  be  characterised  through  their  secretion  of  IFNy, 
IL-2,  IL-12 and TNFa. These cytokines can activate APCs,  NK cells and help 
drive  the  proliferation  and  maintenance  of  CD8+  T-cells  responses.  As 
mentioned  previously,  CD4  populations  are  unquestionably  essential  for the 
maintenance of functional virus-specific CD8+ responses [320],  indeed CD8+
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T-cell  populations  specific to  LCMV  in  adult  mice  could  not  be  sustained  in 
their absence [321, 322].
HCMV-specific CD4 response
The  role  played  by  CD4+  T-lymphocytes  during  HCMV  infection  is  less  well 
defined than with CD8+ cells yet both are crucial for control of HCMV; several 
line of evidence support this view.  HCMV replication  in the salivary glands,  a 
major site  of  HCMV  persistence  and  an  organ  where  CD8+  CTLs  have  little 
or no effect,  has previously been shown to be controlled by  IFNy and TNFa- 
secreting  Th1  CD4  cells  [323,  324].  Active  HCMV  end-organ  disease  in 
seropositive  patients  was  also  seen  to  correlate  with  low  frequencies  of 
TN Fa-secreting CD4+ cells.  Furthermore,  CD8'7 ' knock-out mice are seen to 
prevent  MCMV  disease with  similar kinetics to wild-type  mice; this  suggests 
a  compensatory  role  for  the  CD4+  population  in  HCMV  control  [325]. 
Moreover,  the  control  of  HCMV  replication  through  adoptive  transfer  of 
HCMV-specific CD8+ clones in BMT patients correlated with levels of HCMV- 
specific  CD4+  cell  help  [251,  326].  Furthermore,  dysfunction  and  poor 
reconstitution  of  HCMV-specific  CD8+  T-cells  has  been  demonstrated  in 
allogeneic stem cell transplant patients with  low frequencies of CMV-specific 
CD4+ cells [327].
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Targets of HCMV-specific CD4* response
Using  overlapping  synthetic  peptides,  Kern  et al.  [271]  ,  demonstrated  that 
more  than  60%  of  normal  healthy  HCMV  seropositive  patients  had  a  pp65- 
specific CD4+ T-cell  population with a frequency of approximately 2 cells per 
1000.  This  surprisingly  high  proportion  of  the  CD4+  cell  population  being 
directed  towards  pp65 was  explained  by  its  being  an  abundantly  expressed 
tegument protein that would  likely be  presented to  CD4+ cells  in the context 
of  MHC  II  following  either  endocytosis  or  phagocytosis  of  the  virus. 
Glycoprotein  B  (gB)  of  HCMV  has  also  been  shown  to  be  a target for CD4+  
cells.  Using  cytotoxicity  assays  Gyulai  et al.  [328]  and  Hopkins  et al.  [329] 
showed  gB-specific  MHC  ll-restricted  lysis  in  around  30%  of  their 
seropositive patients.  More  recent studies  have  also shown  other targets for 
the  CD4+  response  such  as  UL86,  UL32,  UL99  and  UL153  in  addition  to 
pp65  and  gB  constitute the  majority of global  HCMV-specific  CD4  response 
[264].
CD4* responses during HCMV infection
Analysis  of  HCMV-specific  CD4  and  CD8  populations  of  seronegative 
patients  during  primary  infection  following  renal  allografts  shows  that  CD8+  
levels  dominate  during  primary  infection  and  upon  ganciclovir  treatment, 
decrease  along  with  viral  load  [330].  However,  as  viral  loads  decrease  the 
HCMV-specific  CD4+  response  increases;  this  correlates  with  findings  of 
large  HCMV-specific  CD4+  populations  in  patients  many  years  after 
seroconversion.  It  has  therefore  been  suggested  that  whilst  CD8+  cells  are 
important  in  controlling  HCMV  infection  when  there  are  levels  of  high
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viraemia,  CD4+ cell  populations  are  necessary during  persistent  infection  in 
order to maintain antiviral immunity [330].
Recently Essa etal. [331] reported that levels of total Th1  CD4+ lymphocytes 
were  decreased  in  HCMV-positive  patients  following  renal  transplantation, 
and  proposed  that  this  may  be  attributed  to  an  immunological  impairment 
that  predisposed those  patients to  HCMV  disease.  Such  a  reduction  in  the 
frequency  of  HCMV-specific  CD4+  cells  has  also  been  shown  to  be  a 
predictive  factor  for  HCMV-associated  disease  [332],  as  lowest  CD4+  cell 
frequencies were found 2-6 months post-transplantation, a period of time that 
coincides  with  most  HCMV-associated  complications.  Moreover,  CD4+  cell 
frequencies  of  below  0.25%  were  shown  to  correlate  with  a  increased 
susceptibility  to  HCMV-associated,  end  organ  disease  [332].  High  doses  of 
immunosuppressive  drugs  administered  following  transplantation  have  been 
proposed  to  disrupt  the  immune  response  to  HCMV  to  different  extents 
between  individuals  and  permit higher levels of viral  replication  and hence a 
greater chance of disease.  Furthermore,  Komanduri  et al.  [333]  reported that 
two  HIV-1-infected  patients with  recurrent retinitis  had  high total  CD4+  levels 
but  reconstitution  of  HCMV-specific  CD4+  populations  was  deficient.  These 
data  reinforce  the  idea  that  large  HCMV-specific  CD4+  populations  are 
essential for control of HCMV replication and disease prevention.
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CD4 Memory and Clonality
De  Vries  et al.  [334]  described  a rapid  reconstitution  of the  CD4+  population 
in  HCMV  seropositive  children  following  BMT  compared  to  seronegative 
patients,  this  may  have  been  due  to  a  clonal  expansion  of  existing 
CD45ROH lQ h   populations,  as  CD45RA  populations  were  replenished  at  a 
much  slower  rate.  Most  of  the  replenished  CD45ROH ,gh  population  also 
lacked  CCR7  indicating  a  more  “effector-memory”  phenotype.  CD4+/CCR7' 
populations  tend  to  secrete  IFNyin  response  to  antigen,  whereas  the  CD4+ 
/CCR7+  populations  preferentially  secrete  IL-2  and,  as  mentioned  above, 
remain  in  secondary  lymphoid  tissues.  After  the  total  CD4+  population  has 
recovered  to  levels  similar  to  those  prior  to  immunosuppression  HCMV 
replication  is  again  controlled  in  the  majority  of  patients  indicating  that  a 
balance  between the  immune  response  and  viral  replication  has  again  been 
reached [332].
Research  by  Bitmansour  et  al.  [335]  suggested  a  hierarchical  pattern  of 
clonal  populations  CD4+  specific for certain  HCMV  epitopes  and that as few 
as  3  of  these  dominant  epitopes  could  constitute  up  to  50%  of  the  total 
HCMV-specific CD4+ response within an individual.  Pp65-specific clonotypes 
alone  constituted  almost  one-third  of  the  total  CD4  response  in  two 
individuals  studied  from  a  group  of  four  healthy  patients.  Khattab  [276]  and 
Beninga  et  al.  [336]  suggest  that  in  addition  to  being  the  major  target  for 
CD8+  cell  responses  in the  majority of  individuals  pp65  also  acts  as  a  major 
target  for  CD4+  cells.  The  oligoclonality  of  these  populations  together  with 
pp65  being  a major CD4+ cell target implies that pp65  may shape both CD8+
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and  CD4+  responses  towards  HCMV.  The  relatively  low frequency  of  these 
dominant  populations  suggests  that,  in  the  context  of  a  genetically  stable 
virus  pathogen  such  as  HCMV,  the  low  diversity  of  CD4+  population  is 
sufficient to control the infection [335].
CD4 cells and HCMV Latency
As  mentioned  previously,  CD4+  lymphocytes  recognise  antigens  in  the 
context of MHC  II expressed solely on APCs,  suggesting that HCMV latency 
may  be  affected  by  HCMV-specific  CD4+  populations.  Le  Roy  et  al.  [337] 
showed  that  IE1-specific  CD4+  cells  were  able  to  lyse  a  HCMV-infected 
astrocytoma  cell  line  expressing  MHC  class  II  transactivator  protein, 
suggesting  that  CD4+  cells  can  control  HCMV  infection  in  APCs.  Certain 
subsets  of  CD4+  cells  are  known  to  secrete  TNFa,  which  was  shown  by 
Prosch  et al.  [338] and  Hummel  et al.  [339] to enhance the activity of the  IE1 
activator/promoter  through  induction  of  the  transcription  factor  NF-kB.  IE1 
expression  may allow latently  infected cells to  be  recognised  by  IE1-specific 
CTLs,  demonstrating  that  secretion  of  TNFa  by  CD4+  cells  could  cause 
reactivation of latent HCMV or by the same rational, prevent latency.
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1.10 Evasion of cellular immune responses
HCMV  encodes  a  variety  of  proteins  that  are  able  to  interfere  with  the 
immune  response.  US2  and  US11  target  the  heavy  chain  of  MHC  I  for 
degradation  [340]  ,  US3  is  able  to  retain  peptide-loaded  MHC  I  complexes 
within  the  ER  and  US6  inhibits  TAP  [341].  US2  and  US3  have  also  been 
shown to  be associated with the down-regulation  of  MHC  class  II  molecules 
[342,  343]  .  Indeed  both  HLA-DRa  and  DMa  degradation  have  been 
demonstrated  in  astroglial  cells with  IFNy-inducible  MHC  II  expression  [344], 
which  would  abrogate  HCMV  antigen  recognition  by  CD4+  cells,  thereby 
preventing  CD4-mediated  lysis  and  precluding  IFNy-induced  upregulation  of 
co-stimulatory  molecules  on  APCs  by  CD4+  cells.  Furthermore,  HCMV  is 
able  to  prevent  the  IFNysignalling  cascade  thus  preventing  activation  of 
macrophages  and  hence  precluding  up-regulation  of  MHC  I  and  MHC  II. 
HCMV  has  developed  another  way  of  achieving  evasion  of  CD8  and  CD4 
Th1  responses, through expression of an  IL-10 homologue UL111a [345],  IL- 
10  is  also  known to  have  a strong  immunosuppressive  capacity  and  may  in 
turn  down-  regulate  T-cell  responses.  Therefore,  it  is  important to  note that 
although  the  CD4  and  CD8  responses  are  able to  control  HCMV  replication 
and  prevent  disease  in  healthy,  immunocompetent  patients  it  is  not  usually 
sufficient  to  clear  the  virus;  which  may  be  due  to  the  virus  being  able  to 
evade the CD8 response.
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1.11 CVID patients
Common  variable  immunodeficiency  is  a  heterogenous  disease that  affects 
approximately  1   in  25000  Caucasians and  is characterised  by an  inability to 
produce  antibodies  which  results  in  low  serum-immunoglobulin 
concentrations  [346].  Symptoms  of  hypogammaglobulinaemia  are  usually 
manifested  after  the  age  of  20  years  [347]  and  they  correspond  with  an 
increased  susceptibility  to  bacterial  infections  of  the  respiratory  and 
gastrointestinal  tract.  Between  10-23%  of  CVID  patients  also  suffer  from  a 
range  of  auto-immune  diseases  such  as  thrombocytopenia  and  haemolytic 
anaemia [348,  349], these patients also frequently suffer inflammatory bowel 
disorders with large lymphocyte infiltration into the gut.
Individuals  suffering  CVID  have  also  been  shown  to  have  defects  in  the 
differentiation  state  of  their  DCs,  which  also  have  decreased  levels  of  co­
stimulatory  molecules  on  their  surfaces  along  with  a  decreased  capacity to 
produce  IL-12  [350],  which  coincides  with  impaired  T-cell  activation  and 
proliferation.  Conversely,  monocytic  expression  of  IL-12  in  some  CVID 
patients  may  polarise  CD4  cells  to  a  Th1  response  and  hence  lead  to  the 
induction in  IFNy production [351].
Despite  these  abnormalities,  the  majority  of  CVID  patients  cope  well  with 
virus  infections.  Their  CD8+  T-cells  are  predominantly  of  a  CCR7-  “effector- 
memory”  phenotype  and  have  an  increase  in  levels  of  intracellular perforin, 
granzyme  A  and  also  an  increased  capacity to  produce  IFNy on  stimulation 
[352].  A  subgroup  of  the  patients  also  have  raised  levels  of  CDR7-  CD8+
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cells  in  the  peripheral  blood  that  could  be  concomitant with  raised  levels  of 
the  lympho-proliferative  cytokine  IL-7  [353].  Virus-specific T-cell  responses 
in these individuals have not been extensively investigated.
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1.12 Aims of project
This  PhD thesis aims to further investigate the role played by HCMV-specific 
CD4+ and CD8+ T-cell  responses in renal transplant patients.  It also seeks to 
determine  whether  virus-specific  T-cell  responses  are  produced  in  CVID 
patients, who despite lacking endogenous  Ig,  are able control the many virus 
infections  asymptomatically.  This  is  presumably  due  to  other  facets  of  their 
immune  responses;  therefore  the  focus  of  part  of  this  work  thus  deals  with 
analysing  their  HCMV-specific  T-cell  responses  and  comparing  them  to 
healthy  HCMV  seropositive  individuals  and  patients  who  are  unable  to 
control  HCMV  replication.  The final  aim  of the thesis  is to  elucidate whether 
the  magnitude  of  functional  T-cell  responses,  as  ascertained  by their  ability 
to produce IFNyon stimulation with HCMV antigens, contributes to protection 
from  HCMV-associated disease.
Previous  work  that  focused  on  HCMV-specific  CD4  and  CD8  responses  in 
renal  transplant  patients  has  not  conclusively  determined  whether  these 
responses  are  protective  against  HCMV  replication.  In  D+FT  patients  the 
emergence  of  Th1-polarised  HCMV-specific  CD4  responses  was  found  a 
median  of  7  days  after  the  detection  of  HCMV  genomes  in  the  blood,  and 
was  proceeded by the detection of  HCMV-specific humoral  responses  [354]. 
The  presence  of  HCMV-specific  CD4+  T-cells  is  also  associated  with  the 
subsequent  appearance  of  CD8  responses,  and  although  CD4+  cells  were 
deemed to be required for the control of initial  infection,  no protective benefit 
was  seen  in  renal  transplant  patients  with  virus-specific  CD8  responses  in 
the  absence  of  CD4  responses  [355].  The  same  group  also  demonstrated
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that the emergence of HCMV-specific CD4 responses was delayed until after 
antiviral  treatment  in  symptomatic  patients  [356].  A  decrease  in  the  HCMV- 
specific  CD4  response  of  symptomatic  renal  transplant  patients  also 
coincided  with  the  appearance  of  virus  replication  and  subsequent  disease 
[332].
There have been  relatively few comprehensive studies on the role of HCMV- 
specific  CD8  responses  in  renal  transplant  patients.  During  the  first  three 
months  post-transplant  HCMV-specific  CTL  responses,  as  determined 
through  cytotoxicity  assays,  were  found  to  inversely  correlate  with  HCMV 
virus  load  as  quantified  by  antigenaemia  [254].  The  percentages  of  HCMV 
tetramer+  CD8+  T-cells  were  also  shown  to  be  higher  in  renal  transplant 
patients  than  healthy  controls  [294].  This  was  complimented  by  findings  of 
Radha etal. [357] who also observed elevated frequencies of CD8+ T-cells in 
seropositive  renal  transplant  patients  when  compared  to  healthy  controls 
although  the  proportion  of  these  that  were  HCMV-specific  was  not 
determined.
The  principal  disadvantage  of  these  studies  is  that  they  only  focus  of  the 
percentages  of T-cell  populations  able to  respond to  antigen  stimulation  and 
not  the  absolute  numbers  of  these  cells  in  the  peripheral  blood;  this 
measurement would give a better indication of how many cells are capable of 
reacting  and  potentially  controlling  infection.  Furthermore,  HCMV-specific 
CD8  responses  were  measured  using  specific  HLA-restricted  epitopes 
instead  of  whole  antigens,  responses  to  specific  epitopes  would  greatly
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underestimate  the  global  CD8  response.  It  is  also  unclear  as  to  what 
constitutes functionality,  in this thesis functionality is determined also by IFNy 
production by activated CD69 expressing T-cells although this might itself not 
be  representative  and  neither  accounts  for  cytolytic  ability  nor  ability  to 
proliferate in  response to appropriate antigen stimulation.  In chapter 6 of this 
thesis  a  comparison  of  the  phenotypes  of  epitope-specific  CD8  populations 
within  three  groups  of  individuals  is  performed  using  cytolytic  potential, 
gauged  by  intracellular  perforin  levels,  as  an  alternative  measurement  of 
functionality.
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These are the aims of the individual results chapters of the thesis:
1)  To  evaluate  the  fluctuations  in  both  the  percentages  and  absolute 
numbers  of  IFNy-producing,  HCMV-specific  and  pp65-specific  CD4+ 
T-cell  populations  in  renal  transplant  patients  and  to  determine 
whether  there  is  any  impairment  in  the  CD4+  responses  in  those 
individuals suffering HCMV-viraemia.
2)  To  evaluate  the  fluctuations  in  both  the  percentages  and  absolute 
numbers  of  IFNy-producing,  IE1-specific  and  pp65-specific  CD8+  T- 
cell  populations  in  renal transplant patients  and to determine whether 
there  is  any  impairment  in  the  CD8+  responses  in  those  individuals 
suffering HCMV-viraemia.
3)  To  ascertain  whether  CTL-escape  mutants  arise  in  patients  that 
remain  HCMV  PCR-positive  for  long  periods  post  transplant  despite 
the presence of an epitope-specific CD8 response.
4)  To  investigate  whether  individuals  suffering  CVID  have  detectable  T- 
cell  responses  towards  HCMV  and  to  compare  the  frequencies  and 
phenotypes  of  HCMV tetramer+  CD8  populations  in  these  individuals 
with age-matched healthy controls.
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2.1 Cell Culture
2.1.  1  Growth and Maintenance of T-2 Cell Lines
TAP-deficient  T2  cells  (lacking  genes  encoding  TAP-1  and  TAP-2)  were 
grown  in  suspension  using  upright  vented  T75  flasks  (Sarstedt,  Leicester) 
with  RPMI  1640  medium  supplemented  with  10%  FCS  and  penicillin 
streptomycin  (Gibco,  see  appendix)  in  a  humidified  incubator  at  37°C  in  5% 
CO2.  Cells were split  1:5 with fresh supplemented  RPMI  1640  medium every 
three  to  five  days.  Cell  density  and  viabilities  were  ascertained  by  staining 
with  4%  trypan  blue  in  PBS  (Sigma)  and  counting  under  a  disposable 
haemocytometer.
2 .1 .2  Isolation of PBMCs from Whole Blood
20ml  of fresh  whole  blood  was  taken  from  patients  and volunteers  obtained 
using  sodium-heparin  syringes  (Sarstedt,  Leicester).  The  blood  was  then 
carefully  overlaid  onto  Ficoll-Paque  Plus  (Amersham  Biosciences)  at  a  1:1 
volume  ratio  in  50ml  sterile  Falcon®  universal  tubes  (Sarstedt,  Leicester); 
these were centrifuged  at 700g for 20min with slow acceleration and without 
braking.  The  tubes  were  removed  from  the  centrifuge  and  the  interphase, 
created  between  the  plasma  layer  and  the  lymphocyte  separation  medium 
(Fig.  2.1), was carefully  removed to avoid contamination with  either adjacent 
layer  and  placed  into  a  fresh  universal  tube.  The  volume  of  the  interphase 
was  made  up  to  30ml  with  unsupplemented  RPMI  1640;  this  was  then 
centrifuged  at  550g  for  10  minutes  (with  fast  acceleration  and  brake)  to 
remove  any  residual  Ficoll.  Then  supernatant  was  discarded  and  the
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resultant pellet was resuspended  in an additional 20ml of RPMI  1640.  Cells 
were washed twice by centrifugation at 450g for 5 minutes, after the second 
wash cells were resuspended  in  10  ml of supplemented  RPMI  1640.  Viable 
cells  were  then  stained  with  4%  trypan-blue  and  then  counted  using  a 
haemocytometer.
Plasma
Interphase containing Lymphocytes 
Lymphocyte Separation Medium (LSM)
Red Blood cells
Figure 2.1  Sedimented layers formed after centrifugation of whole blood over a 
Ficoll-paque plus gradient
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2.1.  3 Freezing PBMCs for ex vivo tetramer staining
Isolated  PBMCs were centrifuged at 450g for 5 minutes and the pellets were 
resuspended  at a density of  >5 x  106 cells/ml with  90%  FCS  (sterile filtered, 
Labtech)  10%  DMSO  (Sigma)  that  had  been  pre-chilled  to  4°C.  The 
suspensions  were  transferred  to  labelled  1.5ml  cryovials  (Alpha 
Laboratories)  and  placed  in  a  4°C  isopropanol-containing  freezing  chamber 
(Fisher).  Freezing  chambers  were  transferred  to  a  -80°C  freezer,  which 
allowed cells to cool at a rate of  1°C/minute, thereby preserving cell viability. 
After 48  hours cells were transferred to a liquid  nitrogen storage  unit and  left 
until use.
2.1. 4 Thawing PBMCs
PBMCs were taken from  liquid  nitrogen storage and  immediately placed in  a 
water  bath  pre-warmed  to  37°C.  When  the  cells  had  almost  completely 
thawed they were transferred to a  15ml falcon tube  (Sterlin) to which  9  ml of 
RPMI  1640  10%  FCS  was  slowly  added  with  gentle,  sporadic  vortexing. 
Cells  were  then  centrifuged  at  450g  twice  to  remove  residual  DMSO  and 
assessed  for  number  and  viability.  Cells  were  then  used  for  subsequent 
immune staining.
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2. 2 PCR
2.2.  1  Primers for amplification of sequences encoding CD8 epitopes
Design of primers
Primers  for  the  amplification  of  pp65  HLA-A*0201  and  -*B35  epitopes  by 
nested  polymerase  chain  reaction  (PCR)  were  designed  using  Primer3 
software available at:
http://www.aenome.wi.mit.edu/aenome  software/other/primer3.html)
All primers were synthesised and purified commercially by MWG-Biotech.
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VLGPISGHV -  epitope 1  
External  Primers
Forw  '  -  :  :  -  -  :
Rev  '  -  T -..  .
Internal Primers
Forw  ' '  -  . -  -
Rev  '  ~" : 1::
PCR amplicon size 409bp
MLNIPSINV -  epitope 2 
External Primers
Forw  '  '  ~   -
Rev  '  "7.
Internal  Primers
Forw
Rev
PCR amplicon size 194bp
NLVPMVATV -  epitope 3 
External  Primers
Forw
Rev
Internal  Primers
Forw
R e v   '   ......
PCR amplicon size 200bp
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2.2.  2  Nested polymerase chain reaction (PCR)
PCR  reactions  were  performed  using  a  Bio-X-act  Short  high-fidelity 
polymerase  (Bioline)  to  minimise  the  potential  emergence  of  random 
sequence changes  during  the  amplification  process.  DNA was  isolated from 
PCR-positive liver transplant patients, of known HLA types (8 x HLA-A02,  1   x 
B35,  with  viral  loads  >3  log  genome  copies/ml  of  whole  blood.  DNA 
sequences  were  initially  amplified  using  the  external  primers  and  2jllI  of 
resultant DNA was amplified using inner sense and antisense primers.
MasterMixes
10X OptiBuffer (Bioline) 5pl
50mM MgCb Solution (Bioline) 2.5|il
100mM dNTP (Promega) 1|il
Template DNA 0.5  pi
External or internal Primer mix  100pM 1nl
BIO-X-ACT Short 4u/pl  (Bioline) 1(il
Water (ddH20)  Up to 50pl
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Cycling Conditions for first stage PCR
Step Temperature (°C) Time (m) Number of Cycles
1 95 5 1
2 55 30 20
3 70 30 20
4 95 30 20
5 70 10 1
6 4 Hold 1
Cycling Conditions for nested PC
Step Temperature (°C) Time (m) Number of Cycles
1 95 5 1
2 55 30 20
3 70 30 20
4 95 30 20
5 70 10 1
6 4 Hold 1
Thermal  cycling  was  performed  using  a  Hybaid  thermal  cycler.  Following 
amplification  the  DNA was  mixed with  loading  dye  and visualised  on  1.5% 
TAE agarose gel.
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2.2.  3 Agarose Gel Electrophoresis and Purification of DNA Product 
1.5%  agarose  gels  were  prepared  by  adding  1.5g  of  multipurpose  agarose 
(Bioline) to  100ml of  1x TAE  (40mM Tris-acetate,  1mM  EDTA buffer,  Sigma- 
Aldrich). Agarose was dissolved by heating in a 850W microwave and cooled 
to  50°C  using  a  water-bath.  2pJ  of  ethidium  bromide  (10mg/ml  Sigma)  was 
then added to the solution and  mixed. The solution was carefully poured into 
gel frames and combs were inserted to make sample loading wells. The gels 
were allowed to cool  and solidify,  combs were removed and gel frames were 
submerged  in  an  Embi  Tec  RunOne®  electrophoresis  cell.  DNA  samples 
were  diluted  1:1  in  blue  dye  sample  loading  (Bioline)  and  loaded  into 
separate wells  alongside  Hyperladder  IV  (Bioline)  and were  run  at  100V for 
approximately 15 minutes.
Amplified gene products were visualised under UV light on a transilluminator 
and  sizes  were  determined  by  comparison  with  Hyperladder  IV  (Bioline). 
Bands of  interest were  purified from  1.5% w/v  low  melting-point agarose gel 
(Sigma)  run  in  1  x TAE  (40mM Tris-acetate,  1mM  EDTA buffer).  Using  a low 
powered  UV  light to visualise the  bands of  interest,  the gels  were  placed on 
to  a  Perspex  tray  to  minimize  exposure  of  DNA  to  UV  to  reducing  the 
formation of thymidine dimers.  The bands were excised with a sterile scalpel 
and  purified  using  the  standard  QIAquick  gel  extraction  protocol  (Qiagen). 
Briefly,  bands of  interest were  excised  and weighed  in  a pre-weighed  sterile 
1.5ml  centrifuge tube,  3  times  (w/v)  QG  buffer was then  added to  the tubes 
and  gently  mixed.  Tubes  were  then  incubated  in  a  50°C  water  bath  for  10 
minutes,  with  periodic vortexing,  until  the gel  had dissolved.  1   gel  volume of
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isopropanol  was  added  to  the  tubes  and  mixed  thoroughly  and  the  solution 
was then added to a QIAquick spin column, which was centrifuged at 13000g 
for  1   minute  on  a  standard  desktop  microcentrifuge.  The  flow-through  was 
discarded  and  the  spin  column  was  washed,  to  remove  residual  agarose, 
with  0.5  ml  QG  buffer for  1   minute.  The flow-through was  discarded  and the 
column was washed again using  PE  buffer. Once more the flow-through was 
discarded  and  the  column  was  centrifuged  again  to  remove  residual  PE 
buffer.  The column was then  placed  in  a  new sterile  1.5  ml  microfuge tube. 
To  elute  the  DNA  50^il  of  nuclease-free  water  was  carefully  added  to  the 
DNA-binding  filter  of  the  column,  and  columns  were  left  to  stand  for  one 
minute  before  centrifugation.  The  eluate  was  collected  at  the  bottom  of  the 
microfuge tube and stored until use at 4°C.
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« -----CTL2 Left
194 bp
CTL3 Right 
204 bp
CTL1
409bp
Figure 2. 2 1.5% agarose gel, run in  1X TAE buffer showing nested PCR products
2.2.  4 Ligations of purified Sequences into pGem-T®-easy Vector
Purified  DNA  products  were  ligated  into  pGem-T^-easy  vector  (Promega) 
using a 3:1  molar ratio using the following equation to calculate amounts of 
insert required.
(^ng of vector x kb size of insert^  x insert.vector molar ratio = ng of insert 
kb size of vector
Ligation  mixes  consisted  of  5pl  of  2X  Rapid  Ligation  Buffer,  1pl  (50ng)  of 
pGEM-'T®  Easy  Vector,  1pl  (3  units)  T4  DNA,  xng  of  DNA  insert  and 
deionized  water  taking  the  final  volume  to  10pl.  Ligations  mixtures  were 
incubated for one hour at room temperature or overnight at 4°C to increase 
the efficiency.
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2.2.  5 Transformations using the ligation reactions
2pJ of the  ligation  reactions were added to 50pJ of freshly-thawed competent 
E.coli strain  DH5-alpha  cells  (Gibco,  BRL)  and  placed  in  1.5  ml  microfuge 
tubes  (Sarstedt).  Contents were  mixed  by gentle flicking  and the tubes were 
placed  on  ice for 20  minutes.  Cells  were then  heat-shocked  at  42°C for 90 
seconds  and  returned to the  ice  box for 2  minutes.  950pJ  of  Super Optimal 
Catabolite  medium  (SOC  medium,  Gibco  at  BRL)  was  subsequently  added 
and tubes were incubated at 37°C in a shaking incubator for a further hour.
100pJ  of  each  transformation  culture  was  plated  onto  the  amp,  IPTG,  X-gal 
LB  agar  plates  (see  appendix)  and  which  were  inverted  and  incubated 
overnight at 37°C.  The  next day individual white colonies were  picked  using 
a  sterile  pipette  tip  and  dipped  into  25ml  falcon  universal  tubes  containing 
5ml  LB  broth  supplemented  with  ampicillin  at  50}xg/ml  and  these  were then 
incubated  overnight  with  agitation  at  37°C.  The  following  day,  800ptl  of 
ampicillin-resistant bacteria suspension was added to 200|il of sterile glycerol 
(Sigma)  in  sterile  1.5ml  centrifuge  tubes,  these  were  vortexed,  snap-frozen 
using dry ice and stored at -70C. The remaining suspension was centrifuged 
at  13000g  for  10  minutes  and  DNA  from  the  pellet  was  purified  using  a 
QIAprep MiniPrep Kit (Qiagen) following standard protocols.
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Briefly,  cell  pellets  were  resuspended  in  250jliI  of  P1  buffer  (with  RNase  A 
added)  and transferred  into  a  1.5  ml  microfuge tube.  250|il  of  P2 buffer was 
then  added  and the  mixture was  inverted  4-6 times  before  addition  of  350pl 
of  P3  precipitation  buffer.  Solutions  were  mixed  quickly  by  inverting  4-6 
times,  to  avoid  localised  protein  precipitation.  Tubes  were  then  centrifuged 
for  10  minutes  at  13000g  on  a  standard  desktop  microcentrifuge.  The 
resultant  supernatants  were  then  added  to  Qiaprep  spin  columns,  which 
were subsequently centrifuged at 13000g for 1  minute. The flow-through was 
discarded  and  the  column  was  washed  with  500|il  of  PB  wash  buffer.  The 
spin  column  was  washed  again  using  750jllI  of  PE  buffer.  The  flow-through 
was also discarded and the columns were spun again for 1   minute to remove 
any residual  PE  buffer. The column was then transferred to a new,  clean  1.5 
ml  microfuge  tube  and  DNA  was  eluted  by  adding  50jllI  of  nuclease  free 
water.  Samples  were  then  stored  at  4°C  until  they  were  used  for  DNA 
sequencing.  DNA  sequencing  was  performed  on  an  ABI  Prism®  capillary- 
based sequence analyser using a BigDye® terminator v3.1  cycle sequencing 
kit  (Applied  Biosystems).  Sequences  were  analysed  and  graphics  were 
generated utilising Chromas 2.23 software available at: 
http://www.technelvsium.com.au
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2. 3 Peptides
Variants of the pp65  HLA-A*0201  epitope  NLVPMVATV  are summarised  in 
table  2.1.  Peptide  variants  were  designed  based  on  individual  glycine 
substitutions  or  like-for-like  based  on  charge  and  shape,  anchor  residues 
were  conserved  in  all.  (Blue  indicates  anchor  residues  Red  indicates 
modified  residues).  Peptides  were  synthesised  commercially  by 
Altabiosciences  (University  of  Birmingham)  and  purified  to  >90%  purity. 
Lyophilised peptides were resuspended in DMSO to 5mg/ml.
Peptide sequences  Name  Comments
N L V P M V A T V Wildtype (wt)
G L V P M V A T V G1N
N L G P M V A T V G3V
N L V G M V A T V G4P
N L V P G V A T V G5M
N L V P M G A T V G6V
N L V P M V G T V G7A
N L V P M V A G V G8T
Q L V P M V A T V Q1N
N L L P M V A T V L3V
N L V P I V A T V I5M
N L V P C V A T V C5M
N L V P M L A T V L6V
N L V P M V A S V S8T
Described in [358]
Table 2.1  List of NLVPMVATV variants with conservative and non­
conservative substitutions
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2. 4 Enzyme-Linked Immuno Spot (ELISpot) using modified peptides
Mouse  anti-human-IFNy  mAb  (1-D1K,  MabTech,  Sweden)  was  diluted  in 
steriIe-fiItered  PBS  (Sigma)  and  used  to  block  96-well  nitrocellulose  plates 
(MabTech,  Sweden)  overnight at 4°C.  Plates were subsequently washed six 
times  in  sterile,  filtered  PBS  and  blocked  with  RPMI  1640  (supplemented 
with  10%  FCS).  PBMCs  isolated  from  HCMV  seropositive  and  control 
(seronegative)  volunteers  were  re-suspended  to  5  x  104  cells/well  in 
supplemented  RPMI  1640.  20pM  of the  wild-type  NLVPMVATV  and  variant 
peptides  were  added  in  triplicate  to  each  well  along  with  1p.g/ml  of  co­
stimulatory anti-CD28 (BD Biosciences, Oxford) and diluted in  RPMI to make 
volumes  up  to  200|il/well.  Cell/peptide  mixes  were  incubated  overnight  at 
37°C  in  an  atmosphere  of  5%  C 0 2.  Cell  suspensions  were  then  discarded 
from  the  plate  and  wells  were  washed  six  times  with  sterile,  filtered 
PBS/Tween-20 (0.05% v/v).  Plates were then coated with biotinylated mouse 
anti-human-IFNy  mAb  (7-B6-1,  MabTech,  Sweden),  diluted  1:1000  in 
PBS/1 %  FCS,  for 3  hours  at  room  temperature.  Plates  were  washed  again, 
as  above,  and  incubated  with  streptavidin-alkaline  phosphatase  diluted 
1:1000  using  PBS  1%  FCS  for  2  hours  at  room  temperature.  Plates  were 
washed  as  before,  substrate  was  then  added  and  spots  were  allowed  to 
develop for approximately  15  minutes.  Reactions  were  quenched  using tap 
water and dried overnight prior to counting using light microscope.
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2. 5 Peptide Stabilization Assay
T2  cells  are  a  somatic  cell  hybrid  of  human  B  and  T  lymphoblastoid lines 
deficient  in  TAP  proteins  and  expressing  low  levels of  surface  HLA-A*0201. 
HLA-A*0201  molecules  can  be  stabilised  and  therefore  upregulated  on  the 
cell surfaces on binding to exogenous HLA-restricted peptides. T2 cells were 
seeded  in  48 well  plates at a density of  5 x  105 cells/ ml  in fresh  RPMI  1640 
and  were  left  at  room  temperature  for  1   hour  to  equilibrate.  They  were 
subsequently  incubated  with  the  peptides  for  16h  at  37°C  5%  CO2,  after 
which  the  suspensions  were  centrifuged  at  400g  for  5  minutes  and  washed 
three  times  in  5ml  PBS  (4°C)  to  remove  any  unbound  peptides.  Cell  pellets 
were  resuspended  and  incubated  with  mouse  anti-human  lgG2b  HLA- 
A*0201  FITC  conjugate  (BB7.2  SeroTec),  diluted  1/10  in  PBS/1 %  FCS,  for 
30  min  at 4°C.  The cells were centrifuged  and washed,  as  before,  and were 
finally  resuspended  in  PBS  0.01%  sodium  azide  (Sigma-Aldricht).  Isotype 
control  (lgG2b)  antibodies  were  also  used  to  stain  cells  using  the  same 
conditions.  Increase  in  mean  fluorescence  intensity  was  analysed  using 
CellQuest™ software on a FACSCAN™ (Becton Dickinson Biosciences).
The  percentage  increase  in fluorescence  intensity was  measured  calculated 
as:
(MFI (peptide)/MFI  (control)) x  100 = increase in MFI
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Red fill -  Isotype control
Blue line -  anti A2-FITC 
binding to unstimulated T2 
cells
Figure  2.  3  (Upper  panel)  Contour plot  of  T2  cells  with  R1  gate to  identify viable 
cells (Lower panel) Histogram showing HLA-A*0201  expression on unstimulated T2 
cells  using  isotype  control  (lgG2b)  and  anti  HLA-A*0201-FITC  antibody  (BB6.72 
SeroTec).
1 0 °  1 0 1   1 0 2   1 0 3   1 0 *  H L A 2 F IT C
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2. 6 Ethical approval
This  study  was  approved  by  the  Royal  Free  and  Medical  School  Local 
Research Ethics Committee.
2. 7 Serology
HCMV  IgG  serology was  performed  on  both  patient  and  volunteer  samples 
by  the  diagnostic  staff  at  the  department  of  virology  at  the  Royal  Free  and 
University College Medical School using the Biomerieux® CMV IgG  assay on 
a VIDAS® automated,  mulitparameter immunoassay system.
2. 8 HLA Typing
High  resolution  typing  of  HLA  class  I  and  II  alleles  was  performed  on  all 
patients and healthy volunteers by the staff at of the Anthony Nolan  research 
institute,  Hampstead,  London.
2. 9 Patient study population and design
To investigate the role of  HCMV-specific CD4+ and CD8+ T-cell  responses in 
the  control  of  HCMV  replication  post  renal  transplant  a  total  of  20  renal 
transplant patients of either  D7R',  D7R+ or D7R+ were  monitored at  monthly 
intervals  for  six  months  post-transplant.  Patients  were  from  a  variety  of 
different  HLA  backgrounds.  For  investigation  of  CTL-escape  emergence  in 
chapter  5,  DNA  was  extracted  from  the  peripheral  blood  of  4  persistently- 
viraemic  liver  transplant  patients  of  known  HLA  backgrounds  that  had 
previously-characterised  HCMV  tetramer  populations,  and  five  further  liver 
transplant patients with acute phase viraemia.
107it Number Sex Age (at Transplant) Donor/Recipient serostatus HLA type Organ Source Immunosuppression Rejection Vlraei
1 M 76 D-  R+ A19  B08 Cadaveric Pred, CycA, MMF, Simulect 3 x methypred y
2 M 31 D+  R+ A01  B07 Live related Tac 1   x methypred n
3 M 47 D+  R+ A2  8  B17 Cadaveric Pred, CycA, MMF y
4 M 63 D-  R+ A01  B0  7 Cadaveric Pred, Tac, MMF n
5 F 18 D-  R+ A02  B35 Cadaveric Pred, Tac, MMF n
6 M 57 D+  R- A02  B27 Live related Pred, Tac, MMF, Simulect n
7 F 48 D-  R+ A01  ? Live related Pred, Tac y
8 M 53 D+  R+ A19  B16 live Pred, Tac, MMF, Simulect 1   x ATN rejection n
9 M 58 D+  R+ A01  B08 Cadaveric Pred, Tac, Simulect y
10 F 42 D+  R+ A02  B12 Cadaveric Pred, Tac, Simulect n
11 M 46 D-  R+ ?  ? ? ? y
12 M 66 D-  R+ A02  B16 Cadaveric Pred, Tac, MMF, Simulect y
13 F 51 D-  R+ A01  B08 Cadaveric Pred, Tac, MMF y
14 F 39 D+  R- ?  ? Cadaveric Pred, Tac, MMF, Simulect n
15 M 31 D+  R+ A01  B08 Cadaveric Pred, Tac, MMF n
16 M 47 D-  R+ A02  B05 Cadaveric Pred, Tac, MMF, Simulect n
17 M 44 D-  R+ A01  B12 Cadaveric Pred, CycA, MMF, Simulect 1   x ATN rejection y
18 M 40 D-  R+ A09  B07 Cadaveric Pred, Tac, Simulect n
19 F 70 D+  R- A09  B12 ? ? y
20 F 48 D-  R+ AO1  BO7 Cadaveric Pred, Tac, MMF n
Antiviral
Valganciclovir
Table  2.2.  Table  shows  information  of  renal  transplant  patients  used  for  FACS-based  studies  in  chapters  3,  4  and  6.  Viral  load 
kinetics of the 9 viraemic individuals can be found in the appendix.  Note:  Patient  14 was removed from data of  Figs 3.7 and 3.8 as 
a potential non-seroconverter.
1082.10 Immunosuppression
Initial  immunosuppression  of  renal  transplant  patients  consisted  of 
prednisolone  plus tacrolimus or cyclosporine, with  an  additional  combination 
of Mycophenolate and Simulect in certain patients.
2.11  Routine HCMV
DNA  was  extracted  from  200pl  of  whole  using  a  Qiagen  extraction  kit 
(Minden,  Germany)  according  to  the  manufacturer’s  instructions. 
Quantification of HCMV was performed using a TaqMan  (ABI)-based method 
adapted from previously published protocol [359].
2.12 Intracellular Cytokine Staining of Stimulated CD4+  and CD8+  cells
Within  2  hours  of  isolation  PBMCs,  taken  from  CMV-seropositive  and 
seronegative volunteers, were seeded at a density of  1   x  106cells/ml in sterile 
vented,  capped  12  x  75mm  polypropylene  tubes  (Elkay).  Cells  were 
stimulated  with  either  IE1  or  pp65  PepMixes  (Jerini),  HLA-restricted  class  I 
epitopes  (Prolmmune)  or  CMV  whole  virus  lysate  and  control  lysate  (both 
Autogen  Bioclear  Ltd)  at a density of  1  x  106 cells/ml  in the  presence of  co­
stimulatory CD28  and  CD49d  antibodies  both  at  1|ig/ml  (BD  Biosciences)  in 
a  humidified  incubator  at  37°C  with  5%  CO2.  Two  hours  after  stimulations, 
suspensions  were  mixed  with  2pJ/ml  of  Brefeldin  A  (GolgiPlug,  BD 
PharMingen) and incubated overnight.
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The  next day cells were washed twice with  PBS 0.1% sodium azide  (Sigma) 
by  centrifugation  at  450g  for  5min.  Pellets  were  resuspended  and  stained 
with  fluorophore-conjugated  cell  surface  antibodies  CD4-PerCP  (5j l l I)  and 
CD3-APC  (1 |xl),  in  the  dark  at  room  temperature  for  15  minutes.  They were 
washed, as before, and fixed using 1 O O j l l I of Medium A fixative (Caltag) for 15 
minutes. Cells were washed again and then resuspended in  100pl of Medium 
B  permeabilization  buffer  (Caltag)  for  15  minutes  in  the  dark,  along  with 
antibodies  against  CD69  (5pl)  and  IFNy  (5pl),  after  this  were  washed  and 
resuspended in 200pl of PBS 2% paraformaldehyde and stored at 4°C for no 
longer  than  48  hours  before  acquisition  using  a  four-colour  FACSCalibre 
(Becton  Dickinson)  and  CellQuest software.  Gates were  set  on  lymphocyte- 
positive  (low  SSC,  medium  FSC)  and  CD3+IFNy+  populations.  CD3+  CD4+ 
populations  were  then  analysed  for  CD69+IFNy+  populations,  and  CD8+ 
populations were taken as being those lymphocytes that were CD3+ but CD4' 
.  Although there  are certain  subpopulations  of  CD3+ cells that  are  CD4' that 
are not CD8+,  such as NK T-cells, they do not contribute more that 3% of the 
population in the peripheral blood.
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Lymphocyte Gate
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CD3+  IFNy+  gate 
(T-cells)
CD3+  CD4' cells 
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Figure  2.  4  FACS  density  plots  and  histograms  showing  staining  on  stimulated 
PBMCs
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2.13 Tetramer staining
Both frozen and fresh  PBMC samples were subjected to staining with  HCMV 
tetramers for A1, A2 and B7 epitopes.  Cells were counted and seeded at  1   x 
106 cells/ml  in a capped polypropylene tube. These were centrifuged at 450g 
for  5  minutes  and  supernatants  were  discarded.  Cell  pellets  were 
resuspended  and  washed,  as  above,  using  PBS  0.5%  BSA  0.1%  sodium 
azide.  The  pellets  were  then  resuspended  and  1  Oj l lI  of  tetramer-PE 
conjugates  were  added,  these  were  incubated  at  37C  for  15  minutes  in  the 
dark  in  a  humidified  incubator.  Cells  were  washed  as  before  and 
resuspended,  then  incubated  in  the  dark  at  room  temperature  using  anti 
CD3-APC  (1|il)  and  anti-CD8-PerCP  (10pJ)  antibodies.  Cell  suspensions 
were  divided  into  two  tubes,  one  of  which  (Tube  A)  was  also  co-incubated 
with  anti  CD58-FITC  antibody  and  cells  continued  to  be  incubated  for  a 
further  15  minutes.  Cells  were  washed,  as  above  and  fixed  using  10Ojul 
medium A fixative reagent (Caltag) for 15 minutes at room temperature. Cells 
were  washed  again  and  permeabilized  using  100pJ  medium  B  reagent,  in 
Tube  B  was  co-incubated  with  10pl  of  anti-perforin-FITC,  for  15  minutes. 
Cells  were  washed  again  and  resuspended  in  100pl  4%  paraformaldehyde 
and  were  stored  at  4C  until  acquisition.  >50,000  cells  were  acquired  using 
the lymphocyte and CD3+ gates (see Fig. 2.4)
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Figure  2.  5  Staining  to  determine  Perforin  and  CD57  phenotypes  of  CD3+   CD8+  
HCMV  Tetramer+   populations  Red  Boxes/lines  indicate  gated/quadranted 
populations respectively.
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2.14 Statistical analysis
All  statistical  analyses were performed  using the GraphPad  Prism ®  statistic 
analysis  programme  (Version  3.04  -   available  at  www.qraphpad.com).  To 
compare  the  medians  of  non-parametric  (sample  data  was  not  normally 
distributed)  un-paired samples the  Mann-Whitney test was used. Whilst non- 
parametric  analyses  of  paired  samples  were  performed  using  the  Wilcoxon 
matched pair test.  Both sets of tests used a 95% confidence interval.
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3.1  Introduction
Previously  work  by  Hassan-Walker  et  al.  [107]  described  how  high  HCMV 
loads  in  immunosuppressed  patients  correlate  with  an  increase  risk  of 
HCMV-associated  disease.  Immunosuppression  results  in  a  reduction  in  T- 
cell  populations and causes a disruption  in the balance between an effective 
immune  response  and  virus  replication.  The  control  of  HCMV  replication  by 
T-cell  responses  and the  potential  for the development of  HCMV-associated 
diseases  in  the  context  of  immunosuppressive  therapies  which  decrease 
these populations needs to be fully addressed.
There  are  several  lines  of  evidence  supporting  the  importance  of  CD4+  T- 
cells  in  the  control  of  HCMV  infection.  First,  an  increased  risk  of  HCMV 
associated-disease  occurs when  CD4+ T-cell  levels fall  below 50  cells/pJ'1   in 
AIDS  patients  [360-362].  The  persistence  and  effectiveness  of  infused 
HCMV-specific  CD8+  T-cell  clones  in  a  BMT  setting  is  increased  when  co­
infused  with  HCMV-specific  CD4  cell  populations;  indicating  that  reductions 
in  HCMV-specific  CD4+  T-cell  levels  has  dramatic  downstream  effects  on 
other facets of the adaptive immune response [251].  Sester etal.  [332]  noted 
that  HCMV-specific  CD4  frequencies  below  0.25%  were  predictive  of  an 
increased  risk of  reactivation  and  disease  in  renal  transplant  patients.  While 
work  by  Gamadia  et  al.  2003  [355]  demonstrated  that  although  HCMV- 
specific  CD8+  cells  were  found  in  both  symptomatic  and  non-symptomatic 
renal transplant patients, the emergence of  IFNy+  HCMV-specific CD4+ T-cell 
populations were  necessary for the  prevention  of  HCMV-associated  disease 
in  seronegative  individuals  transplanted  with  organs  from  seropositive
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donors.  Indeed,  individuals  suffering  HCMV  disease  had  a  delay  in  the 
emergence of their HCMV-specific CD4 responses.
This  chapter  aims  to  further  investigate  the  role  played  by  HCMV-specific 
CD4+ cells  in controlling  HCMV  replication  in the  renal transplant setting.  To 
do  this,  longitudinal  analyses  of  both  the  percentages  and  the  absolute 
numbers  of  HCMV-specific  CD4+  cells  in  twenty  renal  transplant  patients 
were  performed  using  a  whole  virus  lysate  or  peptide  pools  for  pp65  [271, 
276,  335,  363]  and  IE1  [277,  324,  364-366],  both  targets  for  the  CD4+ 
immune response.
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3.2  Kinetics  of  HCMV-specific  CD4*  T-cell  re-emergence  in  Renal  Tx 
Patients
Blood was taken  from  20  renal transplant  patients  of varying  donor/recipient 
HCMV serostatus  using sodium  heparin syringes.  PBMCs were  isolated and 
stimulated  within  three  hours  of  extraction,  with  either  a  commercially 
available  HCMV  lysate or peptide pools that spanned  either the  IE1  or pp65 
sequences,  along  with  co-stimulatory  antibodies  against  CD28  and  CD49d. 
After  2  hours  incubation,  brefeldin  A  was  added  and  stimulations  were 
allowed  to  proceed  for  an  additional  12  hours.  HCMV-specificity  was 
enumerated through  FACs  by  measuring the  frequency  of  CD4+  CD3+  cells 
able to produce IFNy while expressing the activation marker CD69 (Fig. 3.1).
Figure  3.2  shows  the  relative  contributions  of  IE1  and  pp65  to  the  global 
HCMV-specific  CD4+  T-cell  response  as  ascertained  by  responses  to  the 
HCMV  lysate.  Median  responses  towards  the  HCMV  lysate  were, 
predictably,  the  largest  elicited  by any of the three  antigens,  with  responses 
ranging from  <0.05 to  10.4%  (median  1.1%),  while  responses towards  pp65 
ranged between <0.05 and 2% (median 0.26%), the lowest responses where 
towards  IE1  and  these  ranged  between  <0.05  and  0.8%  (with  a  median  of 
below  the  lower  limit  of  detection  <0.05%).  Because  of  the  relatively  small 
contribution of  IE1  to the CD4 response of the patients included, this chapter 
primarily focused on the CD4 responses to the HCMV lysate and pp65.
CD4+  T-cell  responses  to  HCMV  lysate  were  analysed  at  monthly  intervals 
for  six  months  post-transplant  and  compared  with  responses  obtained  from
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healthy  seropositive  individuals  (Fig.  3.3).  The  results  show  increased 
frequencies  of  HCMV-specific  CD4+  cells  in  renal  patients  compared  to 
healthy controls  although this  increase  was  not  significant  (Mann-Whitney  p 
=  >0.05).  A  two-tier  increase  in  HCMV-specific  CD4+  responses  occurred 
between  the  first  and  third  months  (median  frequencies  0.65%  and  0.87% 
respectively,  Willcoxon  test  p  =  0.03)  and  the  third  and  sixth  (median 
frequencies  0.87%  and  1.45%,  p  =  0.01)  post-transplant,  although  the  CD4 
responses peaked at month 4 (median  1.55%).
Since data on  percentages  of  HCMV-specific CD4+  do  not  give  an  accurate 
representation  of  the  absolute  numbers  of  circulating  cells  in  an  individual, 
the  results  were  recalculated  based  upon  the  absolute  number  of 
lymphocytes from each individual at each time point.
Figure  3.4  demonstrates  that,  as  with  percentages  of  HCMV-specific  CD4+ 
cells,  the absolute  numbers of circulating  HCMV-specific CD4+ cells showed 
a  significant  increase  over  the  first  three  months  post-transplant,  and  that 
these  populations  continued  to  rise  until  month  four  when  they  peaked 
(median  7.84  x  106  cells/l)  and  remained  constant for the  next  two  months. 
Results  correlate  well  with  evidence  suggesting  that the  majority  of  HCMV- 
seropositive  patients  becoming  viraemic  during  the  first  three  months  after 
transplant  (all  viraemic  patients  did  see  appendix  patients  1   to  9).  Should 
increases  in  CD4+  populations  be  protective,  it  would  be  conceivable  that 
frequencies of these cells would be decreased in viraemic patients relative to 
non-viraemic patients.  Interestingly, the highest responses (68.3 x  106 cells/l)
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actually  occurred  in  an  individual  who  suffered  repeated  viraemic  episodes, 
although  this  individual  did  not  have  the  highest  percentages  of  CD4+  cells 
that are HCMV-specific.
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Figure 3. 1  FACS analysis plots of IFNy production by a renal transplant patient in response to FICMV and control lysate.  Populations 
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Figure  3.  2  Relative  contributions  of  antigens  to  the  HCMV-specific  CD4+   T-cell 
response
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Figure  3.  3  Fluctuations  in  HCMV-specific  CD4+   populations  as  quantified  by  the 
percentage  of  cells  expressing  IFNy  and  CD69  over  a  six  month  period  post­
transplant.  Dotted line denotes the lower limit of detection (0.1%).  The table below 
shows  median  percentages  of  each  data  set  and  P  values  as  calculated  using 
Willcoxon  test  for  comparison  between  matched  pairs  and  Mann-Whitney  test  for 
unmatched pairs. Significant values are highlighted in red.
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Figure  3.  4  Longitudinal  analysis  of  the  absolute  number  of  circulating  HCMV- 
specific  CD4+   cells,  which  were  able  to  express  CD69  and  IFNy on  stimulation. 
Table shows median number of cells x 106/l of each time-point, and p-values for the 
significance  of  differences  between  samples  using  a  paired  T-test.  Significant 
values are highlighted in red.
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3.3  CD4 responses to the tegument protein pp65
Global  CD4+  responses  to  HCMV  increase  significantly  during  the  first  six 
months post-transplant;  it is therefore  important to know whether constituent 
parts  of  this  overall  response  that  are  focused  on  specific  virus  antigens 
differ  in  their  relative  times  of  emergence.  The  major  tegument 
phosphoprotein, pp65 (or ppUL83),  has previously been shown to be a major 
target for HCMV-specific CD4+ cell  response [271,  276,  335,  363].  Being the 
major  structural  component  of  the  virion,  it  is  also  one  of  the  first  antigens 
available  for  processing  virus  infection  of  any  antigen  presenting  cells  and 
therefore  its  presentation  would  likely  be  associated  with  a  productive 
infection.
Figure  3.5  shows  no  significant  difference  between  median  percentages  of 
pp65-specific  CD4+  T-cells  was  found  between  healthy  seropositive 
individuals  (median  0.27%)  and  renal  transplant  patients  (highest  median 
month  6,  0.46%,  Mann-Whitney  p  =  0.59).  Longitudinal  analysis  of  pp65- 
specific  CD4  responses  in  renal  transplant  patients,  for  the  6  months 
proceeding  transplant,  shows  that  they  are  fairly  stable  throughout  with 
percentages  ranging between  <0.1%  (below the  lower limit of detection)  and 
1.95%.  Median  responses  are  lowest  in  the fourth  month  (0.21%)  and  peak 
in  the  sixth  month  post-transplant  (0.46%).  Significant  increases  occurred 
between  months three and six  (medians 0.28% to 0.46% p = 0.04), four and 
six  (0.21%  to  0.46%  p  =  0.05)  and  month  five  and  six  (0.33  to  0.46%  p  = 
0.003).
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When absolute responses are compared over the same period (Fig.  3.6), the 
number of circulating  pp65-specific CD4+ cells  ranged from  0.05 x  106 cells/l 
to  10.23  x  106 cells/l.  While the  responses  fluctuated  during  the  six  months 
period  the  only  significant  elevation  occurred  during  the  sixth  month  post­
transplant.
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Figure  3.  5  Fluctuations  in  pp65-specific  CD4+   populations  as  quantified  by  the 
percentage  of  cells  expressing  IFNy  and  CD69  over  a  six  month  period  post­
transplant.  Dotted line denotes the lower limit of detection  (0.1%).  The table below 
shows  median  percentages  of  each  data  set  and  P  values  as  calculated  using 
Willcoxon  test  for  comparison  between  matched  pairs  and  Mann-Whitney  test  for 
unmatched pairs. Significant values are highlighted in red.
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Figure 3. 6 Longitudinal analysis of the absolute number of circulating IE1-specific 
CD8+  cells that were able to express CD69 and IFNy on stimulation. Table shows 
median number of cells x 106 /l of each timepoint, and p-values for the significance 
of  differences  between  samples  using  a  paired  T-test.  Significant  values  are 
highlighted in red.
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3.4  Comparing HCMV CD4 responses in renai transplant patients
To  examine  whether  defects  in  the  HCMV-specific  CD4  responses  exist  in 
individuals  predisposed  to  suffering  recurrent  episodes  of  viraemia,  CD4 
responses  to  HCMV  were  compared  between  patients  who  developed 
viraemia and those that did not during the first 6 months post-transplant.
During  viraemia,  patients  seropositive for  HCMV  prior to transplant  undergo 
expansions  of  their  pre-existing  HCMV-specific  CD4+  T-cell  subset 
populations  [335,  367],  rendering  any  differences  in  measurement  of  these 
populations  less  meaningful  than  those  taken  prior  to  viraemic  episodes. 
Therefore  CD4  responses  of  renal  transplant  patients  were  analysed  in  the 
first  month  after  transplant  to  discover  whether  there  was  a  pre-existing 
defect  in  HCMV-specific  CD4  responses  that  predisposed  the  individual  to 
viraemic episodes post-transplant.
There  was  a  non-significant  decrease  in  the  frequency  of  HCMV-specific 
CD4+  cells  in  viraemic  patients  (median  0.53%  and  0.80%,  p  =  0.66)  during 
the first  month  post-transplant compared to transplant recipients who remain 
PCR negative for HCMV throughout the six months post-transplant (Fig. 3.7). 
This  is  consistent  with  data  obtained  when  absolute  numbers  of  circulating 
HCMV-specific  CD4+  cells  were  compared;  viraemic  patients  had  a  median 
of  2.65  x  106  cells/l  while  patients  who  remained  free  from  viraemia  had  a 
median of 4.69 x 106 cells/l (p = 0.21).
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Several  patients  suffered  from  recurrent  HCMV  viraemia  throughout the  six 
month period post-transplant (see appendix). To investigate whether this was 
due to a defect in the overall  HCMV-specific CD4+  response during that time 
period,  a comparison  was  performed  using  data on  HCMV-specific  CD4+ T- 
cell  populations  accumulated  from  viraemic  individuals  and  non-viraemic 
individuals over the six month period post-transplant (Fig.  3.8).  Results again 
showed  a  non-significant  decrease  in  the  percentages  of  HCMV-specific 
CD4+  T-cells  in the  peripheral  blood  of viraemic  individuals  when  compared 
with  non-viraemic  individuals  (median  0.97%  and  1.25%  respectively,  p  = 
0.08).  Although  when  absolute  numbers  were  analysed  the  decrease  was 
more  pronounced  (medians  3.43  and  7.00  x  106  cells/l  respectively,  p  = 
0.02),  indicating  that  the  responses  were  significantly  elevated  in  those 
individuals capable of controlling virus replication.
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Figure 3. 7 Comparison of global CD4+  responses to HCMV between viraemic and 
non-viraemic renal transplant patients. Top panel shows a comparison of CD4+  T- 
cell  percentages  while  the  bottom  panel  has  a  comparison  of  absolute  HCMV- 
specific CD4+  T-cell populations in the peripheral blood.
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Figure 3. 8 Comparison of global CD4+  responses to HCMV between viraemic and 
non-viraemic  renal  transplant  patients  over  the  entire  six  month  period  post­
transplant. Upper panel shows a comparison of CD4+  T-cell percentages while the 
lower  panel  shows  absolute  HCMV-specific  CD4+   T-cell  populations  in  the 
peripheral blood.
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3.5  Comparison of CD4 Responses in Months 1 to 3 and 4 to 6
HCMV  viraemia  in  patients  usually  occurred  during  the  first  three  months 
post-transplant.  To  determine  whether  there  is  any  recovery  in  the 
frequencies  of  HCMV-specific  CD4+  cells  after  this  period,  which  coincides 
with  a  decrease  in  the  associated  risk  of  HCMV  replication,  the  median 
frequencies  of  virus-specific  CD4+  cells  during  the  first  three  months  post­
transplant  were  compared  with  those  of the  months  four to  six,  where virus 
reactivation becomes less frequent (Fig.  3.9). The data showed that absolute 
numbers  of  HCMV-specific  CD4+  T-cells  were  significantly  decreased  in 
months one to three, with a median 3.48 x  106 cells/l  compared to 7.73 x  106 
cells/l  during  months  four  to  six  (Willcoxon  test  p  =  <0.0001).  The  median 
percentage  of  HCMV-specific  CD4+  cells  also  increases  after the  first  three 
months post-transplant from 0.78 to 1.44% (Willcoxon test p = <0.0001).
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Figure  3.  9  A  comparison  of  the  absolute  number  of  HCMV-specific  CD4+  
responses of 20 renal transplant patients in months one to three and months four to 
six post-transplant.  Top  panel  shows the  percentages of  HCMV-specific  CD4+  T- 
cells bottom panel shows the absolute number of HCMV-specific CD4+  T-cells/ml in 
the peripheral blood.
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3.6  The relationship between HCMV-specific CD4+  and CD8+  responses
To  investigate  whether  there  was  a  relationship  between  frequencies  of 
HCMV-specific  CD4  populations  and  HCMV-specific  CD8  both  the 
percentages  and  absolute  numbers  of  CD4  cells  responding  to  stimulation 
with  HCMV  lysate were  compared  with  combined  CD8+  T-cell  responses  to 
pp65  and  IE1  Pepmixes.  No link between the overall  percentages of  HCMV- 
specific  CD4+  lymphocytes  and  the  overall  percentages  of  pp65  and  IE1- 
specific  CD8+  lymphocytes  could  be  established  (Fig.  3.11).  Certain 
individuals with CD4+ T-cell  responses below the threshold  level  of detection 
(<0.1 %)  mounted large  HCMV-specific CD8+ T-cell  responses  (>10%), while 
other individuals with large HCMV-specific CD4+ T-cell responses (>4%)  had 
no  detectable  CD8  responses  to  pp65  and  IE1.  However,  when  absolute 
numbers  of  HCMV-specific  CD4+  and  CD8+  T-cells  (Fig.  3.11)  in  the 
peripheral  blood  were  analysed  the  relationship  was  highly  significant  (p  = 
0.0004),  indicating that there is a link between absolute frequencies of CD4+ 
T-cells and the magnitude of a HCMV-specific CD8+ T-cell response.
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Figure  3.  10  Relationship  between  the  percentages  of  HCMV-specific  CD4+   and 
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post-transplant.
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Figure  3.  11  Relationship between the absolute  number of  HCMV-specific CD4+  
and  CD8+   T-cell  populations  in  the  peripheral  blood  of  twenty  renal  transplant 
patients taken at one month intervals for six months post-transplant.
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3.7 Discussion
This chapter describes  how populations  of CD4+ T-cells,  specific for  HCMV, 
fluctuate in  a group of 20  renal transplant patients over the six  month  period 
renal post-transplant.  Responses of CD4+ T-cell populations specific for pp65 
and  IE1  were  compared  against the  global  HCMV-specific  CD4+  response, 
as  assessed  by  stimulation  with  a  whole  virus  lysate  mixture,  which  should 
contain  the  majority  of  HCMV  antigens  available  for  processing  and 
presentation  by  APCs  to  CD4+  T-cells  (Fig  3.2).  Responses  to  the  whole 
HCMV  lysate  varied  between  <0.05%  (below  the  detection  threshold)  and 
10.4% (median  1.08%); predictably, the range of responses to pp65 (<0.05% 
to  2%,  median  0.26%)  and  IE1  (<0.05%  to  0.89%,  median  0.04%)  were 
significantly  lower,  only  contributing  around  25%  of  the  overall  HCMV- 
specific  CD4+  response.  These  data  indicate  there  must  be  other targets  of 
the CD4+ response to  HCMV such as gB (the UL55 gene product)  and  UL32 
[264].  Despite  previously  being  shown  to  be  a  major  target  for  the  HCMV- 
specific CD4+ T-cells [277,  324,  364-366],  responses to  IE1  were only above 
the  lower  level  of  detection  (<0.05%)  in  two  individuals  analysed  over  the 
entire  six  month  period  analysed.  Because  of this,  responses  to  pp65  were 
used  as  a  more  appropriate  measure  of  CD4+  T-cell  responses  to  a 
constituent of the virion.
Figure  3.3  shows  a  longitudinal  analysis  of  changes  in  the  percentages  of 
HCMV-specific  CD4+  T-cells;  a  general  increase  in  HCMV-specific  CD4+  T- 
cell  populations  in  the  six  months  post-transplant  that  peaks  during  month 
four  (median  1.56%),  the  populations  then  stabilised  during  the  two
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subsequent  months.  A  two-tier  increase  in  HCMV-specific  populations  was 
observed during this period, the first increase occurred  between  months one 
and  three  (p  =  0.03)  and  the  second  between  months  three  and  six  post­
transplant (p = 0.01). Contrary to work performed by Sester et al.  [332], there 
was  no  significant  difference  between  the  percentages  of  HCMV-specific 
CD4+ T-cells in renal-transplant patients and healthy individuals.
Figure 3.4 shows that fluctuations in the absolute numbers of HCMV-specific 
CD4+  T-cell  in  the  peripheral  blood  follow  a  similar  pattern,  this  being  a 
gradual  increase  in  the  magnitude  of  HCMV-specific  responses  until  month 
four, where they peak (median 7.84 x 106 cells/l) and then stabilise in months 
five and six. This once more shows a two-tier shape to the rise in the HCMV- 
specific CD4 population, which  may coincide with  previous observations that 
HCMV reactivation in renal transplant patients usually occurs for the first time 
within the three months  immediately after transplant when T-cell  populations 
are  decreased  because  of  immunosuppressive  therapies  [101,  368,  369]. 
Together these data  indicate that CD4+ T-cell  levels  may  inversely correlate 
with the incidence of viraemia.
To  determine whether the frequencies  of  CD4+  populations directed  against 
constituent  parts  of  the  virus  follow  similar  kinetics  for  re-emergence,  a 
similar  longitudinal  analysis  was  performed  on  populations  specific  to  the 
major  structural  phosphoprotein  pp65.  Pp65  would  be  available  for 
processing  by  APCs  following  initial  infection  as  it  is  one  of  the  most 
abundant  components  of  the  virion;  also  because  it  is  a  late-phase  gene
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product  it  would  also  be  available  for  processing  at  late  stages  in  the  virus 
replication cycle.  Both of these observations indicate that responses to pp65 
could  arise  as  a  consequence  of  a  productive  virus  infection.  Data  showed 
that CD4+ T-cell  responses to pp65 ranged from <0.05% and  1.95%;  median 
responses  towards  pp65  fluctuated  during  the  six  month  period  post­
transplant,  being  lowest during  month four (0.21%)  and  highest in  month  six 
(0.46%)  (Fig.  3.5).  One significant rise  in  median  CD4  populations  occurred 
in  month  six.  Fluctuations  in the absolute frequencies of  pp65-specific CD4+ 
cells  followed  a  similar  pattern  with  median  populations  are  again  lowest 
during  month  four  (0.76  x  106  cells/l)  and  highest  during  month  six  (1.67  x 
106 cells/l)  (Fig.  3.6).  Because  responses to  pp65 fluctuate so  much  and do 
not  mirror  global  responses  as  elicited  by  HCMV  lysate,  they  would  appear 
not to  influence  HCMV-specific  responses  as  much  as  other antigens,  such 
as glycoprotein B (gB) [370].
Several  individuals  monitored  during  the  course  of  this  study  developed 
HCMV viraemia, which could predispose them to HCMV-associated disease. 
A  possible  reason  for  viraemia  would  be  that  T-cell  responses  in  these 
individuals  are  for  some  reason  unable  to  control  virus  replication,  either 
because  they  are  of  insufficient  magnitude  or  functionally  deficient  and 
therefore  unable  control  virus  replication.  The  frequencies  of  virus-specific 
IFNy-producing  CD4+  T-cells  were  therefore  compared  in  viraemic  and  non 
viraemic  patients  during  the  first  month  post-transplant  when  most 
incidences of viraemia occur. These measurements would give an  indication 
of any predisposing defect in their CD4+ responses  rendering the individuals
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more susceptible to viraemic episodes.  Data suggests that although  a slight 
increase  in  the  percentages  (Fig.  3.7  upper panel,  median  viraemics  2.65% 
median  non-viraemics  3.84%  p  =  0.29)  and  the  absolute  levels  (Fig.  3.7 
lower panel,  median viraemics 0.53 x  106 cells/l  median non-viraemics 0.76 x 
106 cells/l  p  =  0.76)  of  HCMV-specific  CD4+ T-cells  occurred  in  the  patients 
able to control virus replication in the six  month period post-transplant, these 
elevations were not significant.
Because these patients almost invariably suffered repeated bouts of viraemia 
during the post-transplant period, overall  responses to HCMV lysate over the 
entire  period  monitored  were  combined  and  compared  to  the  responses  of 
individuals  able  to  control  virus  replication.  A  comparison  of  the  median 
percentages  of  HCMV-specific  CD4+  T-cells  between  these  two  groups 
showed  no significant difference  (Fig.  3.8 upper panel  0.97% and  1.16% p = 
0.08).  Whilst  the  same  analysis  on  median  absolute  numbers  of  HCMV- 
specific CD4+ T-cells similarly showed an elevation (Fig. 3.8 lower panel 3.43 
x  106 cells/l  compared to 7.00 x  106 cells/l)  which was significant  (p =  0.02). 
Together  these  data  indicate  that  CD4+  T  cell  responses  to  HCMV  play  a 
crucial role in the control of viraemia.
The  number of  HCMV-specific  CD4+  T-cells  seems to  correlate  directly with 
protection from  HCMV viraemia - there  also seems to  be  a two-tier increase 
in  magnitude  of  HCMV-specific  CD4+  T-cell  responses.  A  comparison  of 
HCMV-specific  CD4+  T-cell  responses  was  performed  between  months  one 
to  three  and  months  four  to  six  post-transplant  (Fig.  3.9).  Median  absolute
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numbers  rose  significantly  (p  =  0.0001)  from  months  one  to  three  (median 
3.48 x  106 cells/l) to  months four to six  (median  7.78 x  106 cells/l).  This was 
consistent  with  absolute  numbers  of  HCMV-specific  CD4  cells  in  the 
peripheral  blood,  which  rose  from  0.78%  during  the  months  one  to three to 
1.44%  in  months  four to  six  (p  =  0.0001).  One  possible  explanation  for this 
increase  is  that  a  decrease  in  the  immunosuppressive  regimens 
administered  to  the  patients  occurs  in  the  months  post-transplant;  indeed, 
levels  of  calcineurin  inhibitors tacrolimus  and  cyclosporine  A  are  decreased 
during  the  third  month  post-transplant,  from  10-15ng/ml  to  6-10ng/ml  and 
250-350ng/ml  to  150-250ng/ml,  respectively.  Furthermore  administration  of 
the corticosteroid prednisolone is decreased every two weeks post-transplant 
and  stopped  in  the  majority  of  patients  after  2-3  months.  This  would  allow 
recovery  of  T-cell  populations  and  the  resultant  increases  would  correlate 
well  with  a  reduced  frequency  of  viraemia  three  months  post-transplant. 
Therefore the increase in CD4+ T-cell  populations could have indirect effects 
that  help  control  viraemia  such  as  by  increasing  the  frequency  of  HCMV- 
specific CD8+ populations.
To determine whether increases in HCMV-specific CD4+ T-cells has an effect 
on  the  populations  of  HCMV-specific CD8+  T-cells,  the  relationship between 
HCMV-specific  CD4+  cells  and  combined  CD8+  T-cells  responses  elicited 
against  IE1  and  pp65 was  compared within  individuals.  Figure  3.10  showed 
that  there  was  no  direct  correlation  between  the  frequencies  of  HCMV- 
specific  CD4+  and  CD8+  T-cells  in  terms  of  the  percentages  of  each 
population.  Whilst  certain  individuals  had  large  CD4+  T-cell  responses
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against  HCMV  their  CD8  responses  were  undetectable.  Similarly,  certain 
individuals who had  large CD8+ responses in some cases had no detectable 
CD4+  responses.  Conversely,  a  comparison  between  the  absolute  numbers 
of  HCMV-specific CD4+ T-cell  in the  peripheral  blood  and the corresponding 
numbers  of  circulating  HCMV-specific  CD8+  T-cells  a  correlation  could  be 
seen (Fig. 3.11  Spearman’s r = 0.32, p = 0.0004). This data indicates that the 
magnitude  of  individuals’  CD4+  responses  to  HCMV  has  a  bearing  on  the 
same  individuals’  responses  to  targets  of  the  HCMV-specific  CD8+  T-cell 
response.  Although  certain  individuals  may  still  have  high  frequencies  of 
pp65  and/or  IE1-specific  CD8+  T-cell  populations  in  the  absence  of  HCMV- 
specific CD4 responses. This chapter demonstrates that, while there is a link 
between  the  absolute  magnitude  of  HCMV-specific  CD4+  and  CD8+  T-cell 
populations  in  renal  transplant  patients,  CD4+  T-cells  are  not  themselves 
directly  protective  in  viraemic  individuals.  It  may  therefore  be  possible  to 
conclude  that  virus-specific  CD4  populations  have  an  in  trans  effect  on 
HCMV-specific  CD8+  T-cell  populations,  which  may  themselves  be 
protective.
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4.1  Introduction
This  chapter  focuses  on  HCMV-specific  CD8+  T-cell  responses  in  renal 
transplant  patients.  Post-transplant,  these  individuals  require 
immunosuppressive regimens to prevent the  rejection of a donor organ.  The 
resultant  immunosuppression  causes  depletion  of  T-cell  populations,  thus 
increasing  the  chance  of  reactivation,  reinfection  or  primary  infection  of  the 
patient with HCMV.
CD8+  T-cells  recognise target antigens  presented to them  on  the  surface  of 
all  infected  nucleated  cells  in  the  context  of  MHC  class  I  molecules.  Their 
principal  function  is  to  lyse  infected  cells,  a  process  mediated  through  the 
polarised  release  of  lytic  proteins  such  as  perforin  [371-373],  granzymes  A 
and  B  and  granulozymes,  which  are  released  on  ligation  of the  MHC  class 
l/cognate antigen complex with the TCR of the CD8+ T-cell [230, 374, 375].
In  immunocompetent  individuals,  a  fine  balance  is  maintained  between 
HCMV  and  virus-specific  CD8+  T-cells;  any  reduction  in  the  CD8  response 
would  disrupt  this  equilibrium  and  this  may  consequently  result  in 
uncontrolled  HCMV  replication,  which  left  unchecked  could  lead  to  HCMV- 
associated  disease.  Patients  who  are  seronegative  prior  to  transplantation 
and  receive  an  organ  from  a  seropositive  donor  have  an  increased  risk  of 
HCMV-associated disease on virus  reactivation from the donor organ due to 
the  lack  of  an,  albeit  suppressed,  pre-existing  virus-specific  immune 
response being able to prevent high level replication.
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Adoptive  transfer  of  HCMV-specific  CD8+  T-cell  clones  in  haematopoietic 
stem  cell  transplant  recipients  (SCT)  has  been  shown  to  be  successful  for 
preventing  of  HCMV-associated  disease  [376,  377],  although  this  is 
improved  by the  presence  of  HCMV-specific  CD4+  T-cells  .  Several  studies 
have focused on the relationship between  HCMV replication and CD8+ T-cell 
frequencies in the various solid organ transplant patient groups; although few 
of  these  have  addressed the  absolute  numbers  of  responsive  cells  or  have 
looked  longitudinally  at  the  responses  to  the  two  major  immunodominant 
targets for the CD8+ T-cell response, namely pp65 and IE1.
High  frequencies  of  CD8+  T-cells  specific  for  the  structural  phosphoprotein 
pp65  have  previously  been  detected  in  a  number  of  individuals  [257,  266]. 
pp65  is a  major constituent of the virion  and would be immediately available 
for processing by professional antigen presenting cells (APCs) after infection. 
Its  expression  as  a  late  stage  protein  during  the  HCMV  replication  cycle 
could  therefore  allow  it  to  be  viewed  as  a  marker  for  production  replication 
following virus reactivation.
This  chapter  aims  to  quantify the temporal  magnitude  of  functional  CD8+  T- 
cells  responses  to  the  two  immunodominant  targets  of  HCMV-specific  CD8 
response,  IE1  and  pp65,  longitudinally  in  renal  transplant  patients.  Co­
expression  of  the  activation  marker  CD69  with  the  Th1  cytokine  IFNy  in 
response  to  stimulation  of  PBMCs  with  overlapping  15-mer  peptide  mixes 
spanning  IE1  and  pp65  proteins  was  used  as  a  measure  of  functionality  of 
these CD8+ T-cell populations [378].
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These  functional  responses  were  also  used  in  parallel  with  lymphocyte 
counts  to  determine  the  absolute  numbers  of  functional  virus-specific  CD8+  
T-cells  in  the  blood  of  these  renal  transplant  patients;  measured  over  six 
months post-transplant.
A subset of these patients still suffered from virus reactivation  in the  months 
following  transplant  despite  the  presence  of  HCMV-specific  CD8+  T-cell 
responses. To determine whether this phenomenon occurred as a result of a 
deficiency  in  the  magnitude  of  HCMV-specific  CD8+  responses,  a 
comparison  of  these  responses  was  performed  between  viraemic  and  non- 
viraemic individuals.
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4. 2 CD8+  responses to pp65 in renal transplant patients
To  examine  the  fluctuations  in  populations  of  HCMV-specific  CD8+  T-cells 
over the six  months following renal transplant,  PBMCs isolated from 20  renal 
transplant  patients  at  monthly  intervals  were  stimulated  with  overlapping 
synthetic  peptide  pools  spanning  the  entire  sequences  of  IE1  and  pp65 
proteins  [378].  HCMV-specific  responses  towards  these  two  pools  were 
measured  using  FACS to determine the percentage of CD3+ CD4' cells able 
to express CD69 and  IFNy (Fig.  4.1).  Frequencies of CD69+  IFNy+ CD8 cells 
were  compared  to  those  of  healthy  HCMV-seropositive  individuals  and 
analysed  over  time  to  determine  whether  there  were  any  significant 
fluctuations in these populations in the six month period post-transplant.
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Figure 4.  1   FACS analysis plots of  IFNy production  by a  renal transplant patient in  response to overlapping  synthetic peptide  pools 
spanning  IE1  and pp65 sequences.  Populations are gated on lymphocyte +  CD3+  CD4  populations.  Left panels show gating of CD3+  
IFNy+   cells  (T-cells),  central  panels  show  gating  on  CD3+   CD4  T-cell  populations  (used  here  as  CD8)  the  right  panels  show the 
proportion of the CD3+  CD4  cells expressing CD69 and IFNyin response to stimulation.
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4.2.  1 Frequency of pp65-specific CDS* populations post-transplant 
Figure 4.3 shows the fluctuation in pp65-specific CD8+ populations over the 6 
month  period  post  transplant  for  all  20  patients.  The  frequencies  of  pp65- 
specific  CD8+ T-cells,  as  determined  by  IFNy production,  range  from  <0.1% 
(below the detection threshold)  to  6.7%  in the  renal  transplant patients,  and 
<0.1%  to  5.69%  in  seropositive  healthy  individuals.  14  of  the  20  renal 
transplant patients (70%) had pp65-specific responses that were consistently 
above the threshold of detection (Fig. 4.2).
A  comparison  of  pp65-specific  CD8+  cell  responses  between  healthy 
individuals and renal transplant patients revealed no significant differences in 
the  percentage  of  cells  expressing  IFNy and  CD69  on  stimulation  with  pp65 
peptide  mixes  (Mann-Whitney test for unmatched pairs p =  >0.05)  (Fig.  4.3). 
The  frequency  of  pp65-specific  CD8+  T-cells  increased  from  a  median  of 
0.25%  during  the first  month  post-transplant to  0.53%  in  the  second  month, 
although  this  increase  was  not  significant  (Willcoxon  test  for  matched  pairs 
p>0.05).  There  was  a  significant  increase  in  responses  from  month  1   to 
month  3  post-transplant  (0.25%  to  0.53%  p  =  0.03)  and  between  months  2 
and  5,  when  responses  appear  to  peak  (0.53%  to  0.94%  p  =  0.03)  and 
stabilise at month 6.
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Figure  4.  2  Numbers of HCMV seropositive individuals with consistent detectable 
(>0.1%) CD8+  T-cell responses against IE1 and/or pp65Chapter 4: HCMV-specific CD& Responses in Renal Transplant Patients
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Figure  4.  3  Fluctuations  in  pp65-specific  CD8+   populations  as  quantified  by the 
percentage  of  cells  expressing  IFNy and  CD69  over  a  six  month  period  post­
transplant. The dotted  line denotes the lower limit of detection  (0.1%).  The table 
below shows median percentages of each data set and p values as calculated using 
Willcoxon test for comparison  between  matched  pairs  and  Mann-Whitney test for 
unmatched pairs. Significant values are highlighted in red.
152Chapter 4: HCMV-specific CD& Responses in Renal Transplant Patients
4.2.2 Frequency of IE1-specific CDlT populations post-transplant
IE1-specific  CD8  responses  were  measured  in  the  same  way  as  pp65 
(results shown  in  Fig. 4.3).  10/20 (50%) seropositive donors had  IE1-specific 
CD8+  responses  that were consistently  above  background  (<0.1 %).  Median 
responses  to  IE1  were  elevated  in  healthy  individuals  compared  to  those 
after  a  renal  transplant  (0.04%  and  0.26%),  but  this  increase  was  not 
significant  (p  =  0.46).  The  range  of  IE1-specific  CD8  responses  in  renal 
transplant patients was between <0.05% and  14.19%,  and  between  <0.05% 
and  4.23%  in  healthy  seropositive  donors.  Although  there  was  a  greater 
range  in  these  responses  compared  with  those  towards  pp65,  median 
responses to  IE1  were  generally  lower than  to  pp65  in  the  renal  transplant 
patients (0.11% and 0.52% respectively, p = 0.16 Fig. 4.5).
Fig 4.4 shows that median  immune responses to  IE1  were lowest  in the first 
month  post-transplant  (0.04%)  and  peaked  during  the  second  month  post­
transplant  (0.19%)  and  this  increase  was  significant  (Willcoxon  p  =  0.007). 
This  peak  could  correspond  to  viral  reactivation  in  either  previously 
seropositive  patients  or  the  organs  from  seropositive  donors  early  after 
transplantation  driving  the  IE1-specific  CD8+  response.  Frequencies 
continued to fluctuate in the subsequent four months although the only other 
significant increase in these populations occurred between the first and sixth 
month post-transplant (0.04% and 0.14% p = 0.025).
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4.2.  3  Responses  of  combined  pp65/IE1-specific  CDS'  populations 
post-transplant
Because  IE1  and pp65 are believed to represent the principal targets for the 
CD8-T-cell  response,  combining  the  CD8  responses  to  both  of  these 
antigens  may  give  a  more  accurate  representation  of  global  HCMV-specific 
CD8+ T-cell  responses.  Figure 4.6,  shows combined responses to these two 
antigens to vary between  <0.05% to  19.8% following  renal  transplant.  15/20 
(75%)  of  renal  transplant  had  T-cell  responses  to  either  or  both  of  these 
antigens  (Fig.  4.2) while some  lacked detectable CD8+  responses to both of 
these  antigens.  Interestingly,  the  highest  percentages  of  antigen-specific 
CD8+  responses  consistently  came  from  one  individual  who  suffered 
repeated episodes of viraemia during the 6 months post-transplant.
Figure  4.6  shows  CD8+  responses  to  pp65  and  IE1  in  renal  transplant 
patients over the 6  month  period post-transplant.  Lowest median  responses, 
as  before,  occurred  during  the  first  month  post-transplant  (median  0.74%) 
and  peaked  during  the  fourth  month  post-transplant  (2.25%),  with  a 
significant difference  in  median  values  between  months  one  and two  (rising 
from 0.74 to 1.17% Willcoxon p = 0.02). These percentages continued to rise 
significantly,  with  respect  to  the  first  month,  until  month  four  when  the 
percentage of HCMV-specific CD8+ T-cells against pp65 and IE1  peaked at a 
median of 2.25% and stabilised in the months thereafter.
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CD8+ Responses to IE1  in  Renal Transplant Patients
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Healthy  1   2  3  4  5   6
Months Post-Transplant
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month 1 0.04 0.46 month2
month 2 0.19 0.92 0.01 month 3
month 3 0.1 0.84 0.09 0.89 month 4
month 4 0.15 0.97 0.28 0.77 0.68 Month 5
month 5 0.08 0.87 0.13 0.59 0.50 0.93 month 6
month 6 0.14 0.78 0.02 0.92 0.41 0.71 0.12
Figure  4.  4  Fluctuations  in  IE1 -specific  CD8+   populations  as  quantified  by  the 
percentage  of  cells  expressing  IFNy and  CD69,  over  a  six  month  period  post­
transplant.  The  dotted  line  denotes  background  (0.1%).  The  table  below  shows 
median percentages of each data set and p values as calculated using Willcoxon 
test for comparison between matched pairs and Mann-Whitney test for unmatched 
pairs. Significant values are highlighted in red.
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Com parison of pp65 and  IE1-specific CD8+ responses
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Figure 4.  5 The relative contributions of CD8+  responses to pp65 and IE1  in renal 
transplant patients during the six months post-transplant. The dotted line indicates 
the lower limit of sensitivity.
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Figure 4. 6 Fluctuations in  IE1  and pp65-specific CD8+  populations, quantified by 
the percentage of cells expressing  IFNy and CD69, over a six month period post­
transplant. The dotted line denotes background (0.2%). Table below shows median 
percentages of each data set and p values as calculated using Willcoxon test for 
comparison  between  matched  pairs  and  Mann-Whitney test for unmatched  pairs. 
Significant values are highlighted in red.
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4.  3 Percentages CD8  Responses in  Months 1-3 and  Months 4-6  post­
transplant.
The temporal increases in CD8 responses noted in section 4.2 may correlate 
with  the  increased  frequencies  of  viraemic  episodes  during  the  first  three 
months  post-transplant;  presumably when  CD8  populations  are  lower  and  a 
threshold level of immunity has not yet been reached.
To  determine  whether  there  was  a  significant  difference  in  HCMV-specific 
CD8  responses  during  months  one  to  three  post-transplant  compared  to 
months four to six, total  responses to pp65 were subdivided  into two groups, 
months  1  to 3 and months 4 to 6 post-transplant.  Median values of the pp65- 
specific  CD8+  responses  in  the  twenty  patients  were  then  compared  (Fig. 
4.7).
A  significant  rise  in  the  median  percentages  of  pp65-specific  CD8+ 
populations  occurred  after  the  third  month  post-transplant,  with  these 
populations  increasing  from  0.42%  to  0.8%  (Willcoxon  test  p  =  0.002).  The 
same analyses were  performed  using  responses towards  IE1  and combined 
IE1  and pp65 antigens.  IE1  responses increased from  a median of 0.09% to 
0.15%  but this  increase was  not significant  (Fig  4.8).  The combined  median 
antigen-specific  CD8+  cell  percentage  increased  from  0.93  to  2.18%, 
although this rise was not significant (Fig 4.9).
Determining  the  percentage  of  CD8+  T-cells  able  to  produce  IFNy  in 
response to these  immunodominant targets allowed the determination  of the
158Chapter 4: HCMV-specific CD& Responses in Renal Transplant Patients
proportions  of  CD8+  populations  specific  to  virus  antigens,  but  it  does  not 
provide the absolute  numbers of these functional  HCMV-specific cells  in the 
peripheral blood of the individuals. The absolute numbers of cells may give a 
more accurate measure of CD8+ T-cells cells able to control virus replication.
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CD8+ pp65 Responses Months 1-3 vs Months 4-6
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Figure 4. 7 Comparison of pp65-specific CD8+  responses in twenty renal transplant 
patients in months 1  to 3 and months 4 to 6 post-transplant. The dotted line denotes 
lower level of sensitivity (0.1%).
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CD8+ IE1  responses
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Figure 4. 8 A comparison of IE1-specific CD8+  responses in twenty renal transplant 
patients in the first three and second three months post-transplant. The dotted line 
denotes lower level of sensitivity (0.1%).
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Figure  4.  9  Combined  IE1  and  pp65-specific  CD8+   responses  in  twenty  renal 
transplant patients in the first three and second three months post-transplant. The 
dotted line denotes lower level of sensitivity (0.2%).
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4.4 Measuring the Absolute Numbers of HCMV-specific CD8+  T-cells
Whole blood counts taken routinely from renal transplant patients provide the 
absolute  numbers of  lymphocytes  in  peripheral  blood.  Using the  lymphocyte 
gate  provided  through  FACS  analysis  it  was  possible  to  determine  the 
constituent T-cell subpopulations of this gate through staining subpopulations 
with  antibodies to CD3,  CD4 and CD8.  By relating the  percentages of these 
populations  to  the  absolute  numbers  of  lymphocytes  in  the  blood  it  is 
possible  to  calculate  the  absolute  numbers  of  these  cells  that  are  able  to 
produce  IFNy on  stimulation  with  the  relevant  antigen  in  a  given  volume  of 
blood.
As shown  in  Figure 4.10, the range of pp65 responses measured is between 
0  (below the lower level of detection)  and 3.8 x  107 cells per litre,  confirming 
that  some  seropositive  individuals  lack  detectable  pp65-specific  CD8+ 
responses.  The  absolute  numbers  of  pp65-specific  CD8+  cells  was  lowest 
during  the  first  month  post-transplant  (median  0.87  x  106  cells/l).  This 
increased  in the second  (median 2.45 x  106 cells/l),  third  (median  2.53 x  106 
cells/l),  fourth  (median  3.05  x  106  cells/l),  fifth  (median  3.48  x  106  cells/l) 
months and  peaks  in the sixth  month  (median 4.14 x  10s cells/l).  Despite the 
consistent  increases  in  these  populations  the  first  significant  rise  occurred 
between  the  first  and  the  third  months  post-transplant  (Willcoxon  p  =  0.04) 
and continued to increase,  non-significantly, in the subsequent three months.
Absolute  numbers of  IE1-specific CD8+ cells  in this group of  renal transplant 
patients  range  from  0  to  7.6  x  107  cells/l  (Fig.  4.11).  The  lowest  median
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frequencies of IE1-specific CD8+ cells are again found in the first month post­
transplant  (1.2  x  105cells/litre).  This  number  increased  during  the  second 
month to 6.9 x  105 cells/l and then fluctuated for the subsequent four months 
peaking at 6 months post-transplant at 8.2 x 105 cells/ml. The only significant 
increase  in  IE1-specific  populations  occurred  between  months  one  and  six 
post-transplant (Willcoxon p = 0.001).
The  changes  in  the  absolute  numbers  of  combined  pp65  and  IE1-specific 
CD8  cells  are  shown  in  Figure  4.12.  The  combined  CD8+  responses 
gradually increased  over the 6  months post-transplant,  rising  from  a  median 
of 3.1  x  106 cells/ml  in the first  month to  9.8 x  106 cells/ml  in  month  six  (p = 
0.0023),  although the  increase  between  month  1   to  6 and  between  month  2 
and  month  6  (4.57  to  9.8  x  106  cells/ml,  p  =  0.03)  are  the  only  statistically 
significant differences.
164p
p
6
5
-
s
p
e
c
i
f
i
c
 
C
D
8
+
 
c
e
l
l
s
 
x
 
1
0
6
/
l
45^
35
25
15-
5-*-
Chapter 4: HCMV-specific CD& Responses in Renal Transplant Patients
Absolute numbers of pp65-specific CD8+ cells x 106/l
• •• • • • • • • •
• •
• • •
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2  3  4  5
Months Post-Transplant
median
month 1
Month 1 0.87 month2
Month 2 2.45 0.53 Month 3
Month 3 2.53 0.04 0.20 month 4
Month 4 3.05 0.07 0.11 0.58 month 5
Month 5 3.48 0.03 0.07 0.23 0.72 month 6
Month 6 4.14 0.001 0.008 0.12 0.09 0.1108
Figure  4.  10  Longitudinal  analysis  of  the  absolute  number  of  circulating  pp65- 
specific CD8+  cells that are able to express CD69 and IFNyon stimulation. The table 
shows  median  number  of  cells  x  106 /l  of  each  time-point,  and  p-values  for the 
significance  of  differences  between  samples  using  a  paired  T-test.  Significant 
values are highlighted in red.
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Absolute num bers of IE1-specific CD8+ cells x 106/l
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Month 5 0.41 0.20 0.82 0.32 0.56 month 6
Month 6 0.82 0.001 0.11 0.32 0.15 0.06
Figure 4.11 Longitudinal analysis of the absolute number of circulating IE1-specific 
CD8+  cells that are able to express CD69 and IFNy on stimulation. The table shows 
median number of cells x 106 /l of each timepoint, and p-values for the significance 
of  differences  between  samples  using  a  paired  T-test.  Significant  values  are 
highlighted in red.
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Absolute numbers of HCMV-specific CD8+ cells x 106/l
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Figure 4. 12 Absolute number of circulating HCMV-specific CD8+  cells that are able 
to  express  CD69  and  IFNy on  stimulation  in  renal  transplant  patients  over  six 
months. The table shows median number of cells x 106 /l of each time-point, and p- 
values for the significance of differences between  samples  using a paired T-test. 
Significant values are highlighted in red.
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4. 5 Absolute Numbers of HCMV-specific CD8 Responses in Months 1-3 
and Months 4-6 Post-Transplant.
Using the same approach  employed  in section  4.3, the  absolute  numbers of 
HCMV-specific CD8+ responses were grouped into the first three and second 
three  months  post  transplant.  Similar  to  the  data  found  using  the 
percentages  of  HCMV  antigen-specific CD8+ T-cells  (Figs  4.2,  4.3  and  4.5), 
there  is  an  increase  in  absolute  levels  of  HCMV-specific  CD8+  responses 
between  months  one to three  and  months four to six,  although  few of these 
increases are statistically significant (Figs 4.13 to 4.15).
Figure  4.13  demonstrates  an  increase  in  the  absolute  numbers  of  pp65- 
specific  CD8+  cells  from  a  median  of  1.9  x  106  cells/l  to  3.81  x  106  cells/l, 
however,  this  increase  was  not  statistically  significant  (Willcoxon  p  =  0.15). 
Median  numbers  of  IE1-specific  CD8+  T-cells  also  increased  from  3.4  x  105 
cells/l  to  6.2  x  105  cells/l,  but  once  again  this  increase  was  not  statistically 
significant (p = 0.19)  (Fig. 4.14).
A  comparison  of  the  absolute  numbers  of  combined  IE1  and  pp65-specific 
CD8  responses  illustrated  in  Figure  4.15  shows  a  significant  increase  in 
median  CD8  populations  after  the  first  three  months  post-transplant.  The 
median  overall  number of  CD8+  T-cells  able  to  secrete  IFNy on  stimulation 
with pp65 and  IE1  in the peripheral blood increased significantly from 4.25 to 
7.84%  (p  =  <0.05)  between  months  1   to  3  and  4 to  6.  These  data correlate 
well with the observation that patients usually suffer viraemic episodes within 
the first three months post-transplant.
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These  data  provide  information  on  the  kinetics  of  CD8+  T-cell  population 
fluctuations  in  the  months  proceeding  renal  transplantation,  but they  do  not 
provide  information  on  whether  these  populations  can  protect  the  recipient 
from HCMV replication.
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Figure 4. 13 Comparison of the absolute number of pp65-specific CD8+  responses 
in months 1-3 and 4-6 post-transplant.I
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Figure 4. 14 Comparison of the absolute number of IE1-specific CD8+  responses in 
months 1-3 and 4-6 post-transplant.
171C
M
V
-
s
p
e
c
i
f
i
c
 
C
D
8
+
 
T
-
c
e
l
l
s
 
x
 
1
0
6
/
l
Chapter 4: HCMV-specific CDS' Responses in Renal Transplant Patients
100-1
80-
60-
40-
20- • • • • •
• • • • P = 0.045
10.0
7.5
5.0
2.5
0.0
1-3 4-6
Months Post-transplant
Figure  4.  15  Comparison  of  the  absolute  number  of  combined  pp65  and  IE1- 
specific CD8+  responses in the months 1-3 and 4-6 post-transplant.
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4. 6 Comparison of pp65-specific CD8+  responses in viraemic and non- 
viraemic patients
To  establish  whether  a  protective  “threshold”  level  of  pp65-specific  CD8+  T- 
cell  is  required  for  the  prevention  of  high-level  virus  replication,  the 
frequencies  of  pp65-specific  CD8+  T-cells  were  compared  between  patients 
suffering viraemic episodes (those with at least two consecutive HCMV PCFT 
results with  more than  1000 viral genome copies/ml)  in the months following 
transplant and those remained aviraemic (or PCR negative)
Responses  between  viraemic  and  non  viraemic  individuals  during  the  first 
month post-transplant were initially compared to ascertain whether there was 
any pre-existing defect in the proportions of CD8+ cells able to produce  IFNy 
in response to pp65 in patients pre-disposed to viraemic episodes.
The  results  in  the  upper  panels  of  Figures  4.16  and  4.17,  indicate  an 
increase  in  both  the  percentages  (0.13%  in  viraemics  and  0.37%  in  non- 
viraemics)  and the  absolute  numbers of  pp65-specific  CD8+  T-cells  in those 
individuals  who  remain  PCR-negative  for  HCMV  after  transplant,  (median 
cell  count  of  0.11  x  106  cells/l  in  viraemics,  0.35  x  106  cells/l  in  non- 
viraemics),  although  this  was  not  statistically  significant  using  either 
percentages or absolute numbers (Mann Whitney test, p =0 .22 and p = 0.24, 
respectively).
There  were  also  no  significant  differences  between  the  pp65-specific 
responses  of  viraemic  individuals  and  non-viraemic  individuals  during  the
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first  month  post-transplant,  therefore  no  pre-existing  defect  in  these 
responses  could  be  demonstrated.  Despite  this,  many  of  the  patients  with 
active  HCMV  replication  have  recurrent  phases  of  viraemia  over  the  six 
months;  an  analysis  of  pp65-specific  responses  was  therefore  performed 
which  compared  combined  responses  from  patients  with  viraemic  episodes 
to  those  of  non-viraemic  patients  over  the  entire  six  month  period  post­
transplant.  The  results  are  shown  in  the  lower  panels  of  Figures  4.16  and 
4.17.  Figure  4.16  shows there  was  a  significantly  higher overall  percentage 
of  pp65-specific  CD8+  T-cells  in  non-viraemic  (median  0.9%)  compared  to 
viraemic (0.21%) individuals (Mann Whitney test p = 0.019).
A  similar  comparison  was  performed  to  resolve  whether  this  increase  also 
occurred  in  the  absolute  numbers  of  pp65-specific  CD8+  T-cells  in  the 
peripheral  blood.  When  total  responses  over  six  months  were  compared 
between  patients  with  viraemic  episodes  and  patients  without,  a  four-fold 
increase  was  observed  (0.81  x  106 to  4.06  x  106 cells/l  p  =  <0.005)  (Lower 
panel  Fig.  4.17).  Taken  together  these  data  indicate  that  there  was  a 
significant  increase  in  both  the  percentage  of  pp65-specific  CD8+  cells  and 
the  overall  number  of  circulating  HCMV-specific  CD8+  cells  in  the  blood  of 
patients  who  remain  free  from  HCMV  viraemia  in  the  six  months  post­
transplant.
Responses  to  IE1  were  analysed  in  a  similar  way  to  those  above.  There 
were  no  significant  differences  (p=0.97)  in  the  median  percentage  of  IE1- 
specific CD8+ cells in the peripheral blood of viraemic and non-viraemic renal
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transplant  patients  during  the  first  month  post-transplant  (upper  panel,  Fig. 
4.18), indicating that there is no detectable difference in the frequency of IE1- 
specific CD8+ cells of viraemic patients  prior to viraemic episodes.  Similarly, 
the  overall  percentage  of  IE1 -specific  CD8+  cells  during  the  first  6  months 
post-transplant  shown  in  the  lower  panel  of  Figure  4.18,  does  not  vary 
significantly  between  viraemics  and  non-viraemics  (p  =  0.24).  Although  the 
median  percentages  of  the  IE1-specific  CD8+  populations  are  not 
significantly different either in the first  month  post-transplant or for the entire 
six  month  duration  post-transplant  (Fig.  4.19).  Nevertheless,  there  was  a 
statistically significant increase in the absolute  numbers of  IE1-specific CD8+ 
cells  in  non-viraemic  patients  (median  0.76  compared  to  0.1  x  106  cells/l  in 
viraemic  individuals  Mann-Whitney  test  p  =  0.01)  when  analysed  over  six 
months compared to the viraemic patients.
When  responses  to  both  antigens  were  compared  there  again  were  no 
statistically  significant  differences  detectable  between  percentages  of 
antigen-specific  T-cells  either  in  the  first  month  post-transplant  or  over  the 
whole  six  month  period  (Fig.  4.20).  Despite  this,  responses  appeared 
elevated  in  the  non-viraemic  individuals  in  both  time  periods.  Furthermore, 
during  the  comparison  of  response  for whole  6  month  period  the  difference 
between  the  two  groups  was  of  borderline  significance  (p=0.08).  Overall 
frequencies  of  HCMV-specific  CD8+  cells  as  shown  in  Figure  4.21,  are  also 
not  significantly  different  in  the  first  month  post-transplant;  however,  again 
there was  a  highly significant elevation  in total  CD8+  responses  over the  six 
month  period  in  non  viraemic  individuals  (2.32  -   8.9  x  106  cells/l  Mann
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Whitney  test  p  =  0.005)  compared  to  those  individuals  suffering  from 
viraemjc episodes.
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Figure  4.  16  Comparison  of  the  percentages  of  pp65-specific  CD8+   T-cells  in
patients  suffering  viraemic  episodes  and those that  do  not  during  the  first  month
(upper panel) and total six month period post-transplant (lower panel).
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Figure 4.  17 Comparison of the absolute numbers of pp65-specific CD8+  T-cells in
patients  suffering  viraemic  episodes  and those that do  not  during  the  first  month
(upper panel) and total six month period post-transplant (lower panel).
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Figure 4.18 Comparison of the percentages of IE1-specific CD8+  T-cells in patients
suffering  viraemic  episodes  and  those  that  do  not  during  the  first  month  (upper
panel) and total six month period post-transplant (lower panel).
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Figure 4.  19 Comparison of the absolute numbers of  IE1-specific CD8+  T-cells  in
patients  suffering  viraemic  episodes  and those that  do  not during the first month
(upper panel) and total six month period post-transplant (lower panel).
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Figure 4. 20 Comparison of the percentages of total pp65 and IE1-specific CD8+  T-
cells  in  patients suffering viraemic episodes and those that do  not during the first
month (upper panel) and total six month period post-transplant (lower panel).
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Figure 4. 21  Graph to compare the absolute numbers of combined HCMV-specific
CD8+  T-cells in patients suffering viraemic episodes and those that do not during the
first month (top panel) and total six month period post-transplant (bottom panel).
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4.7  Are responses towards IE1 protective at different thresholds?
Previous  work  by  Bunde  and  Kern  described  that  IE1-specific  CD8 
responses above 0.4% were protective against HCMV viraemia in  heart and 
lung  transplant  recipients  [379]  [271].  Throughout  this  chapter  IE1-specific 
CD8+  T-cell  responses  appeared  to  cluster  into  two  distinct  populations,  of 
low and  high frequencies  (Fig.  4.4,  4.5,  4.8,  4.11,  4.14,  4.18,  4.19).  The two 
IE1-specific  CD8+  sub-populations  were  therefore  further  sub-divided  and 
subsequently compared between viraemic and non-viraemic individuals. This 
analysis  was  performed  to  determine  whether  the  magnitude  of  the 
responses  to  these  subpopulations  differed  between  individuals  who 
controlled HCMV replication and those that did not.  The numbers of viraemic 
and  non-viraemic  patients  with  CD8+  T-cell  responses  to  either  IE1  and/or 
pp65  can  be  seen  in  Figure  4.22.  6/9  (66.6%)  viraemic  patients  had 
detectable  T-cell  responses  to  either  pp65  or  IE1,  all  6  of these  individuals 
responded to pp65, three of whom also respond to  IE1.  9/11  (81.8%) of non- 
viraemic  individuals  had detectable CD8+ T-cell  responses to  either  pp65  or 
IE1,  8 of these had responses to pp65,  5 of this group also responded to IE1 
and one patient responded solely to IE1.
Samples  from  viraemic  individuals  with  a  consistently  high  (i.e.  above 
threshold  level  of  detection)  IE1 -specific  CD8  response  had  significantly 
elevated  frequencies  when  compared  to  non-viraemic  individuals  (median 
3.35%  viraemic  and  2.1%  non-viraemic,  p  =  0.04).  Although  there  was  no 
statistical  difference  in  the  percentages  of  CD8+  T-cells  in  those  individuals 
will low IE1  response.
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When the absolute  numbers  of  IE1-specific CD8+  T-cells were  analysed  in 
the  peripheral  blood  there  was  no  significant  difference  between  the 
frequencies  of  IE1  specific  CD8+  T-cells  in  either viraemic  or  non-viraemic 
patients with consistently high percentages of IE1-specific cells (medians 7 x 
106   cells/ml  and  8.56  x  106cells/ml,  p  =  0.66).  Conversely,  non-viraemic 
individuals with lower-tier responses to IE1  had an  increase in the  numbers 
of circulating CD8+  T-cells specific for this antigen (p = 0.01).
Viraemic  Non-viraemic
IE1  pp65  IE1  pp65
Figure 4. 22 Proportion of patients with CD8+  T-cell responses to IE1  and/or pp65 in 
viraemic (left panel) and non-viraemic (right panel) patients.
184%
 
I
E
1
-
s
p
e
c
i
f
i
c
 
C
D
8
+
 
T
-
c
e
l
l
 
r
e
s
p
o
s
e
s
Chapter 4: HCMV-specific CDS' Responses in Renal Transplant Patients
15
10
0.5
0.0
P = 0.04  #
1   1   •
1.0  T
P = 0.58
t------------------------------ r
Figure  4.  23  A  comparison  of  the  percentages  of  stratified  IE1-specific  CD8 
responses in viraemic and non-viraemic patients.
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Figure  4.  24 A comparison of the absolute numbers of stratified  IE1-specific CD8 
responses in viraemic and non-viraemic patients.
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4.8  Discussion
Longitudinal analysis of CD8+ responses in renal transplant patients revealed 
that percentages of IE1  and pp65-specific CD8+ cells rose significantly during 
the  second  and  third  months  after transplant.  The  earlier  increases  in  IE1- 
specific  responses  may arise  as  a consequence of virus  reactivation,  where 
IE1  is  one  of  the  first  proteins  to  be  expressed;  this  may  therefore  be 
processed  and  presented  prior  to  other  latterly-expressed  proteins.  Earlier 
presentation  of  IE1  would  cause  expansions  of  IE1 -specific  CD8+  T-cell 
populations.  These  populations  could  therefore  dominate  prior  to  the 
emergence of CD8 populations specific for proteins such as pp65, which are 
expressed  at  later  stages  of  virus  infection,  which  may  subsequently 
dominate.  Furthermore,  IE1  expression  may  occur  in  the  absence  of  a 
productive infection so pp65 may not be expressed.  Should pp65 expression 
not occur,  pp65 would thus be unable to abrogate processing of  IE1  through 
phosphorylation [262].
Generally fewer renal transplant patients have responses to IE1  (10/20) than 
to  pp65  (14/20),  although  most  individuals  who  mount  a  response  to  pp65 
also mount  IE1-specific responses  (9/14)  (Fig.  4.2).  This contradicts findings 
of  Gilbert  et  al.  1996,  who  speculated  that  responses  to  one  protein  was 
dominant  over  the  other  because  of  pp65’s  ability  to  phosphorylate  IE1 
thereby preventing its processing and presentation [262].
When  combined  responses  to  both  of  these  antigens  were  analysed  it 
became  apparent  that  the  percentages  of  CD8+  cells  that  recognise  these
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targets  stabilised  after three  months,  and  the  percentage  of  these  CD8+  T- 
cells were similar in magnitude to those found in healthy individuals.
Determining  the  absolute  numbers  of virus-specific  CD8+  T-cell  populations 
in the  periphery,  instead of the analysis of  percentages of these  populations 
alone,  gives  a  more  accurate  view  of  how  these  virus-specific  CD8+ 
populations  may be effective in controlling  HCMV. An  example of where this 
might  occur  would  be  an  individual  possessing  a  high  percentage  of  their 
CD8+  T-cells  focused  on  HCMV  who  may  actually  have  substantially  fewer 
total CD8+ cells compared to an individual with a lower percentage of HCMV- 
specific cells but a higher overall level of CD8+ cells in their peripheral blood.
Significant  increases  in  absolute  numbers of  pp65-specific CD8+  cells  in  the 
peripheral  blood  also  occur during the third  month  post-transplant,  although 
this  is  not  borne  out  with  IE1  responses,  which  increased  significantly  in 
absolute  number  only  after  six  months  post-transplant.  This  observation 
indicates that expansions of IE1-specific populations do occur during the first 
few  months  of  transplant,  but,  in  absolute  terms,  these  increases  are  not 
significant.  Similarly,  significant  increases  in  overall  combined  CD8 
responses  to  these  antigens  only  occur  during  the  sixth  month  post­
transplant. There does seem to be a two-tier level of responses between the 
first  three  months  post-transplant  and  the  next three  months.  The  temporal 
pattern  of  CD8  T-cells  against  HCMV  is  consistent  with  previous 
observations that the  majority of viraemic episodes  in  solid organ  transplant 
patients occur within the first three month period immediately after transplant.
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After  this  period,  populations  of  CD8+  cells  may  recover  sufficiently  to 
prevent  the  majority  of  subsequent  reactivations.  Results  show  elevated 
percentages  of  HCMV-specific  CD8+  cells  during  the  second  three  months 
post-transplant  but  these  elevations  were  not  significant.  Nevertheless  the 
absolute  numbers  of  these  same  populations  are  significantly  elevated  in 
during the months four to six post-transplant, this might explain why viraemic 
episodes  have  previously  been  shown  to  occur  less  frequent  after  the  first 
three months post transplant.
To  assess  whether  patients  suffering  viraemic episodes  have  a  pre-existing 
defect  in  their  HCMV-specific  CD8+  responses  that  renders  them  more 
susceptible  to  HCMV-associate  disease,  their  CD8  responses  to  both  IE1 
and  pp65  during  the  first  month  post-transplant  were  compared  to  those 
individuals  who  remained  PCR  negative  throughout.  Despite  seeing  no 
significant  differences  in  either  the  percentage  or  absolute  number  of 
antigen-specific  CD8+  T-cells,  non-viraemic  patients  consistently  had  higher 
median  populations  of  antigen-specific  CD8+  cells  than  those  who  suffered 
viraemia.
Because the  majority of this subgroup suffered  repeated  phases of viraemia 
over  the  six  month  period  monitored,  this  analysis  was  repeated  using 
combined samples taken from  each group over the entire period the  median 
percentages  of  CD8+  cells  specific  for  pp65  were  increased  from  0.82%  to 
4.03%  (p  =  0.02)  and  the  median  absolute  numbers  of  pp65-specific  cells 
also rose significantly from 0.81  x  106 cells/l to 4.06 x  106 cells/l  (p = <0.005).
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While  there  was  no  significant  difference  in  the  corresponding  median 
percentage of IE1-specific CD8 cells (0.09 and 0.15% p = 0.24), the absolute 
numbers  of  IE1-specific cells  also  rose  significantly from  a  median  of  0.1  to 
0.76 x  106 cell/l  (p  =  0.01).  When these  responses were combined  a similar 
phenomenon  was  observed,  non-viraemic  patients  had  a  slight  but  not 
significant  increase  in  antigen-specific  CD8+  populations  but the  increase  in 
the median absolute numbers of antigen-specific CD8+ cells was again highly 
significant  (medians  2.3  x  106  cells/l  to  9  x  106  cells/l  p  =  0.005).  Taken 
together,  these  data  indicate  that  patients  with  elevated  CD8+  T-cell 
responses  to  pp65  and  IE1  are  less  likely  to  suffer  virus  reactivation  and 
therefore there are protective affects.
Fig.  4.20  illustrates  that  measuring  the  percentages  of  antigen-specific 
populations  does  not  necessarily  correlate  with  absolute  levels  these  same 
populations in the peripheral blood. Also,  high levels of antigen-specific CD8+ 
T-cells do not always correlate with protection from viraemia; one patient with 
the  highest  percentages  of  virus-specific  CD8+  T-cells  detected  (median 
16.03%)  and  absolute  number of  CD8+  T-cells  in  the  blood  (median  22.2  x 
106  cells/l)  suffered  repeated  bouts  of  viraemia.  Could  this  be  due  to  IFNy 
production  not  being  an  accurate  indicator CD8  of functionality or could this 
be due to the possible expansion of HCMV CTL escape mutants?
In  summary,  the  majority  of  individuals  analysed  in  this  chapter  have 
detectable  populations  of  CD8+  T-cells  that  are  able  to  secrete  IFNy  in 
response to stimulation  with the two immunodominant targets of the  HCMV-
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specific CD8 response.  However, some individuals lack these responses and 
yet  remain  free  from  viraemia  in  the  months  post-transplant.  Furthermore, 
high  frequencies  of  antigen-specific  CD8+  populations  do  not  necessarily 
confer  complete  protection  against  viraemia.  There  was  also  a  significant 
increase  in  the  median  absolute  CD8+  T-cell  responses  towards  pp65  and 
IE1  in  individuals  who  were  able  to  control  virus  infection  compared  with 
those  who  could  not.  This  highlights  the  importance  of  high  frequency 
HCMV-specific  CD8+  T-cell  populations  for  the  control  of  HCMV  in  renal 
transplant patients.
191Chapter 5 
Do HCMV CTL-Escape Mutants 
Occur in Viraemic Renal 
Transplant Patients?
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5.1 Introduction
Chapter  4  demonstrated  that  renal  transplant  patients  with  higher  median 
numbers of CD8+ T-cells in the peripheral blood capable of producing  IFNy in 
response  to  HCMV  antigens  pp65  (ppUL83)  and  IE1  (UL123),  were  less 
prone to viraemic episodes in the six month period post-transplant.  However, 
several patients suffered recurrent viraemic episodes despite the presence of 
high-frequency  ppUL83  and/or  UL123IE1  responses.  It  can  therefore  be 
concluded  that  the  CD8  response  focused  towards  these  antigens  was 
inadequate  to  control  virus  replication  in  these  individuals.  The  reason  for 
this  could  be  two-fold;  either  a  defect  may  exists  in  the  virus-specific  CD8 
populations,  which could  either be  in terms of the  magnitude or functionality 
of those responses,  rendering them  less functional than those found in other 
individuals or the virus itself may be able to escape  from surveillance by the 
antigen-specific CD8+ T-cells through mutation of the CTL targets.
HCMV has developed a wide variety of immune-evasion strategies; including 
mechanisms for the down-regulation of HLA class I  molecules on the surface 
of  infected  cells  thereby  preventing  them  being  recognised  and  subsequent 
lysis  by virus-specific  CD8+  cells.  Down-regulation  of  HLA  I  molecules from 
the  cell  surface  would  render  HCMV-infected  cells  more  susceptible  to  NK 
cell-mediated  lysis.  Although  HCMV  has  developed  several  strategies  for 
circumventing  the  NK  response,  CTL-escape  mutants  could  arise  allowing 
HLA class  I  molecules on the cell  surface to be  bound  by not  recognised  by 
the  CTL  response,  thereby  facilitating  HCMV’s  ability to  remain  undetected 
by  the  CTL  responses  and  thus  continue  replication  without  needing  to
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circumvent the NK cell  response. CTL escape mutants have previously been 
described  in  several  other  viral  infections  such  as  LCMV  ,  HIV  [380]  and 
HBV [381].
Given the large clonal expansions of  HCMV-specific CD8+populations during 
the natural course of HCMV infection  and subsequent sporadic reactivations 
[299,  314],  there  should  be  a  considerable  selective  pressure  applied  on 
HCMV  to  change  its  CTL  epitopes.  HCMV  CTL  escape  mutants  have 
previously  been  isolated  from  HCMV  seropositive  bone-marrow  transplant 
(BMT)  patients  [358]; yet only one  mutation was detected  in this study.  This 
mutations  occurred  in  the  A*0201-restricted  NLVPMVATV  epitope  within 
pp65,  where  the  M  (Methionine)  at  position  5  was  mutated  into  an  I 
(Isoleucine).  Although this mutant was able to decrease CTL-mediated  lysis 
of cells presenting the peptide, amplification of the DNA sequence of interest 
encoding  this  epitope  was  performed  using  a  non-proofreading  DNA 
polymerase, which itself increases the likelihood of the emergence of artificial 
substitutions.
A  situation  where  an  individual  who  has  repeated  episodes  of  HCMV 
viraemia  in  spite  of  a  detectable  CD8+  response,  would  provide  an  ideal 
setting for the detection of CTL-escape mutants. The aim of this chapter was 
to  elucidate  whether  CTL-escape  mutants  arise  in  liver  transplant  patients 
(different to the renal transplant patients analysed in chapters 3,  4 and 6),  of 
known  HLA  haplotypes,  who  suffer  from  repeated  sustained  viraemic 
episodes despite the presence of detectable epitope-specific CTL responses.
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To complement these studies the  effects  of  certain  amino  acid substitutions 
within  the  HLA-A*0201  epitope  NLVPMVATV  on  HLA  binding  and 
recognition by the epitope-specific CTLs were investigated.
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5.2  Do  Mutations  occur  within  ppUL83  CTL  epitopes  in  response 
viraemic renal transplant patients?
DNA sequences encoding three HLA-A*0201  and one HLA-B*3501-restricted 
CTL  epitopes  present  within  ppl)L83  were  PCR-amplified  from  liver 
transplant  patients  with  known  HLA-haplotypes,  who  remained  persistently 
HCMV  PCR-positive  for  CMV  for  >2  months  post-transplant  despite  the 
presence  of  epitope-specific  CTL  responses.  The  presence  of  epitope- 
specific  CD8+  T-cell  responses  were  assessed  by  class  I  HLA  tetramer 
staining.  Sequences  encoding  the  HLA-A*0201-restricted  epitopes  from 
patients  with  log-phase  HCMV-replication  where  also  assessed  for 
mutations.  Purified  DNA  was  ligated  into  pGem-T-easy  vector  and  used  to 
transform competent bacteria.  Multiple (5) recombinant clones were selected 
from  each  time  point,  DNA  was  extracted  and  sequencing  was  carried  out 
using  an  ABI  Prism®  capillary-based  sequence  analyser  using  a  BigDye® 
terminator  v3.1  cycle  sequencing  kit  (Applied  Biosystems).  One  series  of 
chromatograms depicting representative sequences are shown in Fig. 5.1.
No  variations  in  the  sequences  of  any  of  the  epitopes  analysed  were 
detected in either the four long-term  HCMV-PCR positive patients or the five 
transplant patients with  log-phase  HCMV replication  (Table 5.1).  These data 
indicate  that  mutations  within  HLA-A*0201  CTL  epitopes  of  ppUL83  occur 
either infrequently or not at all. This compounds  previous findings by Zaia  et 
al.  [358]  ,  who  found  only  one  coding  mutation  in  the  HLA-A*0201  epitope 
ppUL83(495-503).  In  their  study,  sequences  encoding  this  epitope  were 
amplified  using  a  regular Taq  polymerase  without  high-fidelity  proof-reading
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capabilities  as  utilised  here.  Furthermore,  neither  patient  epitope-specific 
CD8+ populations nor CMV-PCR status was established.
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Figure 5.  1  Chromatogram showing the sequence of amplified DNA encoding (a) HLA-A*0201  epitope VLGPISGHV (b) HLA-A*0201 
epitope  MLNIPSINV  and  HLA-B*3501  epitope  IPSINVHHY and  (c)  HLA-A*0201  epitope  NLVPMVATV.  Graphics  were  generated 
utilising Chromas 2.23 software available at:  http://www.technelvsium.com.au
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Patients Long 
term  PCR+
Haplotype
Viral
Load
(log)
Days  PT ppUL83(i4-22j
HLA-A*0201
PpUL83(i2o-s;
HLA-A*0201
p  P  U L83 (495-503)
HLA-A*0201
%  NLV- 
specific 
CD8
PPUL83(J23-*,3J|
HLA-B*3501
%  I  PS- 
specific 
CD8
Clone
Frequency
VLGPISGHV M  L   N  I  P   S  I  N  V NLVPMVATV I  P  S  I  N  V  H  H  Y
1 S HLA-B*3501 3.397 54 N/A N/A N/A N/A N/A 5/5
6.170 140 N/A N/A N/A N/A 2.3 5/5
4.260 372 N/A N/A N/A N/A 4.1 5/5
3.797 507 N/A N/A N/A N/A 3.01 5/5
2 C HLA-A*0201 4.954 26 0.395 N/A N/A 5/5
3.262 48 0.325 N/A N/A 5/5
3.647 53 0.275 N/A N/A 5/5
3.201 93 0.65 N/A N/A 5/5
3 Y HLA-A*0201 3.102 17 0.335 N/A N/A 5/5
3.425 38 0.32 N/A N/A 5/5
3.652 57 0.43 N/A N/A 5/5
2.76 67 0.4 N/A N/A 5/5
4 C HLA-A*0201 3.774 26 0.335 N/A N/A 5/5
4.022 30 0.65 N/A N/A 5/5
2.923 90 N/A N/A N/A 5/5
5 M HLA-A*0201 3.022 >180 N/A N/A N/A 5/5
6 G HLA-A*0201 5.243 41 N/A N/A N/A 5/5
7 P HLA-A*0201  3.331 102 N/A N/A N/A 5/5
8 S HLA-A*0201 3.582 56 N/A N/A N/A 5/5
9 Sh HLA-A*0201  3.858 >150 N/A N/A N/A 5/5
Table 5.  1   Table showing information on liver transplant patient samples and the sequence data obtained from clones of 
the amplified sequences encoding designated epitopes
199Chapter 5: HCMV CTL-escape mutants
5.3  Effect of amino acid substitutions in the immunodominant ppUL83 
HLA-A*0201 epitope NLVPMVATV on recognition by CTLs.
To  assess  the  impact  that  mutations  in  the  immunodominant  HLA-A*0201 
epitope  NLVPMVATV  would  have  on  CTL  recognition,  peptide  variants  of 
this  sequence were  designed  based  on  substitutions  of  all  residues  (except 
anchor  residues  at  P2  and  P9)  with  either  a  glycine  residue  or,  where 
possible,  a conservative  (like for like)  amino acid substitution.  Peptides were 
synthesised commercially and purified to >90% purity (Fig. 5.2).
Peptides  were  used to  stimulate  lymphocytes  isolated from  healthy controls 
overnight  (three  HCMV-seropositive,  two  of  these  HLA*A0201  the  other 
HLA*B0701,  and  one  seronegative  HLA*A0201  control,  see  Fig.  5.3)  in  an 
IFNy ELISPOT. Cells secreting  IFNy were counted and numbers were plotted 
as a proportion of those produced by the wild type peptide (Fig. 5.4).
Results  from  the  IFNy  ELISPOT  assays  (Fig.  5.4)  showed  that  key  amino 
acid  substitutions  abrogated  IFNy  production  by  epitope-specific  CD8+ 
lymphocytes.  Substitutions  that  reduced  IFNy  production  most  markedly 
occurred  around  the  centre  of  the  peptide,  at  residues  4  and  5;  and  these 
substitutions  resulted  in  the  production  of  less  than  20%  of  the  IFNy 
response elicited by the wild-type peptide.
Interestingly,  different  substitutions  at the  same  residues  appeared  to  have 
varying  effects on  IFNy induction.  For example,  substituting the  G6V  mutant 
effectively  abolished  IFNy production  whereas  L6V  still  elicited  a  response,
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albeit  lower  than  the  wild-type.  Therefore,  the  nature  of  the  amino  acid 
substitution has a bearing on the ability of the peptide to be recognised. This 
can also be seen with L3V and G3V, and G8T and S8T substitutions.
Surprisingly, substitutions around the anchor residues seemed less important 
than  those  nearer  the  core.  The  G4P  substitution  significantly  lowered  the 
response  (less  than  5%  that  of  wild-type  peptide);  similarly,  none  of  G5M, 
C5M,  I5M and G6V substitutions are were able to stimulated more than 20% 
of the IFNy elicited by stimulation with the wild-type peptide.
These  data  demonstrate  that  certain  substitutions  have  an  effect  on  IFNy 
production  by  epitope-specific  CD8+  cells,  but  it  is  unclear  whether  these 
function  at  the  level  of  HLA  I  binding  or  TCR  recognition.  Thus,  it  was 
important  to  consider  that  certain  substitutions  may  have  resulted  in  the 
peptide  being  less  able to bind the groove of the  HLA class  I  molecule,  and 
thus  rendering  it  less  stable  and  consequently  less  efficiently  presented  at 
the surface of the infected cell.
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1 2 3 4 5 6 7 8 9
N L V P M V A T V w ild -ty p e
G L V P M V A T V GIN
N L G P M V A T V G3V
N L V G M V A T V G4P
N L V P G V A T V G5M
N L V P M G A T V G6V
N L V P M V G T V G7A
N L V P M V A G V G8T
Q L V P M V A T V Q1N
N L L P M V A T V L3V
N L V P I V A T V I5M  [358]
N L V P C V A T V C5M
N L V P M L A T V L6V
N L V P M V A S V S8T
Figure 5. 2 Peptide substitutions designed to conserve the anchor residues (blue) 
substitutions are highlighted in (red)
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NLV A2 Tet PE
Figure  5.  3  FACS plot of one  Healthy HCMV seropositive  HLA-A*0201-restricted 
individual with responses to NLVPMVATV. Blot used gates of lymphocyte and CD3+  
populations
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Figure 5. 4 IFNy ELISPOT showing responses of four individuals to NLVPMVATV peptide variants
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5.4  HLA-stabilisation assay
To  determine  whether  amino  acid  substitutions  in  the  HLA-A*0201  epitope 
influenced  binding  to  HLA-A*0201  molecules  a  T2  HLA-stabilisation  assay 
was  performed.  The  T2  cell  line  is  a  T-and  B-cell  hybridoma  lacking  both 
TAP  1   and  2  genes  required  for  the  processing  of  proteins  into  peptides, 
which  are  necessary  for the  binding  of  HLA  I  molecules.  Without  peptides, 
HLA  class  I  complexes  become  unstable  and  are  rapidly  recycled  from  the 
cell  surface.  Although  low levels  of  HLA-A*0201  are still  detectable,  surface 
expression is increased upon addition of exogenous A2 peptides.
This  assay  can  therefore  provide  information  on  whether  the  peptide 
substitutions  described  above  have  an  effect  on  TCR  recognition  or  HLA- 
A*0201 -binding.  Should  HLA  class  I  molecules  be  stabilised  and  IFNy 
production  be  abrogated,  substitutions  would  be  likely  to  have  an  effect  at 
the  level  of TCR  recognition.  On the other hand,  if  HLA-I  complexes are  not 
up-regulated this  indicates that the substitutions  in  some way  preclude  HLA 
binding.
While the  wild-type  epitope,  NLVPMVATV,  increased the  surface  density of 
HLA-A*0201  by 180% compared to background levels,  most peptide variants 
tested  only  moderately  upregulated  expression  and  thus  cannot  be 
considered  strong  binders  (Fig.  5.5).  However,  G6V  and  S8T  substitutions, 
while weakly stabilising the  HLA class  I complex, were still  able to elicit  IFNy 
production,  indicating  that  the  strength  of  the  peptide/HLA  class  I  binding 
interaction  does  not  necessarily  correlate  with  an  increased  capacity  to
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induce IFNy production by  CD8+ T-cells. Conversely,  methionine for cysteine 
substitutions  at  position  5  (C5M)  strongly  upregulated  HLA-A*0201  stability, 
by  more  than  four  times  that  of  background,  and  yet  were  unable  to  elicit 
IFNy production (Fig. 5.5).
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Figure 5. 5 Increase in HLA-A*0201  expression in T2 cells pulsed with NLVPMVATV variants.  FI (fluorescence intensity) of 1   denoted 
the relative FI of T2 cells incubated compared with the background surface levels.
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HLA A2 FITC
Figure 5. 6 Increase in HLA-A*0201 expression in T2 cells pulsed with NLVPMVATV variants. Blue line represents the isotype control, 
green line = background level of expression in absence of peptide, red line = stimulated with 50fiM of wildtype (wt) peptide and the 
purple line = stimulation with the C5M variant.
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5.5 Peptide competition assay using IFNy ELISPOT
In  order  to  investigate  whether the  C5M  variant  can  out-compete  the  wild- 
type  peptide  at  low  concentrations,  a  competition  assay  was  performed  by 
titrating  various  concentrations  of  the  C5M  variant  into  cells  co-incubated 
with  the  wild-type  peptide.  First,  an  ELISPOT  titration  was  performed  to 
determine the  concentration  of wild-type  peptide  required to  elicit  50%  IFNy 
production; to prevent saturation  of all  epitope-specific TCRs.  0.75uM  75pM 
of  NLVPMVATV was determined to be the peptide concentration  required to 
produce  50%  of  the  spots  of  a  saturated  sample.  C5M  was  co-titrated  with 
the wild-type peptide and the number of spots produced counted (Fig. 5.7).
The  showed  that  the  C5M  peptide  was  able  to  reduce  the  amount  of  IFNy 
elicited  by  the  wild-type  NLVPMVATV  peptide  by  approximately  25%  when 
co  -incubated  at  low  concentrations  (10  nM).  Although  the  C5M  variant 
cannot  completely  prevent  recognition  of  wildtype  (wt)  peptide  by  all  CD8+ 
cells it can reduce it (Fig. 5.8).
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Figure 5. 7 ELISPOT to determine concentration of NLVPMVATV that elicits 50% IFNy production, a peptide concentration of ~0.75pM 
was found to stimulate 50% of the maximum production of IFNy.
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Figure 5. 8 Results of IFNy ELISPOT titrating in the C5 variant against 0.75uM 75pM of wildtype peptide
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5.6 Peptide competition assay using T2 cell HLA stabilisation assay
A titration  was  performed  by  gradually  increasing  the  concentration  of  C5M 
peptide into T2 cells co-incubated with wt peptide to determine whether HLA- 
I  levels  could  be  stabilised  on  the  cell  surface  on  addition  of  lower 
concentrations of the C5M peptide.
The  results  demonstrate  that  C5M  starts  to  stabilise  HLA-I  surface 
expression  at  a  concentration  0.5 |xM  (125  times  more  dilute  than  the  wt 
peptide),  indicating  that  C5  starts  competing  for  the  HLA-I  binding  groove 
with  the  wild-type  peptides  at  low  concentrations.  It  remains  unclear  as  to 
why C5M  stabilises the  HLA  I  molecule so well,  online  algorithms  predicting 
peptide binding affinities do not indicate a high binding affinity for this peptide 
(Fig. 5.8).
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Titrating C5 peptide into cells with wt peptide at 50uM
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Figure  5.  9  FACS  analysis  showing  mean  fluorescence  intensity  (MFI)  created  by stabilisation  of  HLA class  I  complexes  by co­
incubation of T2 cells with wildtype peptide and titrated concentrations of the C5M variant.
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5.7 Discussion
CTL-escape  mutants  have  previously  been  shown  to  arise  in  response  to 
several  virus  infections  caused  by  strong  selective  pressure  provided  by 
large,  virus-specific  CD8+  responses.  Because  CD8+  T-cells  are  therefore 
less able to recognise these altered epitopes and their ability to lyse infected 
cells will  be  reduced,  this enables the virus to persist and potentially allow it 
to replicate to higher levels.
Certain  renal  transplant  patients  suffer  from  repeated  bouts  of  HCMV 
viraemia  despite  the  presence  of  HCMV  epitope-specific  CD8+  cells,  as 
detected  by  HLA  class  I  tetramers.  These  patients  could  provide  the  ideal 
environment for the  generation  of  CTL  escape  mutants.  Sequence  analysis 
of  regions  encoding  CTL  epitopes  was  performed  on  DNA  amplified  from 
DNA  extracted  from  several  patients,  of  known  haplotypes,  who  suffered 
phases  of  prolonged  and/or acute viraemia,  showed  no  detectable variation 
(Table  5.1).  It  is  possible  that  CTL  escape  mutants  arise  within  these 
individuals,  but  remain  as a minority population  enabling a small  reservoir of 
HCMV to  persist,  while the vast  majority of  infected cells can  be  recognised 
and in  many cases cleared.  This compounds previous findings by Zaia  et at. 
[358]  ,  who  found  only  one  coding  mutation  in  the  HLA-A*0201  epitope 
ppUL83(495-503)•  In  their  study,  sequences  encoding  this  epitope  were 
amplified  using  a  regular Taq  polymerase  without  high-fidelity  proof-reading 
capabilities  as  utilised  here.  Furthermore,  neither  patient  epitope-specific 
CD8+ populations nor HCMV-PCR status was established.
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Whether these mutants would be as replicatively fit as the wild type virus and 
the  mutations  result  in  a  decreased  capacity  of  the  virus  to  replicate  is 
unclear.  It  is  also  important  to  consider  whether  novel  CD8+  T-cell 
populations  arise,  which  become  specific  for  these  novel  mutant  epitopes; 
should  this  occur  it  is  reasonable  to  assume  that  the  mutant  populations 
would  occur  transiently.  This  might  also  result  in  the  relative 
immunodominance  of  the  wild-type  epitope-specific  response  shifting 
towards another, previously less immunogenic, epitope.
It  is  also  important to  also  mention  that  any  such  mutations  would  occur  in 
the  context  of  other  well-defined  CTL  evasion  strategies  that  would  further 
facilitate virus escape.
Nevertheless,  there  is  a  large  potential  for  CTL  escape  mutants  to  arise  is 
this  setting,  although  the  exact  nature  of  these  mutations  remains  poorly- 
defined. To address the possible implications that amino acid substitutions of 
a  known  CTL  epitope,  NLVPMVATV,  would  have  on  CTL  recognition  a 
series  of  synthetic  peptides,  with  both  conservative  and  non-conservative 
substitutions,  were  designed  (Fig.  5.2).  Previous  work  used  alanine walking 
[382]  to  ascertain  the  effect  of  substitutions  in  the  NLVPMVATV  on  CTL 
recognition;  nevertheless,  this  alone  would  not  allow  the  determination  of 
how flexible each of the amino acids are to change nor how accommodating 
the resultant CTL response would be.
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Using an  IFNy ELISPOT the variant peptides were used to stimulate PBMCs 
isolated  from  HCMV  seropositive  individuals  and  the  numbers  of  cells 
producing  IFNy  were  compared  to  responses  elicited  by  the  wildtype. 
Substitutions at positions 4, 5 and 6 of the epitope caused the most profound 
reductions  in  IFNy  production  <20%  that  of  wildtype,  while  substitutions 
around  the  anchor  residues  seemed  to  have  a  lesser  effect.  One  possible 
reason  for this  is that the  centre  of the  epitope  is  most  likely to  be the  part 
most easily accessed by the TCR of the epitope-specific T-cell and therefore 
the  part  most  important  for  recognition.  Also,  because  proline  residues,  s 
(such  as  the  one  found  at  position  P4,)  introduce  ‘kinks’  into  protein 
structures,  the  effect  of  which  cannot  be  mimicked  by  other  amino  acid 
substitutions,  any  variant  at  this  position  should  greatly  alter  the  peptide 
structure, thus presumably disrupting both the recognition of the epitope and 
its capacity to bind and stabilise HLA class I molecules.
Certain amino acid substitutions at specific residues seemed to have greater 
effects than  others  at the  same  residues,  e.g.  at  residues  3,  6  and  8  where 
the  conservative  substitutions  were  able  to  induce  a  larger  IFNy  response 
than the non-conservative glycine substitutions (Fig. 5.4).
To address whether the substitutions  had  a direct effect on TCR  recognition 
or  whether  they  affected  the  ability  of  the  epitope  to  bind  and  therefore 
stabilise HLA class I complexes a T2 HLA stabilisation assay was performed. 
This  assay showed that the wildtype  NLVPMVATV epitope was only able to 
moderately  increase  the  stability  of  the  HLA  class  I  complex  compared  to
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background  levels.  This indicated that a highly stable complex between  HLA 
class  1/  and  a  peptide  is  not  essential  for  induction  of  IFNy  production. 
Furthermore,  a  C5M  substitution  was  able to  strongly  increase  HLA  class  I 
stability,  to  more  than  four  times  that  of  the  background,  whilst 
simultaneously  being  unable  to  induce  IFNy  production.  Such  a  mutation 
would  be  advantageous  to  HCMV  for  it  would  enable  the  retention  of  HLA 
class  I  molecules on  the  surfaces  of  infected  cells,  preventing  NK-mediated 
lysis whilst being able to circumvent the epitope-specific response.
Although  The emergence of such  a  mutation  would  require three  nucleotide 
substitutions  and  would  therefore  be  unlikely to  spontaneously  arise.  Given 
that  HCMV  is  a  DNA  virus,  one  would  assume  that  it  would  be  more 
genetically stable than  RNA viruses, such as  HBV and  HIV,  which  are prone 
to  accumulating  CTL-escape  mutants.  Nevertheless,  the selective  pressure 
applied by antivirals  has  resulted  in the evolution of a variety of  mutations  in 
both  UL54  and  UL97  with  antiviral  resistance.  Furthermore,  these  resistant 
mutants  evolve  when  the  viral  load  is  low;  as  a  result  of  the  antiviral 
therapies  used.  In  this  scenario  the  selective  pressure  would  be  exerted  by 
high  numbers of epitope-focused CTLs when the virus is  replicating at  much 
higher frequencies; thus resulting  in a higher probability of the emergence of 
such mutants.
Nevertheless,  should  this  mutation  occur  it  is  possible  that  even  at  low 
concentrations  this  peptide  could  out-compete  the  wild-type  through  the
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strength of its interaction with  HLA-A*0201  and possibly allow mutant virus to 
escape the CTL response.
By co-titrating the C5M  variant with the wild-type  peptide  it was  evident that 
the  C5M  could  reduce  the  absolute  IFNy production  elicited  by the  wildtype 
peptide in an  IFNy ELISPOT by 25% even at low concentrations. When both 
were  present  at  a  1   pM  concentration,  IFNg  production  was  approximately 
halved,  although  titrating  in  the  C5M  variant  at  high  concentrations  could 
never  inhibit  IFNy production  completely.  Similarly,  co-incubation  of T2  cells 
with  these  two  peptides  showed  an  increase  in  the  surface  expression  of 
HLA class  I  with only 0.5 pM  of the C5M,  indicating that competition for that 
HLA  class  I  binding  site  starts  at  a  low  concentration  and  eventually  C5M 
seems to  upregulate  HLA class  I  on  most cells to  levels  normally reached  in 
the presence of wildtype peptide at 50 pM.
One  explanation  for  the  strong  C5M/HLA-A*0201  association  could  be  the 
formation  of  a disulphide  bond  between  the  Cysteine  at  position  5  and  any 
cysteines  present  in  the  HLA-A*0201  peptide-binding  groove.  Such  an 
interaction alone would probably be insufficient to stabilise the  HLA complex, 
as  anchor  residues  are  still  required  for  stabilisation  of  the  complex,  but  it 
could  increase  the  avidity  of  the  interaction.  This  would  depend  on  the 
environment in which any reactions occur and the concentration of cysteines 
in the medium.  RPMI  1640  used during the stimulations contains cysteine so 
there  is  the  possibility  that  disulphide  bonds  may  form  prior  to  interactions 
with  the  HLA  molecule  and  furthermore,  formation  of  the  bond  usually
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requires  a  basic  environment  which  is  unlikely  to  be  the  situation  in  the 
present case.
Although  cells  may  still  express  some  wildtype  peptide  on  their  surfaces, 
because  IFNy is  still  produced  during  stimulation,  it  is  clear that competition 
for  the  HLA  complexes  occurs.  Therefore,  whilst  C5  may  not  be  able  to 
abrogate  IFNy production  in  a  heterogeneous  population  completely,  should 
HCMV alter a major CTL epitope to obtain a similar mutant, this would render 
cells  infected  by  this  variant  less  susceptible  to  CTL  lysis.  These  mutants 
could  conceivably occur in  patients suffering  repeated viraemic episodes  as 
described  above,  and  although  no  such  mutants  could  be  detected  in  the 
sequence  analysis  their  frequency  may  have  been  below  the  detection 
threshold of the assay <20% of the total virus population.
In  addition  to  the  potential  for  CTL  escape  mutants  arising  during  HCMV 
infection,  there  is  also  the  possibility  of  CD8+  T-cell  responses  to  HCMV 
being  functionally  defective  in  individuals  unable  to  prevent  viraemia.  IFNy 
secretion  has  indirect effects on  infected cells,  causing  up-regulation  of  HLA 
molecules  and  allowing  infected cells to  be  more easily recognised  by other 
CD8+ cells as well as activating other aspects of the immune response;  but it 
is not directly cytolytic.
Is  it  possible  that  these  epitope-specific  CD8+  T-cell  populations  have  a 
defect  in  their cytolytic  potential  or that they  may  be  replicatively  senescent 
and thus less able to react to a virus infection?
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6.1 Introduction
Individuals  suffering  from  common  variable  immunodeficiency  syndrome 
(CVID) are an important clinical  model for the study of various aspects of the 
adaptive  immune  response.  During the third  decade  of  life these  individuals 
cease  to  be  able  to  produce  immunoglobulins  against  invading  pathogens 
[346,  347].  This increases their susceptibility to a multitude of predominantly 
bacterial  infections;  yet despite this, they are still  able to control  and  resolve 
many acute virus  infections without complications.  Because they are  unable 
to mount B-cell  responses it is not possible to ascertain the serostatus of the 
patients  towards  previously-encountered  pathogens.  However,  using  T-cell- 
based immune assays, such as ICS analysed by FACS, it may be possible to 
establish which organisms  have been  encountered at an  earlier stage of  life 
and could therefore be used as a crude determination of previous infection.
The  majority of  healthy  HCMV-seropositive  individuals  mount  large,  HCMV- 
specific  T-cell  responses  that  expand  as  a  result  of  sporadic  low-level, 
asymptomatic  reactivations  throughout  life.  Data  from  previous  chapters 
indicated  that  renal  transplant  patients,  unable  to  control  HCMV  replication 
whilst on immunosuppressive regiments in the months post transplant,  had a 
significant  decrease  in  the  frequencies  of  their  HCMV-specific  CD8+  T-cell 
populations compared to those that were able control  HCMV replication.
The  aim  of  this  chapter  was  to  use  FACS  analysis  of  intracellular  cytokine 
staining  to  determine  whether  CVID  patients  mount  detectable  CD4+  and 
CD8+  T-cell  responses  to  HCMV;  these  virus-specific  responses  were
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subsequently  compared  between  these  patients  and  age-matched  healthy 
controls.  Because  none of the CVID  patients  in this group has  ever suffered 
a  symptomatic  HCMV  infection,  even  prior  to  CVID  being  diagnosed,  it  is 
possible  to  conclude  that  although  immunoglobulins  afford  some  level  of 
protection during the resolution of primary HCMV infection, long-term control, 
in  these  patients,  may  be  the  result  of  some  other  facet  of  the  immune 
response; namely the T-cell responses.
Phenotypic  analyses  were  also  performed  on  epitope-specific  CD8+  T-cell 
populations  using  HLA-restricted  class  I  tetramers.  Phenotypic  analyses 
focused  on  the  proportions  of  epitope-specific  cells  that  displayed  the 
senescence  marker  CD57  [303,  383,  384]  and  the  intracellular  lytic  protein 
perforin.  Together,  these  markers  would  give  an  indication to the  proportion 
of late-stage,  replicatively-senescent,  potentially cytolytic cells in the CD8+ T- 
cell populations. These populations were compared in CVID patients,  healthy 
age-matched  controls  and  also  renal  transplant  patients  who  suffered 
repeated  bouts  of  viraemia  to  determine  whether  there  was  a  functional 
aspect  to  these  cell  populations  that  rendered  certain  individuals  less 
susceptible to HCMV replication.
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6. 2 CVID responses to HCMV antigens
Similar  to  previous  chapters,  CD4+  and  CD8+  T-cell  responses  to  HCMV 
lysate,  pp65  and  IE1  were  measured  in  CVID  patients  by  ICS  using  FACS, 
by  overnight  stimulation  of  freshly  isolated  PBMCs  with  antigens  in  the 
presence  of  CD28  and  CD49d.  This  assay  was  used  to  provide  a  crude 
determination  of  past  HCMV  infection,  which  would  previously  have  been 
unidentified  due  to  the  lack  of  any  detectable  B-cell  responses.  HCMV- 
specific  T-cell  responses  above  the  lower  limit  of  detection  for  either  CD8 
and/or  CD4  responses  were  found  to  be  present  in  sixteen  of  the  nineteen 
patients analysed (84%).
The  median  CD8+  T-cell  response  of  these  sixteen  individuals  towards  IE1 
was  0.55%  (range  0.02%  to  4%),  while  towards  pp65  it  was  3.22%  (range 
0.31% to  14.41%)  (Fig.  7.1).  Interestingly,  this  means that all  CVID  patients 
analysed with detectable CD4 and/or CD8 response towards HCMV also had 
CD8+  T-cell  responses  against  pp65  that  were  above  the  lower  limit  of 
detection.
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HCMV-specific T-cell responses in CVID patients
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Figure 6.1 Analysis of CD4+  and CD8+  T-cell responses to HCMV antigens in CVID 
patients
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6. 3 Comparison of T-cell responses
CVID  patients  found  to  have  either  CD4+  and/or  CD8+  T-cell  responses 
above  the  lower  detection  threshold  (>0.1%)  were  considered  to  have 
previously  encountered  HCMV.  Further  analyses  were  performed  to 
determine  whether  the  HCMV-specific  T-cell  responses  of  CVID  patients 
were comparable with those of healthy HCMV seropositive volunteers.
Figures  6.1,  6.2  and  6.3  show  the  comparative  CD8+  T-cell  responses  to 
HCMV  antigens  between  individuals  with  CVID  (n  =  16)  and  age-matched 
healthy  individuals  (n  =  15)  and  also  the  median  percentages  of  HCMV- 
specific  responses  from  viraemic  renal  transplant  patients  analysed  over  a 
period of six months post-transplant (n = 8).
The frequency of CD8+ T-cell  populations specific for pp65 were significantly 
elevated  in  individuals  with  CVID  compared  to  those  of  healthy  controls 
(median  2.97%  and  0.44%  respectively,  p  =  0.01).  The  same  responses 
were  compared  between  CVID  patients  and  viraemic  renal  transplant 
(median  2.97%  and  0.25%  p  =  0.009).  CD8+  T-cell  responses  towards  IE1 
were also elevated in CVID individuals compared to healthy controls (median 
0.56%  and  0.22%  p  =  0.02).  However,  there  was  no  significant  increase 
when compared to viraemic individuals  (median 0.56% and 0.08% p = 0.22). 
When  CD8+  T-cell  responses  to  pp65  and  IE1  were  combined  there  was 
again  a  significant  elevation  in  the  HCMV-specific  responses  of  CVID 
patients compared to  healthy controls  (median  4.27% and  0.74% p =  0.003) 
and also over viraemic individuals (median 4.27% and 0.65% p = 0.02). Such
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increases  in  the  percentages  of  HCMV-specific  CD8+  populations  in  CVID 
populations  when  compared  to  healthy  individuals  may  be  related  to  the 
increase  in  the  frequencies  of  HCMV-specific  CD4+  T-cell  or  possibly 
increased  exposure to  HCMV through  ongoing  replication,  which  cannot  be 
detected in the peripheral blood.
A  similar  comparison  was  performed  to  ascertain  whether  there  are  any 
differences in the frequencies of global  HCMV-specific CD4+ T-cells between 
these  two  groups;  to  do  this,  responses  towards  HCMV  lysate  were 
measured  (as  in chapter 3).  Figure  6.4 shows that the  HCMV-specific  CD4+ 
T-cell  populations of CVID patients were not significantly different to those of 
healthy  age-matched  controls.  Median  HCMV-specific  CD4  responses  were 
0.95%  in  CVID  patients,  0.79%  in  healthy  age-matched  controls  and  1.33% 
in viraemic renal transplant patients; none of these differed significantly.
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6.4  Analysis and comparison of HCMV-specific Tet+  populations
In order to ascertain whether the epitope-specific CD8+ T-cell  populations of 
CVID patients were similar to those found in healthy individuals and viraemic 
transplant  patients,  tetramers  specific  for  HCMV  A1,  A2  and  B7-restricted 
epitopes  were  analysed  for  intracellular  levels  of  perforin,  the  presence  of 
which  would  be  an  indicator  of  the  cytolytic  potential  of  the  cells,  and  the 
senescence  marker  CD57  expression  of  which  would  correlate  an  effector 
memory  phenotype  and  a  decreased  capacity  to  proliferate  in  response  to 
antigen stimulation.
A  significant  increase  was  apparent  in  the  percentage  of tetramer+  CD8+  T- 
cells  in  CVID  patients  when  compared  with  healthy  age-matched  controls 
(CVID  n  =  9,  median  4.65%  and  healthy  n  =  9,  0.84%  P  =  0.03)  and  also 
when  compared to viraemic  renal  transplant  patients  (Fig.  7.11  CVID  n  =  9, 
median 4.65% and viraemic n = 7, 0.95% P = 0.03).
When  expression  levels of CD57 in  HCMV epitope-specific CD8 populations 
were compared  (Fig.  7.12),  there  was  an  elevation  in  CVID  patients  (n  =  9, 
median 79%) compared to healthy controls (n = 9,  median 58%) but this was 
not  significant  (p  =  0.06).  There  was  also  no  significant  difference  in  the 
median  percentages  of  tetramer-positive  cells  expressing  CD57  between 
CVID patients and viraemic renal transplant patients (n = 7,  median 55.8%,  p 
= 0.07).
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Figure  6.  2  Comparison  of  pp65-specific  CD8+   T-cell  responses  between  CVID 
patients, healthy age-matched controls and viraemic renal transplant patients.
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Figure  6.  3  Comparison  of  IE1 -specific  CD8+   T-cell  responses  between  CVID 
patients, healthy age-matched controls and viraemic renal transplant patients.
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Figure 6.  4 Comparison of combined IE1  and pp65-specific CD8+  T-cell responses 
between CVID patients, healthy age-matched controls and viraemic renal transplant 
patients.
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Figure  6.  5  Comparison  of  global  CD4+   T-cell  responses  to  whole  virus  lysate 
between CVID patients, healthy age-matched controls and viraemic renal transplant 
patients.
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6.  4 Analysis and comparison of HCMV-specific Tet* populations
In order to ascertain whether the epitope-specific CD8+ T-cell populations of 
CVID patients were similar to those found in  healthy individuals and viraemic 
transplant  patients,  tetramers  specific  for  HCMV  A1,  A2  and  B7-restricted 
epitopes  were  analysed  for  intracellular  levels  of  perforin,  the  presence  of 
which  would  be  an  indicator  of  the  cytolytic  potential  of  the  cells,  and  the 
senescence  marker  CD57  expression  of  which  would  correlate  an  effector 
memory  phenotype  and  a  decreased  capacity  to  proliferate  in  response  to 
antigen stimulation.
A significant  increase was  apparent  in  the  percentage  of tetramer+  CD8+ T- 
cells  in  CVID  patients  when  compared  with  healthy  age-matched  controls 
(CVID  n  =  9,  median  4.65%  and  healthy  n  =  9,  0.84%  P  =  0.03)  and  also 
when  compared to viraemic renal  transplant  patients  (Fig.  7.11  CVID  n  =  9, 
median 4.65% and viraemic n = 7, 0.95% P = 0.03).
When expression  levels of CD57 in  HCMV epitope-specific CD8 populations 
were compared  (Fig.  7.12),  there was  an  elevation  in  CVID  patients  (n  =  9, 
median 79%) compared to healthy controls (n = 9,  median 58%) but this was 
not  significant  (p  =  0.06).  There  was  also  no  significant  difference  in  the 
median  percentages  of  tetramer-positive  cells  expressing  CD57  between 
CVID patients and viraemic renal transplant patients (n = 7,  median 55.8%,  p 
= 0.07).
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Similarly,  a  greater  proportion  of  intracellular  perforin  was  evident  in  the 
tetramer+  cells  of  CVID  patients  (90%)  compared  to  healthy  age-matched 
controls  (77.5%)  although  this  again  was  not  significant  (p  =  0.06).  The 
difference between  intracellular perforin levels of CVID patients and viraemic 
(median 78%) individuals was also not significant (Fig. 7.13 p = 0.6).
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Figure 6.  6  FACs analysis of CD57 staining in CD8+  CD3+  Tetramer populations. Upper panels show (from left to right) the forward 
scatter (x) against side scatter (y), CD3 (x) against CD8 (y), HLA-A*0201  HCMV tetramer (x) against CD8 (y), CD57 (x) against CD8 
(y).  Lower  Panels  show  CD57  (x)  against  HLA-A*0201  HCMV  tetramer  (y)  and  the  proportion  of  these  HCMV  tetramer+   cells 
expressing CD57 (x).
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Figure 6. 7 FACs analysis of perforin staining in CD8+  CD3+  Tetramer populations. Upper panels show (from left to right) the forward 
scatter (x) against side scatter (y), CD3 (x) against CD8 (y), HLA-A*0201  HCMV tetramer (x) against CD8 (y), perforin (x) against CD8 
(y).  Lower  Panels  show  perforin  (x)  against  HLA-A*0201  HCMV  tetramer  (y)  and  the  proportion  of  these  HCMV tetramer+   cells 
expressing perforin (x).
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Figure  6.  8  CD57  and  Perforin  Phenotypes  of  four  CVID  patients,  left  panels  show
tetramer+   (x)  population  against  CD8+   (y)  population,  central  panels  show  CD57  (x)
against tetramer (y), right panels show perforin (x) against tetramer (y).
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Figure  6.  9  CD8+   Phenotypes  of four age-matched  healthy controls,  left panels  show
tetramer+   (x)  population  against  CD8+   (y)  population,  central  panels  show  CD57  (x)
against tetramer (y), right panels show perforin (x) against tetramer (y).
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Figure 6.  10 Examples CD8+  Phenotypes of four viraemic renal transplant patients left
panels show tetramer+  (x) population against CD8+  (y) population, central panels show
CD57 (x) against tetramer (y), right panels show perforin (x) against tetramer (y).
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Figure 6.  11  A comparison of the percentages of HCMV epitope-specific tetramer 
stained  CD8+   cells  between  CVID  patients,  age-matched  healthy  controls  and 
viraemic renal transplant patients.
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Figure 6.  12 A comparison of the percentages of HCMV epitope-specific tetramer 
stained  CD8+   cells  (upper  panel)  and  CD8+   cells  that  express  the  senescence 
marker CD57 (lower panel).
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Figure 6.  13 A comparison of the percentages of HCMV epitope-specific tetramer 
stained  CD8+   cells  (upper  panel)  and  CD8+   cells  (lower  panel)  that  express 
intracellular perforin.
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6.5 Discussion
This chapter demonstrated for the first time that patients suffering  CVID  had 
detectable  CD4+  and  CD8+  T-cell  populations  specific  for  HCMV  antigens. 
This is the first example of virus-specific T-cell responses being shown in this 
patient group  and  allows  a determination  of the  previous  infection  history of 
the  individual,  which  may  be  of  clinical  significance  for  these  individuals  in 
the  future;  for  instance,  in  the  event  of  an  organ  transplant  where 
donor/recipient HCMV serostatus is required.
This chapter not only shows the that T-cell responses to HCMV exist in these 
individuals  but  that,  in  the  case  of  HCMV-specific  CD8+  T-cell  responses, 
they are elevated in comparison to healthy age-matched controls (p = 0.006). 
This  increase  is  more  apparent  for  responses  against  pp65,  a  product  of 
either a primary or a productive lytic replication, than  responses against  IE1; 
indeed,  all  CVID individuals with detectable  HCMV-specific T-cell  responses 
had CD8+  T-cell  responses towards  pp65 that were  above the  lower  limit of 
detection  (16/16  had  responses  >0.3%).  These data suggest that elevations 
in virus-specific CD8+ T-cell responses could be compensating for the lack of 
endogenous  humoral  responses.  Furthermore,  because these  patients  have 
neither  suffered  any  known  HCMV-associated  disease  nor  had  any 
detectable episodes of viraemia indicates that their humoral  responses were 
not as critical  for the control  of  HCMV  infection  as cell-mediated  responses. 
Although  these  individuals  do  receive  regular  infusions  of  polyclonal  sera, 
which  might  alleviate  any  potential  illness,  there  was  a  stage  prior  to
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diagnosis  in  which  Ig  levels  were  low  and  no  incidences  of  CMV  disease 
were reported.
Because  of  the  elevation  in  HCMV-specific  CD8+  responses,  it  was 
reasonable to suggest that there would  be a concomitant rise  in the  HCMV- 
specific  CD4+  T-cell  responses  of  those  same  individuals.  This  assumption 
proved to be unfounded as CD4+ T-cell  responses to  HCMV lysate were  not 
significantly  different  between  either  the  healthy  controls  or  the  viraemic 
individuals tested.  This  phenomenon was  also  apparent in  chapter 3,  where 
there  was  no  significant  variation  in  the  CD4+  T-cell  responses  to  HCMV 
between  viraemic  and  non-viraemic  transplant  patients.  Taken  together 
these data indicate that there is  no apparent link between the frequencies of 
HCMV-specific CD4+ T-cell responses and an increase in the susceptibility of 
an individual to suffering HCMV viraemia.
CD8+  T-cells  specific  for  immunodominant  HLA  class  l-restricted  CMV 
epitopes  were  compared  between  individuals  of  known  haplotypes  for each 
group.  Only  individuals  of  known  haplotypes,  with  detectable  HCMV 
tetramer-positive  populations  were  selected  from  each  group.  Median 
frequencies  of tetramer-positive  cells  were  found  to  be  highest  in  the  CVID 
patients  (n  =  9,  median  4.65%);  these  responses  were  significantly  higher 
than found  in age-matched  healthy controls  (n  = 9,  median 0.84%,  p = 0.03) 
and also to renal transplant patients suffering  repeated viraemic episodes  (n 
=  7,  0.91%  p  =  0.04).  Although  responses  to  HLA-restricted  CTL  episodes 
are  higher in  CVID  patients,  they are  not  representative  of total  CD8+ T-cell
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responses  to  HCMV.  Measuring  the  percentage  of  CD8+  T-cells  that  can 
recognise  a  given  epitope  would  also  not  allow  the  determination  of  the 
proportion of those cells that are potentially functional.
The  proportion  of tetramer-positive cells  expressing  the senescence  marker 
CD57 was  also  measured  and  compared  between  the three  groups.  CD57+ 
T-cell  populations  have been  postulated to arise as a direct consequence of 
repeated  bouts  of  T-cell  proliferation,  brought  about  by  sporadic  virus 
reactivation; this results in a decreased ability to proliferate in  response to in 
vitro stimulation with cognate antigen  in vitro,  a decrease in telomere length, 
which would correlate with past expansions, and an increased cytolytic ability 
[384].  These cells are generally thought of as  late-stage  effector memory T- 
cells as they also tend to have a higher cytolytic ability.
Although the  median  percentages  of tetramer+  CD8+  cells  expressing  CD57 
were  highest  in  CVID  patients  (median  79%),  median  percentages  of  the 
same  population  in  healthy  individuals  (58%)  were  not  significantly  different 
(p  =  0.08),  this  was  also  the  case  with  viraemic  renal  transplant  patients 
(median  55%,  p  =  0.07).  CD57  levels  were  elevated  in  CD8  populations of 
CVID patients as a whole with a median of 54% compared to 31% in  healthy 
individuals  (p  =  0.03),  and  36%  in  viraemic  transplant  patients  (p  =  0.03). 
There  was  no  significant  differences  between  median  levels  of  CD57 
expression  between  the  viraemic  individuals  and  healthy  controls  (p  =  1). 
Higher frequencies of these CD57+ CD8 T-cells in the CVID group may have 
occurred  as  a direct consequence of  repeated episodes of  past virus  and/or
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bacterial  replication  which,  although  not  symptomatic,  may  have  resulted 
because  of  the  lack  of  immunoglobulins.  This  may  have  led  to  larger 
expansions of end-stage populations necessary for control of the infection.
Analysis  of  intracellular  perforin  levels  of  CD8+  T-cell  populations  also 
yielded  similar  results,  in  that there  was  an  elevation  in  the  percentages  of 
tetramer-positive  cells  with  intracellular  perforin  in  CVID  patients  (median 
90%)  compared  to  healthy  controls  (median  77.5%  p  =  0.06)  but  not  when 
compared  with  viraemic  transplant  patients  (78%  p  =  0.6).  These  results 
were  slightly  altered  when  analysed  in  the  context  of  overall  CD8 
populations;  the  median  percentage  of  CD8+  cells  containing  perforin  in 
CVID  patients  was  62%,  which  was  significantly  higher  than  that  found  in 
healthy  patients  (34%,  p  =  0.02),  although  not  significantly  different  from 
viraemic renal transplant patients (55%, p = 3.4).
Together these data,  while  looking  at  narrowly-focused  CD8+  T-cell  subsets 
of  all  three  groups,  show that  epitope-specific  responses  for  HCMV tend  to 
be  of  a  late-stage,  potentially-cytolytic,  effector  memory  phenotype  with  the 
majority of cells  expressing  perforin  and CD57.  Levels of these  markers  are 
increased  in  epitope-specific CD8+  T-cells  in  comparison  to  overall  CD8+  T- 
cell populations,  indicating that HCMV does influence the type of CD8+ T-cell 
responses it elicits. Tetramer-positive populations were significantly elevated 
in  CVID  patients  when  compared  to  healthy  individuals  and  viraemic  renal 
transplant  patients.  Intracellular  levels  of  perforin  were  increase  in  the 
tetramer-positive  populations  of  CVID  patients  when  compared  to  healthy
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controls  but  not  when  compared  to  viraemic  patients  and  this  phenotypic 
phenomenon was consistent when CD57 expression levels were analysed.
Although the high percentages HCMV-specific effector-memory CD8+ T-cells 
in the peripheral blood may prevent viraemia in CVID patients, as none of the 
CVID patients were  PCR-positive (data not shown),  and thus circumvent the 
need  for  an  autologous  humoral  response,  these  seem  insufficient  for 
controlling  virus  replication  in  individuals  who  become  viraemic  and  retain 
normal  B-cell  responses.  Previous chapters have demonstrated a decreased 
absolute  number  of  virus-specific  CD8+  T-cells  in  viraemic  individuals 
compared  to  non-viraemic  individuals,  indicating  it  there  is  a  protective 
threshold of CD8 responses required for control of HCMV replication.
As  a  possible  caveat  for  this,  a  number  of  CVID  patients  in  this  study 
suffered  from  an  inflammatory  colitis-like  syndrome  with  frequent  bloody 
diarrhoea  similar  to  that  seem  in  certain  immunocompromised  HCMV- 
infected  individuals.  Furthermore,  biopsies  examined  showed  the  presence 
of  HCMV particles  in the gut tissues,  interestingly these symptoms  lessened 
on  administration  of  ganciclovir.  This  possibly  indicates  that  although  large 
numbers  of  T-cells  may  control  virus  replication  in  the  peripheral  blood,  the 
expression  of  virus  transcripts  in  various  tissues  may  be  recognised  by  a 
powerful  potentially  cytolytic  CD8  response  which  may  destroy  infected 
tissues preventing full virus replication whilst causing immunopathologies.
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In  this  thesis  longitudinal  analyses  of  HCMV-specific T-cell  responses  were 
performed  in  twenty  renal  transplant  patients  of  different  donor/recipient 
serostatus  for  6  months  post-transplant  (see  Appendix).  This  study  serves 
improved  the  understanding  of  the  natural  history  of  HCMV-specific  T-cell 
response  dynamics  in  the  context  of  the  renal  transplant  patient  group. 
Moreover,  it  gives  clues  as  to  how  the  HCMV-specific  CD4+  and  CD8+ 
subpopulations  relate  to  the  incidences  of  HCMV  replication,  which 
themselves  may  correlate  with  the  progression  of  HCMV-associated 
diseases.  Previous  studies  have  looked  at  HCMV-specific  CD4  and  CD8 
populations  although  T-cell  responses  may  have  been  misrepresented 
because they focused solely on percentages of IFNy-producing T-cells rather 
than  the  absolute  numbers  of  these  cells  in  the  peripheral  blood  [294,  332, 
355, 357, 385-387].
The  thesis  then  sought  to  discover  whether  HCMV  CD8-escape  mutants 
evolve  in  a  highly  selective  environment,  where  high  viral  loads  persist  in 
certain  renal  transplant  patients  despite  the  presence  of  large  epitope- 
specific  CD8  responses.  Finally,  this  work  tried  to  elucidate  whether  the 
potential  cytolytic  phenotype  and  the  magnitude  of  HCMV-specific  CD8+ 
populations  helps  to  prevent  disease  by  comparing  epitope-specific  CD8 
populations  in  renal  transplant  patients  suffering  repeated  bouts  of  HCMV 
viraemia,  healthy  adults  and  patients  with  CVID,  who  despite  lacking  an 
endogenous  B cell  response are able to control virus  infections,  presumably 
through their T-cell responses.
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Chapter 3
Chapter  3  focused  on  how  Th1 -polarised  CD4+  T-cell  responses  against 
HCMV  fluctuated  in  20  renal  transplant  patients  over  the  6  months  post­
transplant.  Results  indicated that during the first six  months  post-transplant, 
functional  HCMV-specific  CD4-responses,  as  measured  by their capacity to 
produce  the  Th1  cytokine  IFNy  in  response  to  HCMV  antigens,  rose 
gradually. This rise was significant in terms of both the percentage  (Fig.  3.3) 
and  absolute  number  (Fig  3.4)  of  circulating  CD4+  T-cells  able  to  produce 
IFNy  following  stimulation  with  virus  lysate.  There  was  an  association 
between  the  magnitude  of  CD4  responses  and the  likelihood  of this  patient 
group  to  suffer  episodes  of  HCMV  viraemia  (Fig.  3.8)  and  this  compounds 
findings of Sester et al.  [332] who stated that CD4 responses were crucial for 
the  control  of  HCMV  replication.  CD4  responses  increased  three  months 
post-transplant,  when  immunosuppressive  therapies  were  reduced,  and  the 
rise  between  months  1   to  3  and  months  4  to  6  was  statistically  significant 
(Fig.  3.9).  All  incidences  of  HCMV  replication  occurred  during  the  first three 
months post-transplant (see appendix), this corresponds to previous findings 
which  indicate  show  that  HCMV  reactivation  usually  occurs  during  the  first 
three months post-transplant.
To determine whether the there was a link between the magnitude of HCMV- 
specific CD4 responses and CD8 responses,  which would also be protective 
against  HCMV-replication,  a  correlation  between  both  the  percentages  and 
absolute  numbers  of  CD4+  T-cell  responsive  the  HCMV  lysate  and  the 
percentages  and  absolute  numbers  of  CD8+  T-cells  responses  to  two
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immunodominant  targets,  IE1  and  pp65  was  performed.  No  relationship 
between  the  percentages  of  HCMV-specific  CD4  cells  and  CD8  cells  could 
be  detected  (Fig.  3.10),  yet  there  was  a  correlation  between  the  absolute 
numbers  of  HCMV-specific  CD4+  T-cells  and  CD8+  T-cells  (Fig.  3.11).  This 
indicates  that  CD4  responses  are  important  in  controlling  virus  replication 
either  directly  or  indirectly,  possibly  by  influencing  the  size  of  virus-specific 
CD8 responses which may be able to lyse virus-infected cells.
Chapter 4
The  aim  of  chapter  4  was  to  further  investigate  the  kinetics  of  the  HCMV- 
specific CD8  response after renal transplantation  and the  role  it  plays  in the 
control of HCMV replication.  Similar to chapter 3, the dynamics of the CD8+ 
responses  in  the  6  months  post-transplant  was  measured,  this  time  to  IE1 
and  pp65,  two  targets  that  have  previously  been  shown  to  be 
immunodominant  in  the  HCMV-specific  CD8  response.  Of  the  twenty 
individuals  included  in  this  study  only  fifteen  had  CD8+  responses  to  either 
antigen  that  were  consistently  above  the  detection  threshold,  fourteen  had 
responses  to  the  tegument  phosphoprotein  pp65,  ten  of  which  had 
responses to the immediate early protein  IE1  and nine who had responses to 
both  (Fig.  4.2).  Moderate  increases  in  both  the  percentages  and  absolute 
numbers  of  pp65  and/or  IE1-specific  CD8+  T-cell  responses  occur  over the 
six  months  post-transplant  (Figs  4.6  and  4.12),  and  again,  this  increase 
follows the pattern of the CD4 populations where responses rise significantly 
after the third  month  post-transplant.  To  determine  whether CD8  responses 
protected against a susceptibility to viraemia,  frequencies of CD8  responses
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to  both  IE1  and  pp65  were  combined  and  compared  between  individuals 
suffering  viraemic  episodes  and  those  that  remained  free  from  episodes  of 
HCMV  replication  in  the  six  months  following  transplant.  Both  the 
percentages  and  the  absolute  numbers  of  combined  pp65  and  IE1-specific 
CD8  responses were shown to be significantly decreased  in  individuals who 
suffer  viraemic  episodes  post-transplant;  demonstrating  that  the  magnitude 
of  HCMV-specific  IFNy-producing  CD8+  T-cell  responses  can  be  protective 
against  HCMV  replication  (Figs.  4.16-4.21).  The  frequencies  of  CD8 
responses to  IE1  and/or pp65 were also  not significantly different to those of 
healthy  controls  (Figs,  4.3,  4.4  and  4.6);  this  is  contrary to  previous  reports 
[355,  357]  where  viraemic  post-transplant  patients  had  increased  HCMV- 
specific CD8  responses when  compared to  healthy controls,  although these 
studies  focused  solely  on  HLA-restricted  epitope-specific  responses  rather 
than more representative responses to entire antigens as shown here.
This  discovery  may  help  determine  which  patients  are  more  susceptible  to 
HCMV  viraemia  and  therefore  more  predisposed  to  associated  diseases 
after  renal  transplant  and  further  allow  antiviral  therapy  to  focus  on  a  high 
disease-risk  group.  Previous  reports  have  described  IE1-specific  CD8 
responses  to  be  protective  against  HCMV  disease  in  the  first three  months 
post  lung  and  liver  transplant  [379].  In  work  presented  here  there  was  no 
association  between  the  magnitude  of  IE1-specific  responses  alone  and 
decreased incidences of viraemia (Figs. 4.23 and 4.24).  However,  since pre­
emptive  therapy  was  given  to  all  patients  with  high  level  replication  it  is 
possible  that  while  such  responses  were  unable  to  control  replication,  they
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may  have  been  sufficient  to  reduce  the  peak  viral  loads  attained  in  the 
absence of therapy and thereby prevent disease.
One of the  individuals  presented  in this chapter had the  highest frequencies 
of  pp65  and  IE1-specific  CD8  cells  and  yet  still  suffered  viraemic  episodes. 
One  explanation  for this  may  be that this  same  individual  had  a decreased 
amount of “help” as would normally be provided by virus-specific CD4+ cells. 
Janssen and colleagues previously demonstrated that antigen-specific CD8+ 
populations we  more  susceptible to trail-mediated  apoptosis  in  the  absence 
of helper CD4 responses [388].
One  other  explanation  for  this  may  be  that  CD8  responses  are  “helpless” 
[388]  this occurs when  CD8  responses occur  in the  absence  of  helper CD4 
responses and would result in possible apoptosis of antigen-stimulated virus- 
specific CD8 cells.  More recently it has been shown that during chronic virus 
replication  T-cell  apoptosis  is  be  driven  through  expression  of  PD-1 
(programmed  death  1)  on  the  surfaces  of  repeatedly-exposed  .exhausted 
CD8+ cells [389].
Chapter 5
Although  a  link was  found  between  the  decreased  frequencies  of  pp65  and 
IE1-specific  CD8+  T-cells  and  an  increase  in  the  incidence  of  HCMV 
viraemia,  certain  patients suffering viraemic episodes did so  in spite of  large 
CD8+  T-cell  responses.  Chapter  5  addressed  the  question  of  whether 
mutations  within  CTL  epitopes  may  be  able  to  explain  this  phenomenon.
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DNA  isolated  from  the  peripheral  blood  of  four  individuals  who  suffered 
prolonged  episodes  of  HCMV  viraemia  despite  the  presence  of  detectable 
tetramer-specific  CD8+  responses,  was  analysed  for  the  presence  of  CTL 
escape mutants.  No mutations were found within the HLA-restricted epitopes 
of  these  individuals  nor were they found  in  sequences  from  individuals  with 
acute-phase  high-level  viraemia  (Table  5.1).  This  might  indicate  that 
mutations either do not arise in these epitopes, or that mutant populations do 
not  make  up the  bulk of the  HCMV  populations  or that the  CTL populations 
directed  against  the  epitope  are  insufficient  for  control  of  virus  replication. 
Also  there  is  the  possibility  that  transient  mutants  arise  in  the  virus 
population,  which  allow  restricted  escape  but  are  not  maintained  [390]. 
Although  a  mutation  in  this  epitope  has  previously  been  described  [358] 
sequence  amplification  was  performed  using  a  non-proof-reading 
polymerase which  may have introduced  artificial  mutants  [358].  Because the 
possibility  remained  that  a  subpopulation  of  HCMV  in  these  individuals 
contained  mutant  epitopes that would  allow virus  persistence through  being 
able  to  circumvent  the  CTL  responses,  a  series  of  mutations  in  the 
immunodominant  HLA-A0201  epitope  NLVPMVATV  were  synthesised  (Fig. 
5.2)  and analysed in their capacity to elicit immune  responses,  as  measured 
by I FNy production, and to stabilise MHC class I  molecules.
ELISPOT  assays  using  the  both  the  wt  and  variant  epitopes  demonstrated 
that the wt peptide was  best capable of eliciting  IFNy production when  used 
to  stimulate  PBMCs  isolated  from  HLA-A0201-restricted  healthy  HCMV 
seropositive individuals  (Fig.  5.4).  Variants with mutations around the anchor
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regions were also capable of eliciting  IFNy production,  albeit to a lower level 
than the wt peptide, and were generally better recognised by epitope-specific 
CTLs than  variants  with  mutations  within  the  core  of the  peptide.  Using  the 
peptides  to  stabilise  MHC  I  molecules  on  TAP-deficient  T2  cells  it  was 
demonstrated  that  high  avidity  interactions  with  MHC  I  molecules  were  not 
essential  for  recognition  by  the  TCR  of  epitope-specific  CD8+  T-cells  (Fig. 
5.5).  Interestingly the C5M variant peptide was better capable of stabilising 
cell-surface  MHC  I  molecules  whilst  simultaneously  being  unable  to  elicit 
IFNy  production.  The  possible  emergence  of  such  a  mutant  in  the  HCMV 
population  would  enable  CTL  evasion  whilst  not  rendering  infected  cells 
susceptible to NK-mediated lysis [391].
Chapter 6
Because  no  CTL-escape  mutants  could  be  detected  in  patients  with  high 
viral  loads  in  spite  of  large  focused  CTL  responses  chapter  6  sought  to 
establish whether a functional impairment could be ascribed to the inability of 
CD8+ T-cell responses to control virus replication. This chapter focused on a 
patient  group  who  usually  resolve  most  virus  infections  asymptomatically; 
these  individuals  suffer from  CVID,  which  renders  them  unable  to  produce 
normal  levels  of  immunoglobulins.  Although  this  makes  them  more 
susceptible to bacterial  infections,  which can  be overcome through  infusions 
of  polyclonal  antibodies,  this defect does  not  appear to  have  any  noticeable 
effect  on  their  capacity  to  control  virus  infections.  The  HCMV  serostatus  of 
these  patients  could  obviously  not  be  defined  unless  it  was  known  prior to 
the  manifestation  of  any CVID-associated  symptoms,  therefore the  capacity
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of  their  T-cell  responses  towards  HCMV  was  measured  using  FACS 
analysis.  The  majority  of  these  individuals  were  found  to  have  high 
frequencies  of  HCMV-specific  CD4  and  CD8  cell  populations  indicative  of 
prior  infection.  Furthermore,  their  CD8  responses  to  HCMV  antigens  pp65 
and IE1  were significantly increased when compared to healthy age-matched 
controls  (Figs.  6.2  and  6.3).  The  magnitude  of  these  responses  could  then 
give  a  clue  as  to  the  mechanism  by  which  they  are  able  to  control  HCMV 
replication.
When  epitope-specific subpopulations  of the CD8  response were  compared 
between  CVID  patients,  healthy  age-matched  controls  and  viraemic  renal 
transplant  patients,  epitope-specific  responses  were  also  elevated  in  CVID 
compared  to  the  other  groups.  Phenotypic  analyses  of  these  populations 
showed  that,  of  the  tetramer+  populations  there  was  an  elevation  in  the 
percentage  of  these  cells  that  were  CD57  positive  in  the  CVID  patients, 
although  this  was  not  significant.  However,  looking  at  overall  CD8+ 
populations there was a significant increase in the percentages of CD8+ cells 
expressing  CD57  when  compared  to  those  found  in  both  healthy  age- 
matched  controls  and  viraemic  renal  transplant  patients.  Expression  of  the 
activation  marker CD57  has  previously been  shown to  be  associated with  a 
late-stage,  replicatively-senescent,  cytotoxic  CD8+  phenotype,  therefore  the 
percentages  of  these  same  populations  containing  the  cytolytic  granule 
perforin  were  compared  [392].  In  the  epitope-specific  population  levels  of 
intracellular  perforin  were  highest  in  the  CVID  patients  although  this  was 
again not a significant increase compared to the other two groups (Fig. 6.13).
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However,  perforin  levels  were  significantly  increased  in  CVID  CD8+ 
populations  as  a  whole  when  compared  to  healthy  age-matched  controls. 
Interestingly,  the  perforin  levels  in  viraemic  renal  transplant  patients  were 
also  significantly  higher  than  those  of  healthy  individuals  (Fig.  6.13);  this 
suggests  that  cytolytic  potential  alone  is  not  protective  alone  should  the 
magnitude  of  the  response  be  insufficient.  The  fact  that,  in  terms  of 
percentages of the overall CD8+ T-cell populations, the healthy age-matched 
controls had phenotypically similar epitope-specific responses to the viraemic 
transplant  patients  indicates that  any  defect  in  the  viraemic  individuals  may 
lie  in  the  absolute  number  of  these  cells  in  circulation  or  in  their  functional 
capacity.
One caveat arising from the assumption that large virus-specific,  potentially- 
cytolytic  CTL  responses  are  capable of  controlling  HCMV  replication  comes 
from  an  interesting  phenomenon  demonstrated  in  the  CVID  patients.  Many 
individuals  with  CVID  suffer a variety of  inflammatory  disorders  and  a  large 
proportion of these endure a colitis-like syndrome, a similar phenomenon has 
been  described  as  an  HCMV-associated  disease.  Biopsies  taken  from  the 
gut  of  several  CVID  patients  at  the  Royal  Free  Hospital  have  shown  the 
presence of  HCMV particles  in the gut issue along with  large T-cell  infiltrate, 
despite  none  of  these  patients  having  HCMV  DNAemia.  Furthermore,  the 
symptoms  displayed  in  these  patients  have  been  shown  to  ameliorate  on 
administration  of  ganciclovir.  It  can  therefore  be  speculated  that  the  large 
infiltrates of HCMV-specific CD8+ cells in these individuals, expressing higher 
than  normal  levels  if  perforin  and  CD57  may  home  to  the  gut  tissue  in
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response  to  HCMV  replication.  The  resultant  cytolytic  response  may 
subsequently cause the destruction of the gut epithelium, which in turn leads 
to  gut  inflammation.  Further  work  could  therefore  focus  on  the  role  that 
HCMV-driven  immunopathology  has  in  certain  inflammatory  diseases  and 
whether  the  magnitude  and  the  phenotype  of  such  a  response  has  any 
bearing on symptoms.
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List of Companies and Reagents used 
Caltag Medsystems
Fax Number  0800 2799114
GAS0025-100  Medium A
GAS0015-100  Medium B
Jerini Peptide Technologies
Fax Number  (+49) 3097 893105
PepMix IE1 
PepMix pp65
Gibco (at Invitrogen)
Fax Number  0800 243485
21875-034  RPMI-1640 (with L-glutamine)
18265-017  Library-efficiency  DH5-alpha competent cells
Prolmmune Limited, Oxford, England
Fax Number  0870 7120588
F008-2B-G  HLA A*0201  NLVPMVATV-PE  Pentamer
F045-2B-G  HLA B*0702 TPRVTGGGAM-PE  Pentamer
P008-0B-G  2mg NLVPMVATV  peptide
P045-0B-G  2mg TPRVTGGGAM  peptide
Sarstedt, Leicester, England
Fax Number 0116 2366099
01.1613.100  S-Monovette® Na-Heparin syringes 7.5ml
83.1813.302  75cm3 vented yellow cell culture flasks
86.1254.001  10ml Serological pipettes
86.1685.001  25ml Serological pipettes
86.1171.001  3.5ml sterile wide-bore transfer pippette
62.547.254  50ml sterile Falcon® tubes
62.554.002  15ml sterile tubes
Labtech
Fax Number
4-101 -500  Foetal Calf Serum
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Mabtech, Sweden
Fax Number  (+46) 87162701
3420-3-250
3420-6-250
3310-10
Elkay
Fax Number
Anti-Hu IFNg mAb 1-D1K 
Anti-Hu IFNg mAb 7-B6-1  Biotin 
Streptavidin ALP-PQ
01256 811116
0002005STR  12 x 75mm sterile polypropylene tubes and caps
Becton Dickinson Biosciences, Oxford, England
Fax Number  01865 781627
555029 GolgiPlug (Brefeldin A)
345770 anti-CD4 PerCP
345774 anti-CD8 PerCP
340449 anti-IFNg FITC
341652 anti-CD69 PE
348040 anti-CD28-leu
333169 anti-CD57 FITC
345767 anti-CD3 APC
342003 FACS Flow buffer
340345 FACS Clean buffer
340976 anti-CD49d
556377 anti-perforin FITC
Sigma Aldricht
Fax Number 0800 378785
D2650 DiMethylSulphOixde (DMSO)
D8537 Phosphate Buffered Saline (PBS)
S4881 Staphylococcus Enterotoxin B (SEB)
B3928 Blue-White Select screening reagent
T9650 10X TAE buffer
D3937 Direct-Load 1  kb DNA ladder
T8154 1X Trypan Blue solution (0.4%)
G1146 Glutamine-Penicillim-Streptomycin
L3522 Luria Broth (Miller’s LB)
A6560 Agarose (type VII) Low gelling temperature
Fisher
Cry-180-020  CryoBoxes
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Amersham Biosciences
Fax Number  01494 544350
17-1440-03  Ficoll  Paque Plus (Sterile, endotoxin-tested)
MWG from world-wide web
All Oligonucleotide primers were purchased here
Autogen Biociear Limited
Fax Number  01249 817266
10-144-000
10-595-001
BDH
Fax Number
10224BQ
Promega
Fax Number
A1360
U1240
Bioline
BIO-33029 
BIO-41025 
BIO-21065
Oxoid
LP0011
Qiagen
27106
28106
1 mg CMV virus lysate 
1 mg control lysate
Propan-2-ol (iso-propyl-alcohol)
pGem-T Easy Vector system I
40 umol dNTPs (dATP, dCTP, dGTP, dTTP)
Hyperladder IV DNA marker
Agarose Multi-purpose molecular grade
500 units Bio-X-Act (short) DNA polymerase
Agar bacterial (agar No.1)
Qiaprep Spin MiniPrep kit 
Qiaquick PCR purification kit
ISL
Fax Number 01803 526776
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BV5100  Disposable Counting Chambers
Alpha Laboratories
Fax Number
LW3332  1.2ml Free-standing Cryovials
V
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Appendix
pGem-T Easy Vector system I
X m n  I 2009
N ae  I 
2707 S ea  11890
1  start
fl ori
Amp
pGEM»-T Easy 
Vector
(3015bp)
tacZ
on
109
118
127
141
N co  I 
fisfZI 
N o t I 
S ac  II 
fcoRI
N ot\ 
Bstl I 
P s t I 
S al I 
N de  I 
S ac  I 
flsfX I 
N si\
SP6
Preparation of LB plates with ampicillin
15  grams  of  agar were  added to  11  of  LB  medium,  which  was  subsequently 
autoclaved  and  allowed  to  cool  to  50 G   before  being  supplemented  with 
ampicillin to a final concentration of 100pg/ml. 30 ml of LB agar ampicillin mix 
was  then  quickly  added  to  a  90mm  Petri  dish  and  allowed  to  set.  40|liI  of 
Blue-White  Select™  screening  seagent  (Sigma-Aldrich)  containing  X-Gal 
and  IPTG  was  then  spread  onto the  surface  of the  set  agar and  allowed to 
absorb for 30  minutes at 37 G   prior to  use.  Plates were stored at 4°C for up 
to two weeks.
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Lymphocytes counts and CMV viral loads from 9 viraemic renal 
transplant patients (See Table 2.2)
Patient 1
18000
12000
10000
Patient 7
20000
15000
■Lymphocytes 
Viral load
0  2  3  4  5  6  7  8  9  10  11  14  16  18  21  23  25  28  30  32  35  38  43  46  49  53  58  66  73  80  87  100  112  120  129  143  179  199  212
Days P  oat-transplant
313Appendix
Patient 3
2500
2000
1500
1000
500
0
8  9  13  14  16  19  21  23  26  28  30  33  36  40  43  47  50  54  57  63  70  70  72  77  84  91  97  97  99  104  110  114  119  141  153  166  180  190  211
Days Post-transplant
Patient 9
6000
5000
4000
3000
2000
1000
0
13  14  15  17  20  22  24  27  29  31  35  38  42  45  49  52  55  58  62  63  70  73  77  84  90  99  105112120121  122123 124125 120 128133 135 156 205 254 317 356378 378394
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Patient 11
Viral load
■  — Lym phocytes
Patient 12
■Lymphocytes 
Viral Load
t3  16  18  20  23  25  27  30  33  37  40  44  47  51  54  59  62  66  67  67  72  79  86  94  94  100  107  110  114  128  136  137  138  143  156  173  198
Days Post-transplant
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19  20  21  22  23  24  25  28  28  31  33  35  38  41  47  49  52  56  59  62  67  74  83  86  90  96  103  112  115  123  136  153  154  159  182
Days Post transplant
Patient 17
Lymphocytes
5000
4000
1000
  L   S *  — A __________ I
26  29  31  33  36  39  43  46  50  53  58  60  61  62  63  64  65  66  68  71  74  75  77  78  80  82  85  88  92  95  96  101  108 115 115  122 155 179 186 191  197 214 235
0
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Patient 19
2500
Lymphocytes
2000
1500
1000
500
316 0
2  4  5  7  9  12  14  17  22  27  34  38  44  52  58  65  72  80  87  97  101  108  115  122  134  146  150  160  175  183  190  203 231  237 253  267 288 373  444
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